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ABSTRACT
The pro-inflammatory cytokine, Interleukin-1β (IL-1β), is well known for its ability to initiate
and propagate inflammatory responses at sites of infection and tissue injury. Paradoxically at
odds with this classic view, it is now clear that IL-1β signaling modulates a number of
physiological functions in the central nervous system. In this regard, IL-1β is involved in sleep
and body fluid regulation in the basal forebrain and hypothalamus, respectively, and plasticity
changes that underlie cognition in the hippocampus. Evidence from a previous study in my
laboratory further suggests that IL-1β regulates the innate seizure threshold, which arguably is a
reflection of the homeostatic balance between excitation and inhibition (E/I) in the
brain. Recognizing that the IL-1β signaling receptor, Interleukin 1 Receptor 1 (IL-1R1), is highly
concentrated on granule neurons of the dentate gyrus of the hippocampal formation and that
dysfunction of this brain region can shift the E/I balance toward excitation, my research focused
on the possibility that constitutive IL-1β signaling in the hippocampal
formation modulates brain E/I balance. The specific goal was to elucidate the cellular source(s)
and release mechanism of IL-1β in the hippocampus and to examine the functional significance
of this release in maintenance of the seizure threshold. In Aim 1, I used the PTZ acute
seizure model and mice lacking IL-1R1 to confirm the previous results demonstrating that IL-1β
signaling is required for maintenance of the innate seizure threshold. In Aim 2, using a brainpermeable antagonist of the ATP-activated purinergic receptor, P2RX7, I found that IL1β immunoreactivity accumulated in pyramidal neurons of the CA3 and to a lesser extent in the
CA1 subregions of the hippocampus. A subsequent study using hippocampal neuron cultures
indicated P2RX7-dependent neuronal release of IL-1β and found that its subcellular localization
included both cell bodies and processes of these neurons. Thirdly, I found that P2RX7 increased

activity-dependent gene expression in cultures of hippocampal neurons and lowered the seizure
threshold in a manner that resembled the phenotype of mice lacking IL-1R1
signaling. Together, results from this aim indicated strong possibility of basal IL-1β release from
hippocampal neurons occurring via an ATP-dependent mechanism and contributing
to maintaining the E/I balance of the normal brain. Additional results from studies in Aim
3 suggest that the rate of production and release of IL-1β is not affected by changes in neuronal
excitation and that IL-1β may affect neuronal excitation via modulation of cyclooxygenase-2
function in hippocampus. Overall, the results from my dissertation research extend the
knowledge of the biological function of IL-1β in the normal brain. A better understanding of this
function could facilitate development of novel therapies to treat seizure induction in epileptic
brains and perhaps reduce the probability of acquiring epilepsy in at-risk individuals.
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Chapter 1: Background

1

1.1

Overview

Seizure, the hallmark symptom of epilepsy on a physiological level occurs due to excessive
neuronal activity that happens due to the lowering or imbalance of an innate brain property,
seizure threshold (physiological synchrony of excitatory and inhibitory neurotransmitter system
for maintenance of brain homeostasis). Several endogenous neuromodulators have been found to
play a role in the maintenance of this physiological balance. One such neuromodulator is the
cytokine, Interleukin-1b. Interleukin-1b is shown to regulate the maintenance of seizure
threshold, and this dissertation shall further characterize the biology of its regulatory role in the
hippocampus of the limbic cortex within central nervous system utilizing a murine system of
acute seizure and hippocampal neuronal cultures.
1.2

Epilepsy

Epilepsy is a clinical term that has been defined at http://www.ilae.org/ as “a transient occurrence
of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the
brain” (Fisher et al. 2014). Epilepsy is a chronic brain disease associated with cognitive,
psychological, and learning deficits alongside other pathophysiological and social sequelae
(Fisher et al. 2014; Bialer et al. 2006).
Epilepsy is one of the most prevalent neurological diseases affecting every aspect of
demographics and can occur alone or combined with other neurological conditions such as
autism, Alzheimer’s disease, brain injury or brain cancer (Gaitatzis, Trimble, and Sander 2004;
Pitkänen et al. 2014; Bozzi, Provenzano, and Casarosa 2018). Epilepsy affects over 50 million
people worldwide, particularly people under the age of 20 or above 60 years (de Boer, Mula, and
Sander 2008; Bialer et al. 2006). It has been estimated that there is a 1 in 26 people have risk of
acquiring epilepsy in their lifetime (Sirven 2015). Pharmacological or neuromodulatory (e.g.
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deep brain stimulation) intervention have been developed that are effective in suppressing the
symptoms of epilepsy but not correct it. However, some patient populations may develop
resistance or may be unresponsive to the pharmacokinetics, making this condition harder to
manage clinically (Beghi et al. 2006).
The neurobiology of epilepsy is complicated, a number of risk factors increases the likelihood of
acquiring epilepsy through the process of epileptogenesis. These risk factors, such as brain
trauma, ultimately lead to cascade of molecular and cellular events causing permanent shift
towards hyperexcitable state (Scharfman 2007; Staley 2015). Every cell types of brain including
endothelium and glia in addition to neurons can be involved in this process (Avoli et al. 2005).
Over last few decades, studies in humans have refined the diagnostic criteria and studies from
models have helped in better understanding the molecular mechanisms that underlies the disease
progression and neurobiological alterations in the epileptic brain (Bradford 1995; Fisher 1989;
Scharfman 2007; De Lanerolle, Lee, and Spencer 2010). While this has contributed to
development of better anti-epileptic therapies, much remains unknown about the pathogenesis of
epilepsy.
1.2.1

Classification of epilepsy

The International League Against Epilepsy (ILAE) has sought to classify epilepsy to more
clearly define this complex disease. Initially, ILAE classifies diagnostic scheme of epilepsy
based on ictal phenomology, seizure types, syndrome, etiology and impairment (Engel 2006).
Subsequently, these classifications have been revised and updated to better understand this
disease progression and cure (Engel et al. 2011; Fisher et al. 2014; Pack 2019).
The International League Against Epilepsy classifies epilepsy on three levels- the epilepsy type,
the seizure type, and the epilepsy syndrome (https://www.epilepsydiagnosis.org/epilepsy/
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epilepsy-classification-groupoverview.html). Epilepsy type is classified based on abnormal
electrical activity: generalized (involving whole brain at the onset), focal (discrete brain region
such as temporal lobe), combined general and focal and of unknown origin. The syndrome on the
other hand is classified based on the age of the patient when epilepsy occurs. Epileptic seizure
types primarily are self-limiting seizures which includes absence (formerly petite mal) or
convulsive (formerly grand mal) seizure and continuous seizures which includes generalized and
focal status epilepticus (convulsive or nonconvulsive seizure which lasts for longer than 5
minutes or when seizures occur close together and the individual doesn't recover in between
seizures) (Engel 2006; Shorvon 2011).
Epilepsy is also classified on the basis of etiology, they are idiopathic, symptomatic, provoked
and cryptogenic (Shorvon 2011) (https://www.epilepsydiagnosis.org/aetiology /epilepsiesetiology-groupoverview.html). For such a complex disease, it is obvious, one classification of the
disease is not sufficient. Hence the multi-aspect classification of the disease helps provides a
better understanding of the disease for the clinicians, researchers, and patients.
Various aspects of epilepsy have been reviewed over years (Fisher 1989; Sloviter 2005; Pitkänen
and Lukasiuk 2009; Vezzani et al. 2013; Scharfman 2007; Staley 2015). Previous students from
my research lab have reviewed epilepsy in their theses. Claycomb (Claycomb 2011) provided
comprehensive review on neurobiology of epilepsy and Gong (Gong 2018) included a review of
the genetic basis of epilepsy.
For my dissertation study, I will focus on the mechanism that underlies the homeostatic balance
of excitatory and inhibitory functions of CNS, in particular to the role of Interleukin-1b in the
maintenance of that homeostatic balance. To study homeostatic balance of excitatory and
inhibitory functions, I will utilize acute seizure model, which causes a shift in this balance to

4

favor excitation. An epileptic seizure is the key symptom of epilepsy, which is an abnormal
synchronous electrical activity of populations of neurons in the brain (Bialer et al. 2006; Fisher et
al. 2014).
1.2.2

Seizure and seizure threshold

Seizures are key symptoms of epilepsy. Seizures are consequences of abnormal synchronous
electrical activity in the populations of neuron in the brain (Bialer and White 2010; Fisher et al.
2014). A seizure however does not necessarily mean the person would have epilepsy. Epilepsy is
defined as occurrence of two or more seizure independent of each other (Engel 2006; Fisher et
al. 2014). The seizure threshold is the innate biological property of the brain that is defined by “a
concept that seeks to reconcile the balance of inhibitory and excitatory neuronal stimuli with an
individual predisposition to seizures” (Wills, Theeler, and Ney 2009; Oh and Bainbridge 2012;
Bozzi, Provenzano, and Casarosa 2018). Therefore, a seizure is an aberrant occurrence that
happens either due to excessive excitatory neuronal activity or absence or failure of inhibition of
neuronal excitation or both (Wills, Theeler, and Ney 2009; Fisher et al. 2014).
1.2.3

Excitation/inhibition balance in CNS

In CNS, neuronal activity is essentially a balance or homeostasis between excitation and
inhibition [glutaminergic and GABAergic functions (Cline 2005; Žiburkus, Cressman, and Schiff
2013)]. Neuronal activity is a physiological process in the central nervous system (CNS) which
maintains homeostatic balance of excitatory and inhibitory (E/I) functions to create effective
synapse (anatomical zone for functional communication between neurons). Neuronal
communication over time becomes effective by developing synaptic strength (homeostatic
synaptic plasticity). Synaptic plasticity is important for sustaining several physiological
functions of the brain (Žiburkus, Cressman, and Schiff 2013; He and Cline 2019), including
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memory formation and adult neurogenesis (Saaltink and Vreugdenhil 2014; Lopatina et al.
2019). Billions of neuronal connections utilize intrinsic homeostatic modulation (synaptic
scaling) to achieve synaptic plasticity which in turn conserves the homeostatic excitatory and
inhibitory mechanisms in CNS (Turrigiano 2012).Any deviation in the intrinsic homeostatic
modulations which keeps the E/I balance in place can trigger neuronal disorders (Lopatina et al.
2019). To site example, homeostatic excitation/inhibition balance is altered due to
neurodevelopmental disorders or environmental or metabolic stress (Saaltink and Vreugdenhil
2014).
Deviation in the homeostatic excitation/inhibition balance can trigger neuronal dysfunction as
exemplified by seizure and epilepsy. Bonansco et al. comprehensively review how glutamatergic
(excitatory) plasticity and GABAergic (inhibitory) plasticity in epileptic brain differs from the
normal brain (Bonansco and Fuenzalida 2016). Similarly, a hypothesis behind autism spectrum
disorder-epilepsy co-morbidity is a multi-etiological factor of neurodevelopment (genetic,
metabolic, environmental) leading to an altered state of excitatory and inhibitory structure
resulting in persistent excitation/inhibition imbalance (altered seizure threshold) and neuronal
hyperexcitability (seizure) (Bozzi, Provenzano, and Casarosa 2018). Likewise, decreased
inhibition leading to unchecked oscillatory activity leads to seizure (Bozzi, Provenzano, and
Casarosa 2018) or imbalance in striatal-thalamocortical connection causes motor and cognitive
impairment leading to Parkinson’s disease (Llinás et al. 1999) or reduced GABAergic signaling
presented in autism (Nelson and Valakh 2015).
Seizure threshold, therefore, can be reiterated as balance between excitatory (glutaminergic) and
inhibitory (GABAergic) forces in the brain which affects the susceptibility of an individual
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to seizures and seizure can henceforth be described as altered excitation/inhibition balance where
excitation is favored.
1.2.4

Model to study alteration in E/I balance

Alterations in E/I balance can be studied either through electrophysiology (recording of electrical
activity) (Žiburkus, Cressman, and Schiff 2013) or via perturbing the E/I balance by inducing
hyperexcitability via certain chemical agents (Steppuhn and Turski 1993), sounds (Wieraszko
and Seyfried 1989) or electric stimuli (Zatz and Roth 1975), etc. In my dissertation research, I
employed the chemo-convulsant, pentylenetetrazol (PTZ) as a model to perturb the E/I balance
in mice and bicuculline in cultured hippocampal neurons in order to understand physiological
mechanism that maintains it.
Pentylenetetrazol (PTZ): Pentylenetetrazol or PTZ is a GABA receptor inhibitor (MacDonald
and Barker 1978) that binds to the picrotoxin binding site of GABAA receptor (Ramanjaneyulu
and Ticku 1984). PTZ has been used extensively to test the efficacy of anti-seizure drugs in
response [reviewed in (Krall et al. 1978)]. It is also broadly used to study acute seizure activity in
laboratory animals (Steppuhn and Turski 1993). In this regard, it is used as a model of neuronal
hyperexcitability to study the molecular mechanisms that maintains the E/I balance (seizure
threshold) in normal brain. PTZ is also used to gradually sensitize the brain in a model called
kindling (Da Silva, Pereira, and Elisabetsky 1998) which is a process of acquiring epilepsy
(epileptogenesis).
PTZ induced seizures may be convulsive or non-convulsive depending on the dosage
(Claycomb, Hewett, and Hewett 2011). Acute PTZ induced seizures occur rapidly (within
minutes) in a progressive fashion. Initially, animals become non-responsive, followed by short
period of myoclonic muscle jerks that may transition to convulsive seizure behaviorally
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exhibited by tonic-clonic jerks. This progression of seizure activity was classified by Ronald
Racine (Racine 1972a; 1972b; Racine, Okujava, and Chipashvili 1972) and revised later
(Lüttjohann, Fabene, and van Luijtelaar 2009).
In addition to studying the PTZ stimulated molecular and biochemical changes that occur in CNS
(Yount, Ponsalle, and White 1994; Ferraro et al. 1999; Klioueva et al. 2001), researchers have
recorded activation of BOLD-fMRI signals triggered by PTZ during seizure (Keogh et al. 2005;
Brevard et al. 2006) to study seizure circuit. PTZ induced acute seizure ultimately resolve within
minutes without causing tissue damage or inflammation (Claycomb, Hewett, and Hewett 2011),
therefore ascertains to be the optimal model to study E/I balance.
For studies herein, PTZ will be injected intraperitoneally and seizure behavior assessed using a
seizure scale modified from Racine scale (Claycomb, Hewett, and Hewett 2011) and explained
in methods section 2.3.3 of Chapter 2).
Bicuculline: Bicuculline, first identified in 1970, is a competitive GABAA receptor antagonist,
inducing GABA mediated synaptic inhibition (MacDonald and Barker 1978; Steppuhn and
Turski 1993). The role and function of bicuculline have been reviewed thoroughly by G.
Johnston (Johnston 2013). Bicuculline is utilized as a chemo-convulsant in experimental animals
where GABA receptor antagonism by indirect disinhibition shifts the excitation/inhibition
balance favoring excitation (Dhir, Naidu, and Kulkarni 2006; Librizzi et al. 2012).It is also used
in cultured neurons to shift E/I balance via disinhibition (Stark and Bazan 2011). However,
bicuculline is chemically not stable and is therefore administered in the form of quaternary salts
(Johnston 2013). For studies herein, disinhibition in cultured hippocampal neurons will be
elicited with bicuculline methobromide treatment, quaternary salt of bicuculline and
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transcriptional activity of the immediate early genes, c-Fos will be assessed [(Gong 2018) and
explained in section 3.3.3.2 Of chapter 3).

1.3 IL-1b: The protein of interest
Several modulatory proteins have been implicated in regulation of the excitatory/inhibitory
balance in the brain. Of importance to my research, several cytokines, which have been
extensively studied for their role in the immunological system, have been now implicated in
contribution of maintenance of the E/I balance of the brain (Vitkovic et al. 2000; Li et al. 2011;
Friedman and Dingledine 2011). These cytokines were initially studied for their contribution in
the pathobiology of several neurological diseases including seizure and epilepsy. Alterations in
the levels of these cytokines in neuroinflammatory or neurodegenerative conditions also cause a
shift or tilt in this excitatory/inhibitory balance (Turrin and Rivest 2004).
Of these, IL-1b, TNF-α, IL-6, etc. have been shown to have physiological roles in brain
independent of their classical immune functions (Krueger et al. 1998; Vitkovic et al. 2000; PlataSalamán et al. 2000; Turrin and Rivest 2004; Chennaoui et al. 2015; Yirmiya and Goshen 2011;
McAfoose and Baune 2009). The dual functions of these well-known molecules in both
physiology and in pathophysiology are, therefore, currently receiving much attention in this
regard.
The following section will discuss the biology of one such cytokine – Interleukin 1b (IL-1b) and
its role in brain physiology. As a pro-inflammatory cytokine of the immune system, IL-1b is
primarily known to be an important mediator, under pathophysiological conditions of the brain,
including pathophysiology of seizure and epileptogenesis (Rothwell and Luheshi 2000; Gibson,
Rothwell, and Le Feuvre 2004; Simi et al. 2007; Rijkers et al. 2009; Vezzani et al. 2011; Maroso
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et al. 2011; Hewett et al. 2012). This section will primarily review the endogenous modulatory
role of IL-1b in certain physiological brain functions independent of its classical neuro-immune
functionalities.
1.3.1

The Interleukin-1 family

Interleukin 1b belongs to the IL-1 family of Toll-like receptors superfamily. It consists primarily
of with seven agonist ligands (IL-1, IL-1b, IL-18, IL-33, IL-36, IL-36b, IL-36), three receptor
antagonists (IL-1Ra, IL-36Ra, IL-38) and one anti-inflammatory cytokine (IL-37). These are
listed with key specifics in table 1.1 [modified from (van de Veerdonk and Netea 2013;
Garlanda, Dinarello, and Mantovani 2013)]. The receptor of IL-1b belongs to IL-1 receptor
family (IL-1R) formed from 6 receptor chains, forming four functioning signaling receptor
complexes, two decoy receptors, and two negative regulators (Boraschi and Tagliabue 2013).
Detailed structure, function and other biological activities of all the members of IL-1 family have
been reviewed extensively by several authors (van de Veerdonk and Netea 2013; Garlanda,
Dinarello, and Mantovani 2013; Mantovani et al. 2019; Boraschi and Tagliabue 2013; Garlanda
et al. 2013).
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Cytokine

Alternative
names

Receptors

IL-1F1
IL-1F2
IL-1F3
IL-1F11

IL-1R1, IL-1R2
IL-1R1, IL-1R2
IL-1R1
ST2

IL-1F4
IL-1F7
IL-1F6
IL-1F8
IL-1F9
IL-1F5
IL-1F10

Alternate
names

Coreceptor

Alternate
names

IL-1RacP
IL-1RacP

IL-1R3

IL-1 subfamily
IL-1α
IL-1b
IL-1Ra
IL-33

IL-1R4

IL-1RacP

IL-18Rα
IL-18Rα

IL-1R5

IL-18Rb

IL-36R/IL-1RrP2
IL-36R/ IL-1RrP2
IL-36R/ IL-1RrP2
IL-36R/ IL-1RrP2
IL-36R/ IL-1RrP2

IL-1R6

IL-1RacP
IL-1RacP
IL-1RacP

IL-18 subfamily
IL-18
IL-37

IL-1R7

IL-36 subfamily
IL-36α
IL-36b
IL-36
IL-36Ra
IL-38

Table 1.1. Nomenclature of members of the IL-1 family with their receptors and coreceptors.
1.3.2

IL-1β Signaling pathway

IL-1β is a secretory protein, signals through the functional plasma membrane receptor complex
of Toll-like receptor superfamily (Barton and Medzhitov 2003; Garlanda et al. 2013) consisting
of the ligand-binding chain, Interleukin-1 receptor 1 (IL-1R1) (McMahan et al. 1991; Sims et al.
1993). IL-1Receptor accessory Protein (IL-1RacP or IL-1R3) binds to the Toll IL-1 Receptor
(TIR) domain of the cytoplasmic tail of the ligand bound IL-1R1 to form a high-affinity receptor
complex (Dinarello 2009; Weber, Wasiliew, and Kracht 2010a; Boraschi and Tagliabue 2013).
Upon ligand binding, Myeloid differentiation primary response 88 (MyD88) is recruited to this
complex. It serves as an adaptor protein for binding and autophosphorylation of serine threonine
kinase, Interleukin receptor-associated kinase-4 (IRAK-4). IRAK-4 subsequently phosphorylates
the IRAK-1 to recruit and oligomerize Tumor necrosis factor associated factor 6 (TRAF-6)
which initiates downstream signaling via p38 Mitogen associated Kinase (MAPK) and Nuclear
Factor -κB (NF- κB) (Axel Weber, Wasiliew, and Kracht 2010; Boraschi and Tagliabue 2013;
Mantovani et al. 2019). In CNS, IL-1β signaling in neurons only induces p38 MAPK whereas
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both p38 MAPK and NF- κB are induced in astrocytes, yielding distinct functional response of
IL-1β based on cell types (Srinivasan et al. 2004)
Canonical IL-1β signaling is constrained by a decoy receptor and a naturally occurring
antagonist. The decoy receptor of IL-1β, IL-1RII cannot transduce signal owing to its short
cytoplasmic tail due to absence of TIR domain (Colotta et al. 1993; McMahan et al. 1991) and
thus functions to curb any downstream IL-1β signaling. In addition, a naturally occurring
antagonist of IL-1, IL-1receptor antagonist (IL-1ra, Anakinra) inhibits IL-1β signaling by
binding to IL-1R1 (Simi, Tsakiri, et al. 2007; Dinarello 2009). Several studies, including studies
in CNS, have used exogenous IL-1ra to block IL-1β signaling and perform sensitive assessment
of IL-1β function in those specific mechanism (Dinarello 2004).
IL-1RacPb (AcPb), an isoform of IL-1RacP, the accessory protein of IL-1R1, is only present in
CNS and constitutively expressed by neurons (Huang et al. 2011). IL-1RacPb mediates Src
kinase phosphorylation, which in turn have shown to moderate direct neuronal response such as
phosphorylation of ion channel, NMDA induced calcium influx etc.(Viviani et al. 2003; Salter
and Kalia 2004; Huang et al. 2011).
1.3.3

Localization in the brain – the ligand and its signaling components

Constitutive expression of IL-1β mRNA was first found in the hypothalamus, hippocampus and
cerebellum of rat brain, in the granule cells of the dentate gyrus and in cerebellar Purkinje cells
(Yabuuchi et al.1993). As researched and reviewed by multiple researchers, presence of low
levels of IL- 1β immunoreactivity is found throughout the brain of rodents in normal conditions,
particularly in the hippocampus, hypothalamus, and basal forebrain (Breder, Dinarello, and
Saper 1988; Lechan et al. 1990; Watt and Hobbs 2000).
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Several cell type in CNS is capable of expressing IL-1β, as being reported in microglia (Giulian
et al. 1988), astrocytes (Lieberman et al. 1989), oligodendrocytes (Blasi et al. 1999) and
pertinent to this research study, neurons (Lechan et al. 1990; Breder, Dinarello, and Saper 1988;
Watt and Hobbs 2000; Kaneko et al. 2006; Gomes et al. 2013; Viviani et al. 2014). These cells
are also capable of responding to IL-1β as each cell type expresses fuctional IL-1β receptor, IL1R1 (Farrar et al. 1987; Cremona et al. 1998; Ban and Milon 1991; Ban 1993; French et al. 1999;
Friedman 2001; Hammond et al. 1999; Pinteaux et al. 2002; Nadjar et al. 2005). Recently, a
study involving Cre-lox technology was able to place IL-1R1 expression in different cell types of
CNS, which includes DG neurons, astrocytes, ventricular and endothelial cells (Liu et al. 2019).
Rat hippocampal neurons in culture also express IL-1R1 primarily in the postsynaptic density,
alongside MyD88 and IL-1RacP (Viviani et al. 2003). Separate novel isoform of IL-1RacP, IL1RacPb, that is present in neurons, which mediates an alternate signaling pathway (Smith et al.
2009; Huang et al. 2011). I have shown strong basal expression of IL-1R1 in the dentate gyrus
(DG) and Cornu Ammonis 1(CA1) sub-regions of the hippocampus in mice brain (Fig.7.1,
appendix). Studies herein also confirm that mice hippocampal neurons also express IL-1R1, IL1RacP and MyD88 in culture (Chapter 5). This current study focuses on characterizing molecular
mechanisms underlying IL-1β release and functions in moderation of E/I balance in
hippocampus. It is therefore relevant to review endogenous expression of IL-1β ligand and its
signaling components in CNS, particularly in hippocampus.

13

1.4

Neurobiology of Interleukin-1b

IL-1β is a well-characterized cytokine of the innate and adaptive immune system (Breder,
Dinarello, and Saper 1988; Gibson, Rothwell, and Le Feuvre 2004; Allan, Tyrrell, and Rothwell
2005; Fogal, Hewett, and Hewett 2005) and is an important mediator in the communication
between the peripheral immune and central nervous systems (CNS) (Hansen et al. 1998;
Vitkovic et al. 2000;Samad et al. 2001; Patricia Parnet et al. 2002; Wolf et al. 2007; Liu et al.
2013). Within the CNS, while it contributes to the pathogenesis of various neuro-inflammatory
and neurodegenerative maladies (Ho and Blum 1997; Allan, Tyrrell, and Rothwell 2005; Fogal,
Hewett, and Hewett 2005; Simi et al. 2007; Shaftel, Griffin, and O’Banion 2008), it also
modulates certain physiological functions (Fang, Wang, and Krueger 1998; Mason et al. 2001;
Yirmiya, Winocur, and Goshen 2002; Avital et al. 2003; Goshen et al. 2007; de la Mano et al.
2007). Thus, IL-1β is a neuromodulator in both the normal and misfunctioning CNS.
1.4.1

IL-1β in neuroinflammation and neurodegeneration

IL-1b is a multifunctional proinflammatory cytokine (a protein released from/of immune cells
that mediated immune functions). Initially described in the 1940s, as endogenous pyrogen, it is
now associated primarily with innate immunity as a central mediator of endotoxic shock and in
autoimmune diseases like Rheumatoid Arthritis and Multiple Sclerosis (Dinarello 2002; Daun
and Fenton 2000). As an immune modulator, it is produced primarily in activated macrophages
and lymphocytes of the immune system in response to infection, toxins and other inflammatory
mediators [reviewed in (Mantovani et al. 2019)]. IL-1b has been a key player in different
inflammatory and infectious conditions, including malignancies and transplantation, which are
comprehensively reviewed by Dinarello et. al. (Dinarello 2002; Garlanda, Dinarello, and
Mantovani 2013; Mantovani et al. 2019). IL-1β is a key pro-inflammatory player which has been
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implicated by multiple researchers in several neuro-inflammatory and neurodegenerative
conditions such as cerebral ischemia, traumatic brain injury, multiple sclerosis, excitotoxicity,
epilepsy, Alzheimer’s disease, Parkinson’s Disease, etc. as reviewed in (Rothwell and Luheshi
2000; Gibson, Rothwell, and Le Feuvre 2004; Allan, Tyrrell, and Rothwell 2005; Simi et al.
2007; Fogal and Hewett 2008; Vezzani et al. 2011).
Inflammation in the central nervous system causes rapid induction in expression and release of
several inflammatory mediators – cytokines, chemokines, prostaglandins, complement proteins,
etc –leading to classic inflammatory response. In addition, increased permeability of the bloodbrain barrier facilitates the invasion by peripheral immune cells (Hopkins and Rothwell 1995).
Microglia are the primary source of inflammatory IL-1b in CNS (Perry and Teeling 2013; Liu
and Quan 2018). Predominantly microglia and also astrocytes are the effector cells involved in
acute and chronic neuroinflammation. Pathological concentrations of IL-1b activates the
classical MAPKs/NF-kB signaling pathways in glial cells leading to cellular activation and
production of various secondary mediators such as cytokines (IL-6, IL-8), adhesion molecules (ICAM, V-CAM) and neuroprotective and neurotoxic factors (NGF, MMP- 9) (Simi et al. 2007).
Simi et al. reviewed the cell-specific effects to IL-1b signaling in neuroinflammation and
degenerative disorders. IL-1b promotes astrocyte proliferation and astrogliosis, upregulates
adhesion molecules in endothelial cells to recruit leucocyte, promotes GABAergic inhibition and
NMDAR phosphorylation in neurons. Therefore, IL-1b has different effector function in
different cell types, inducing both toxic and protective functions, in response to
neuroinflammation and degeneration (Simi et al. 2007).
IL-1β is connected to neuroinflammation by, i) level of IL-1β immediately rises following
traumatic insult in the brain causing neuronal damage (Eriksson et al. 1999), ii) exogenous IL-1β
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(cerebral injection) exacerbates ischemia, excitotoxicity and traumatic injury and iii) blocking
IL-1β functions reduces neuronal injury (Eriksson et al. 2000), as summarized by Rothwell and
Luheshi (Rothwell and Luheshi 2000). In the CNS, IL-1β often is associated with a bystander
effect where immune responses lead to exacerbated neuronal tissue damage.
IL-1β in seizure and epilepsy: IL-1β is implicated in several acute seizure studies and studies
involving the process of epileptogenesis (a progression by which brain achieves lowered seizure
threshold and becomes susceptible to spontaneous seizure activity) utilizing different models of
seizure and epilepsy.
IL-1β showed a rapid elevation in IL-1β mRNA in different parts of the brain following kainate
(kainic acid/kainate- a potent neuroexcitatory amino acid agonist which acts by activating
kainate receptors for glutamate) and PTZ induced model of the acute seizure (Minami et al.
1990). Kainic acid-induced model of seizure in several studies has shown induction of IL-1β
mRNA (Yabuuchi , Minami, Katsumata 1993; Eriksson et al. 1999; 2000; Vezzani et al. 1999)
along with increase in IL-1ra mRNA and protein (Eriksson et al. 1999; 2000). A different model
of seizure, pilocarpine (a cholinergic agonist which activates muscarinic cholinergic receptors)
induced status epilepticus also elevated IL-1β mRNA and protein (Voutsinos-Porche et al. 2004;
Marcon et al. 2009) and IL-1R1 protein (Ravizza and Vezzani 2006a) in the brain. Status
epilepticus induced by electrical stimulation in the hippocampus also increased expression of IL1β mRNA and protein and its receptor (Ravizza and Vezzani 2006b).
Systemic IL-1β injection significantly increased PTZ induced seizure susceptibility (Miller and
Turner 1990). Treatment with intrahippocampal IL-1β injection 10 min before kainate injection
increased the duration of seizure, without affecting seizure latency or events (Vezzani et al.
1999). Here, exogenous IL-1β contributed to the maintenance of seizures in the hippocampus.
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Exogenously administered IL-1ra via intra cerebrovascular injection significantly lowered
electrically-induced seizure activity (De Simoni et al. 2000). On other hand, mice treated with
IL-1ra before bicuculline treatment decreased seizure severity. Similarly, mice with
overexpression of IL-1ra had less severe bicuculline-induced seizures (Vezzani et al. 2000).
Caspase-1 activates IL-1β via proteolytic cleavage, therefore, blocking caspase-1 function would
be presumed to reduce generation of the mature form of ligand, implicating IL-1β inactivity.
Systemic administration of Caspase-1 inhibitor abrogated seizure activity in pertussis vaccineinduced seizure (Donnelly et al. 2001). Two caspase-1 inhibitors, Pralnacasan and VX-765,
significantly increased seizure latency and decreased the number and duration of seizures when
induced by intra-hippocampal kainate application (Ravizza et al. 2006; Maroso et al. 2011).
Moreover, Caspase-1 null mice had increased seizure latency and less severe seizures compared
to wild-type mice.
Our previous results demonstrated that the incidence of PTZ-induced convulsions and KAinduced status epilepticus was increased in mice in which IL-1β signaling was disrupted
genetically (Claycomb, Hewett, and Hewett 2012), indicating role of endogenous IL-1b in the
maintenance of seizure threshold.
IL-1b is also implicated in epileptogenesis or progression towards altered seizure threshold in the
brain. IL-1b and IL-1RI mRNA rapidly increases in the cortex, amygdala, and hippocampus in
rats with rapid electrical kindling of the amygdala (Plata-salaman et al. 2000). However, IL-1b
transcript returned towards baseline after 3 weeks. IL-1b may be associated with kindling
accusation but not maintenance. On the other hand, audiogenic kindling did not elevate IL-1b
mRNA (Da Silva, Pereira, and Elisabetsky 1998).
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Rats treated with IL-1b (i.c.v.) required more electrical stimulations of the amygdala to become
kindled. Higher dose of IL-1b significantly decreased the severity and duration of kindled seizures
in amygdala-kindled rats. IL-1b treatment retarded kindling development in a dose-dependent
manner (Sayyah et al. 2005). Inhibition of IL-1b production via caspase-1 inhibitor prevented the
rapid kindling of the hippocampus (Ravizza 2008). Continuous intra-cerebrovascular injection of
IL-1β transiently delays the process of kindling compared to saline-treated rats whereas LPS
treatment accelerated the process of PTZ-induced kindling of seizures (Kołosowska et al. 2014).
Claycomb demonstrated no difference in PTZ-induced kindling in mice in IL-1R1 KO mice
(Claycomb 2011).
While some evidence suggests that IL-1β possesses proconvulsant properties (Vezzani et al.
1999; 2000; Plata-Salamán et al. 2000; Heida, Moshé, and Pittman 2009; Maroso et al. 2011),
other results are consistent with an anticonvulsive function of IL-1β (Miller and Turner 1990;
Sayyah et al. 2005). This may be related, at least in part, to the model or approach used
(Pinteaux, Trotter, and Simi 2009). However, the role of IL-1β in this brain disorder is
complicated and depends on the disease model/paradigm utilized, microenvironment, and the
cell type in question [reviewed in (Rijkers et al. 2009; Vezzani et al. 2013a; 2013b; Vezzani
2014)]. IL-1β is also implicated in febrile seizure (Dubé et al. 2005), however, it is not discussed
in detail here.
Role of IL-1β in epilepsy remains paradoxical, however, it is important to recognize, firstly, role
of IL-1β depends on the model of seizure or epileptogenesis, secondly, it is important to
delineate role of endogenous v/s exogenous IL-1β, as the role of endogenous IL-1β in
maintenance of the seizure threshold in normal brain (Claycomb, Hewett, and Hewett 2012),
which when absent increased seizure severity.
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1.4.2

IL-1β and its implication in CNS physiology

Interleukin-1β has physiological functions in CNS. The physiological role of IL-1β involves
neurogenesis (Friedman 2005), the hypothalamus-pituitary axis of neuroendocrine functions
(Watt and Hobbs 2000), fever response (Parnet et al. 2002; Nadjar et al. 2005), central stress axis
(Goshen and Yirmiya 2009) and pain sensitization (Samad et al. 2001), sleep (Fang, Wang, and
Krueger 1998), learning (Ross et al. 2003) and memory (Huang and Sheng 2010; Yirmiya and
Goshen 2011).
These physiological functions of IL-1β in CNS are identified when its normal physiology is
disrupted by disease or via application of exogenous IL-1β. For example, somnogenic function
of IL-1β was identified with sickness behavior (Krueger 2008). IL-1β sits in between a complex
balance of physiology v/s pathophysiology in CNS. The effector functions of physiological IL1β depends on its concentration and the microenvironment within CNS. Increased IL-1β levels
during neuroinflammation can affect these physiological functions. For example, long term
potentiation was negatively impacted by inflammatory IL-1β levels (Vereker and Lynch 2000)
and prolonged neuroinflammation in transgenic mice overexpressing IL-1β showed contextual
memory impairment (Hein et al. 2012).
Some physiological functions of IL-1β that are associated with hippocampus are discussed here.
Pertinent to this study, physiological functions of IL-1β associated with maintenance of E/I
balance via synaptic regulation of neurotransmitters will be discussed.
Modulates neurogenesis: IL-1b is detected in the mammalian brain during the formation of the
cortical plate (Dziegielewska et al., 2000). Its expression is also detected in late prenatal and
early postnatal period. However, it is lower in adult CNS (Zunszain et al. 2012). During
neurodevelopment, microglia-derived IL-1b acts as a mitogen for astroglia which in turn aids in
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neurogenesis (Giulian et al. 1988). Adult neurogenesis in mice was affected in the DG of the
hippocampus by IL-1b in IFN-g induced clinical depression like behavior (Kaneko et al. 2006).
Model of clinical depression mediated lowered neurogenesis was co-related with elevated IL-1b
in the hippocampus via the kynurenine pathway (Zunszain et al. 2012). Mild stress reduced
neurogenesis in mice which was absent in IL-1R1 KO mice (Goshen et al. 2008). Both acute and
chronic exogenous IL-1b exposure reduced hippocampal neurogenesis (Goshen et al. 2008). On
the other hand, IL-1ra overexpression lowered neurogenesis (Spulber 2008). IL-1b induces
neurotrophic factors (Friedman 2005). Although exogenous acute IL-1b injection induced
expression of neurotrophic factors and neuroprotection, sub-acute exposure to IL-1b caused
opposite effect (Song, Zhang, and Dong 2013).
Sleep: Sleep is an important physiological function of the brain, that on the molecular level
involves intricate neuronal functioning (Krueger et al. 2008). IL-1β increased non-rapid eye
movement sleep (NREMS) whereas inhibition of IL-1β reduces spontaneous sleep (Krueger et
al. 1998). Central administration of IL-1β increases NREMS and suppresses REMS (Opp, Obal,
and Krueger 1991). In both cases, IL-1β levels were low and did not trigger fever response
(Krueger et al. 1998; Opp, Obal, and Krueger 1991).
Mice lacking IL1R1 spend less time in NREMS under baseline conditions (Krueger et al. 1998;
Fang, Wang, and Krueger 1998). IL1β is also known to induce fever response and thus
implicated in fever associated sleep responses due to inflammatory challenges (Fang, Wang, and
Krueger 1998; Taishi et al. 2012; Garlanda et al. 2013).
Synaptic plasticity: Synapses depending on the rates of their neuronal activity undergo
molecular and sub-cellular changes (synaptic plasticity) to alter efficacy (synaptic strength).
Long term potentiation is the biological process by which specific synaptic stimulation results in
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long lasting increase in strength of synaptic transmission. Long term potentiation (LTP) which is
considered to be the cellular equivalence of memory, is persistent augmentation of synaptic
efficacy in CNS.
IL-1b mRNA level was elevated 1 hour after LTP in rat hippocampal slices and rat ipsilateral
hippocampus with robust potentiation (Schneider et al. 1998). IL-1b mRNA level remained
elevated up to 8 hours following induction of LTP (del Rey et al. 2013).
Exogenously applied IL-1b when applied 20 minutes before tetanic stimulation of rat mossy
fiber path in hippocampal slices caused a reduction in LTP magnitude, but blocking IL-1b did
not affect LTP (Katsuki et al. 1990). Similarly, IL-1b applied ten and sixty minutes before
tetanus induced potentiation, attenuated the LTP in CA1 region of rat hippocampal slices
(Bellinger, Madamba, and Siggins 1993). Recent study where 1ng/ml IL-1β was applied before
thirty minutes of high-frequency stimulation in mouse brain slice showed impaired LTP in
Schaffer collateral-CA1 synapses or the associational/commissural (A/C) fiber- CA3 synapses
dependent on NMDA reception activation. However, NMDA independent pre-synaptic LTP was
not impaired in mossy fiber-CA3 synapse showing the varied synapse-specific effect of IL-1β in
the hippocampus of mice brain (Hoshino et al. 2017).
IL-1ra application 30 min after the induction of LTP in the DG of the hippocampus in vitro
reduced synaptic activity back to baseline levels (O’Connor and Coogan 1999). In a separate
study, when IL-1ra was applied 40 minutes before stimulation in a hippocampal slice, the initial
increase in synaptic activity was not affected but was also not sustained and it subsided by thirty
min (Ross et al. 2003).
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LTP was not induced in Schaffer collateral in vitro or mossy fiber in vivo in IL-1R1 null mice
(Avital et al. 2003). However, no impairment in LTP was observed in IL-1Ra or IL-1b KO mice
(Ikegaya et al. 2003), posing the question of how IL-1b may signals in this model of LTP.
LTP in hippocampus can be affected by IL-1b by either of the following ways. Firstly,
exogenous IL-1b inhibits LTP in vitro (Bellinger, Madamba, and Siggins 1993; Katsuki et al.
1990; Cunningham et al. 1996) or in vivo (Murray and Lynch 1998; Vereker and Lynch 2000).
Secondly, effect of IL-1b is dose dependent (Schneider et al. 1998; Loscher, Mills, and Lynch
2003; Goshen et al. 2007; Spulber et al. 2009). Elevated concentrations of IL-1b inhibited
induction of LTP (Katsuki et al. 1990; Bellinger, Madamba, and Siggins 1993; Lynch 2014)
particularly in the hippocampus, including CA1 (Bellinger, Madamba, and Siggins 1993; Ross et
al. 2003), CA3 (Katsuki et al. 1990), and dentate gyrus (Connor and Coogan 1999; Lynch 2014)
and on the other hand, blocking endogenous IL-1b signaling with IL-1ra treatment attenuated
maintenance of LTP (Ross et al. 2003). This indicated physiological IL-1b is necessary for
induction and maintenance of LTP.
Learning and Memory: Hippocampus is the part of the brain associated with learning and a
certain form of memory formation. As mentioned earlier, physiological IL-1β functions are
highly prevalent in the hippocampus. Evidence indicates both beneficial and detrimental effects
of IL-1β based on context and particular model of study. Administration of IL-1β (i.c.v) impaired
hippocampal-dependent spatial memory (tested through performance in Morris water maze)
(Yirmiya, Winocur, and Goshen 2002) and contextual fear conditioning in mice (Pugh et al.
2001) and rats (Hein et al. 2007). However, it had no impact on hippocampal independent
process. IL-1Ra transiently reduced the underlying neuroplasticity changes. Inhibiting IL-1β
signaling via IL-1ra administration or by IL-1R1 deletion also impaired hippocampal based
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spatial memory and diminished fear conditioning memory in mice (Yirmiya 2002; Avital et al.
2003).
Stress or inflammation also affects learning and memory via IL-1β signaling. Bacterial
lipopolysaccharide (LPS) injection impaired hippocampus-dependent contextual fear
conditioning, memory in the passive avoidance paradigm, and deteriorates spatial learning in
rats, and these effects were reversed by IL-1ra administration (Pugh et al. 1998). IL-1β mediated
memory impairment is studied in different inflammatory conditions such as traumatic brain
injury (Clausen et al. 2011).IL-1β causes cognitive decline with age as implicated in studies with
patients with Alzheimer’s disease (Lynch 1998). IL-1β level was elevated in older mice. It was
implicated in cognitive decline (Gomes et al. 2013; Simen et al. 2011). However, these effects of
IL-1β are affected by certain factors such as age (Bilbo et al. 2008; Takemiya et al. 2017), doses
(Brennan, Beck, and Servatius 2003; Goshen et al. 2007) kind of memory studies and memory
types [short term v/s long term (Spulber et al. 2009; Hein et al. 2012)], etc.
In summary, high doses of exogenous treatment of IL-1β or its elevation due to inflammation in
the brain impairs hippocampus-dependent memory functions and on other hand inhibiting the
signaling also causes similar impairment, indicating a physiological role of endogenous IL-1β in
the maintenance of these memory functions.
Regulation of neurotransmission: IL-1b modulates both GABAergic and glutamatergic
functions in CNS (Miller and Fahey 1994; Zhu et al. 2006).
Glutamate function: IL-1b facilitated the augmentation of neuronal calcium when induced by
glutamate in hippocampal neurons (Wang et al. 1999). It increased the NMDA receptor-mediated
current and the amplitude of the voltage-dependent Ca2+ current (Yang et al. 2005). Pretreatment
of neurons with IL-1b enhanced NMDA induced rise in intracellular calcium and this effect was
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abolished with IL-1ra treatment in cultured hippocampal neurons (Viviani et al. 2003). However,
frequencies of spontaneous excitatory postsynaptic currents (sEPSC) and miniature excitatory
postsynaptic currents (mEPSC) were decreased with the application of 10 or 100 ng/ml IL-1b,
implying it acted presynaptically to decrease the frequency of neurotransmitter release. As the
amplitude of mEPSC remained unchanged, it seemed unlikely that IL-1b acted on post-synaptic
neurotransmitter receptor (Yang et al. 2005). The effect of IL-1b on the NMDA-induced outward
currents in mechanically dissociated hippocampal neurons was studied using a perforated patch
recording technique. Thirty (30)–hundred (100) ng/ml IL-1b inhibited the mean amplitude of the
NMDA- induced outward currents. Hundred (100) ng/ml IL-1b also increased the mean ratio of
the NMDA-induced inward current amplitudes significantly. This implied, IL-1b facilitated
NMDA receptor mediated response (Zhang et al. 2008). IL-1b shares dynamic relationship with
NMDA function. Treatment with NMDA (50µM for 10 minutes) on cultured hippocampal
neurons, but not with IL-1b (0.05ng/ml for 30 minutes) led to a significant increase in the IL1R1/GluN2B complex (GluN2B is a subunit of NMDAR) even though both treatments increased
IL-1R1 in the synaptic sites (Gardoni et al. 2011).
GABAergic function: IL-1b application equivalent to pathophysiological conditions (1–10 ng/ml)
decreased the peak magnitude of current elicited by 30µM GABA irreversibly, which was
prevented by IL-1ra (Wang et al. 2000). IL-1b potentiated GABA mediated inward currents in
chick cortical neurons and enhanced GABAergic signaling in slice preparation (Miller and Turner
1990). Alongside, IL-1b increased muscimol (GABA agonist) induced Cl- uptake in synaptosome
(Miller and Fahey, 1994). IL-1b enhances GABA-mediated inhibition within the hippocampus
(Hellstrom et al. 2005).
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Physiological role of IL-1b that encompasses hippocampal functions are discussed here. Beyond
that, physiological role of IL-1b is also extended to fluid and hormone regulation in hypothalamus,
effects on ion channel which in turn affects neuronal excitability (Schäfers and Sorkin 2008) and
central axis of stress (Shintani et al. 1995; Goshen and Yirmiya 2009). Above mentioned studies
identifying role of IL-1b in physiological function demonstrate a common theme, although
physiological level of IL-1b is required for the specific function, excessive IL-1b impair the
physiological function. Excessive IL-1b impaired synaptic plasticity and memory, affected
synapse function which in turn affected E/I balance, although presence of IL-1b is required for
maintenance of LTP, learning and memory and neurotransmitter functions. Physiological function
of IL-1b in CNS therefore requires a fine balance (Pozzi et al. 2018).
1.5

IL-1β Synthesis, Processing, and Release

Transcription and translation: IL-1β gene has a TATA box within the promoter region alongside
the cAMP-responsive element, an NF-kB binding site, AP-1 site, and Sp-1/PU binding site
(Shirakawa et al. 1993). Transcriptional and translation regulation of IL-1β has been reviewed in
(Fenton 1992; Allan, Tyrrell, and Rothwell 2005).
Processing and release: IL-1β processing and release is a multistep mechanism. It is produced as
pro-peptide that must undergo proteolysis to form the mature peptide. There are several ways
through which IL-1β can be processed within the cell and similarly can be released via different
mechanisms. It's intracellular processing to its functional form requires help of a multimeric
protein complex, inflammasome and proteolytic enzyme, Caspase-1, and activation of purinergic
ATP receptor, P2X7R for its release outside the cell. Different cell types and stimuli can vary IL1β processing time, subcellular localization and release mechanisms (Dinarello 2002; 2009).
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Pro-IL-1β lacks a peptide leader sequence and therefore not processes via endoplasmic reticulum
/Golgi pathway secreted outside the cell independent of the endoplasmic reticulum and Golgi
apparatus (Rubartelli et al. 1990; Anelli and Sitia 2008). The primary source of IL-1β at sites of
inflammation is the macrophage and processing and release mechanism of IL-1β in macrophage
is extensively studied (Mankan et al. 2012; Ward et al. 2010; Pelegrin, Barroso-Gutierrez, and
Surprenant 2008; Barbera-Cremades et al. 2012). In CNS, the IL-1β processing and release
mechanism is studied in detail in microglia, which are the primary source of IL-1β in CNS
during inflammation (Yao et al. 1992; Sanz and Virgilio 2000; Mingam et al. 2008; Bianco et al.
2005).
Firstly, ligand binding to a pattern recognition receptor (PRR) activates NF-kB to induce a 31 kD
pro- IL-1β and NLRP, a key component of inflammasome, the multimeric protein complex
required for Caspase-1 processing (Latz, Xiao, and Stutz 2013). Inflammasomes are large
(~1μm) intracellular multimeric protein complexes that comprise a pattern recognition receptor
(PRR), an adapter molecule and the enzyme caspase-1 amongst other proteins (Pétrilli, Papin,
and Tschopp 2005). Secondly, assembly and activation of the inflammasome initiates a chain of
events within the cell that catalyzes proteolytic cleavage of pro-IL-1β to 17kD mature peptide
(Brough and Rothwell 2007). This step and subsequent release of IL-1β is triggered by P2X7R
activation (Ferrari et al. 2006; Weber, Wasiliew, and Kracht 2010; Piccioli and Rubartelli 2013;
Latz, Xiao, and Stutz 2013).
Mechanism of IL-1b release varies depending on cell types and conditions. Five different release
mechanisms of IL-1β have been shown (1) exocytosis of IL-1β-containing secretory lysosomes
where pro-IL-1β is cleaved by Caspase-1 in the lysosome, (2) release of IL-1β via shedding of
plasma membrane microvesicles which is seen in microglia, (3) fusion of multivesicular bodies
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with the plasma membrane and subsequent release of IL-1β-containing exosomes as seen in
macrophage (Pelegrin, Barroso-Gutierrez, and Surprenant 2008) where inflammasome activation
and caspase-1 are simultaneously required for IL-1β packaging, (4) export of IL-1β through the
plasma membrane using specific membrane transporters under sustained NLRP3 activation, and
(5) release of IL- 1β upon cell lysis, as reviewed in (Weber, Wasiliew, and Kracht 2010; Piccioli
and Rubartelli 2013; Latz, Xiao, and Stutz 2013). The release of IL-1β from stimulated
monocytes posits that extracellular ATP activates the purinergic P2X7 receptor, leading to
processing and secretion of mature IL-1β (An and Wewers 2004). P2X7R is a member of the
P2X family of ionotropic receptors of purinergic signaling. Upon engaging ligand, P2X7R
permits the rapid efflux of K+. This initiates activation of the inflammasome and three
phospholipases, phosphatidylcholine-specific phospholipase C (PC-PLC), and calciumindependent (iPLA2) and calcium-dependent phospholipase A2 (cPLA2)., Calcium-independent
phospholipase A2 is involved in processing whereas phosphatidylcholine-specific phospholipase
C and calcium-dependent phospholipase A2 are required for secretion. The ATP-mediated K+
efflux causes phosphatidylcholine-specific phospholipase C induction, which in turn allows the
rise in intracellular free calcium concentration required for activation of phospholipase A2. This
activation is ultimately responsible for IL- 1β secretion via any of the above-mentioned release
pathways (Walev et al. 2000; Ferrari et al. 2006; Silverman et al. 2009) as seen in microglia
(Sanz and Virgilio 2000) and macrophage (Pelegrin, Barroso-Gutierrez, and Surprenant 2008).
Recently, it has been shown, Caspase-1 activation in macrophage in turn activates Gasdermin D
(pore forming protein), which is involved in pyroptosis mediated IL- 1β secretion (Ramos-Junior
and Morandini 2017; Monteleone et al. 2018). Non pyroptotic myeloid cells initially require
Gasdermin D to be translocated to the plasma membrane for IL- 1β secretion initially, however,
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later IL- 1β secretion is Gasdermin D independent. A very recent study have indicated role of
Gasdermin in CNS, where its activation by Caspase-1 mediated enhanced cell permeability for
IL-1β release from hippocampus in acute stress response (Frank et al. 2020).
1.5.1

Neurobiology of IL-1b release

Proteins required for inflammasome formation, Caspase-1 and P2X7 expression (Walsh,
Muruve, and Power 2014; Mingam et al. 2008) are present in CNS particularly in microglia
where it has been well studied. Proteins of the inflammasome (Savage et al. 2012; Hua et al.
2015; Wang et al. 2017), Caspase-1 (Denes, Lopez-Castejon, and Brough 2012) and P2X7R
(Sperlágh and Illes 2014) have been implicated in both brain physiology and pathophysiology.
The role of the inflammasome in CNS is reviewed in (Walsh, Muruve, and Power 2014). The
neurobiology of P2X7R, which is required for activation of inflammasome of and IL-1b release,
and therefore, pertinent to this thesis research, is discussed below.
1.5.2

P2X7R

P2X7R belongs to a large family of purinergic plasma membrane receptors (Burnstock 2008;
Kumaria, Tolias, and Burnstock 2008; Tsuda, Tozaki-Saitoh, and Inoue 2012).P2X7R is ATP
gated, nonselective cation channels, of ionotropic P2X receptors. The structural motif of P2X7R
consists of two transmembrane domains (TM1, TM2), a short intracellular N- terminal domain, a
large, glycosylated, cysteine-rich extracellular loop, and an intracellular C-terminal domain.
Molecular physiology of P2X7R is reviewed in (Sperlágh and Illes 2014). P2X7R is expressed in
a variety of different cell types including immune effector cells and cells of CNS. Apart from
being a low-affinity receptor of ATP (which itself is a neurotransmitter in CNS apart from its
normal role of being the source of energy), P2X7R also serves to release IL-1b from its cell
(Kanellopoulos and Delarasse 2019; Miras-Portugal et al. 2017).

28

1.5.2.1 Neurobiology of P2X7R
P2X7R is a low-affinity ATP receptor associated with IL-1b release best studied in microglia
and macrophages (Sanz and Virgilio 2000; Pelegrin, Barroso-Gutierrez, and Surprenant 2008).
Endogenous P2X7R is expressed in various cell types of CNS including neurons, astrocytes and
microglia (Sperlagh et al. 2006). Exact physiological expression profile of P2X7R in CNS
particularly in neurons is ambiguous mainly due to issues with antibody specificity and presence
of many alternative splice variant which produces different isoform of the receptor. These factors
led to several issues of using commercially available antibodies to delineate the distribution of
P2X7R expression due to pseudo-immunoreactivity in the P2X7R KO mice and several
physiological stimuli causing changes to its expression (Sperlagh et al. 2006; Sperlágh and Illes
2014). GFP tagging downstream of P2X7R promoter clearly shows the expression of P2X7R
expression in both neurons and microglia of the hippocampus, particularly in DG subregion
(Engel et al. 2012). P2X7R modulates certain physiological function in CNS including synaptic
functions (discussed further in 1.4.2.2), neurogenesis (Leeson et al. 2019), memory and learning
(Labrousse et al. 2009; Domingos et al. 2018), and in the pathophysiology of neuroinflammation
and neurodegeneration (Le Feuvre, Brough, and Rothwell 2002; Cotrina and Nedergaard 2009;
Sperlágh and Illes 2014).
1.5.2.2 Relevance of P2X7R in E/I balance
The high expression levels of P2X7R observed in the hippocampus (Kamei et al. 2005; Engel et
al. 2012; Sebastián-Serrano et al. 2016) occurs in excitatory nerve terminals and colocalized with
VGLUT1 transporter of DG and CA3 region (Kamei et al. 2005). P2X7R is a low-affinity ATP
receptor and has roles in neurotransmitter release and other synaptic function (Miras-Portugal et
al. 2017). In particular, P2X7R activation regulates the release of both glutamate and GABA
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(Papp, Vizi, and Sperlágh 2004; Kamei et al. 2005). Overexpression of the P2X7R in
hippocampal brain slices decreases both sodium current amplitude and intrinsic neuronal
excitability, whereas P2X7R inhibition has the opposite effect (del Puerto et al. 2015) implying
P2X7R may modulate homeostatic E/I balance in the brain. P2X7R KO mice show impaired IL1β expression in the hippocampus of mice brain, where the mice demonstrated impaired
hippocampal based spatial memory (Labrousse et al. 2009).
P2X7R has been demonstrated to have paradoxical role in seizure and epilepsy (Engel et al.
2012). In patients with temporal lobe epilepsy, P2X7R antagonist, JNJ-47965567 suppressed
epileptic seizures and reduced gliosis (Jimenez-Pacheco et al. 2016). P2X7R levels were elevated
in intra-amygdala induced kainic acid injection, and seizure severity and hippocampal neuronal
damage were reduced by pharmacological antagonism of P2X7R (Mesuret et al. 2014; Engel et
al. 2012). Alongside, P2X7R antagonism (using pharmacological inhibitors - Brilliant Blue G,
AFC-5128, JNJ-47965567 and Tanshinone IIA sulfonate) in rats showed that the mean seizure
stage was lowered in PTZ induced kindling model than saline-treated rats. They also required
more PTZ injection compared to saline-treated rats to reach their first convulsive seizure (Fischer
et al. 2016). RNAi mediated P2X7R silencing in pilocarpine treatment reversed the increased
edema in the hilus, dentate gyrus, CA1, and CA3 of hippocampus, reduced mortality rate
following status epilepticus, increased the time to onset of a spontaneous seizure and reduced the
number of seizures compared to only pilocarpine treated rats (Amorim et al. 2017). Inhibiting
P2X7R activation had neuroprotective effects on the kainic acid mediated intra-amygdalar focal
onset status epilepticus of seizure and epilepsy (Henshall and Engel 2015).
However, on the contrary, in rats, P2X7R antagonism showed no significant difference in seizure
severity with PTZ induced acute seizure or differed in seizure threshold in maximal electroshock
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seizure threshold test (Fischer et al. 2016). Alternatively, P2X7R KO mice showed elevated
seizure susceptibility in pilocarpine-induced seizures (Kim and Kang 2011).
The evidence for its role in seizure and epilepsy is paradoxical.
1.6

COX-2 as a possible candidate of IL-1b signaling in the maintenance of neuronal

excitation
IL-1b modulates its physiological and inflammatory functions m via several downstream
mechanisms of which some of the important downstream mechanisms are induction of specific
gene expression and synthesis of cyclooxygenase2 (COX-2), inducible nitric oxide synthase etc.
causing PGE2 production, platelet activation, and nitric oxide production, causing pain,
vasodilation, hypotension and fever response (Dinarello 2002; 2009; 2018). In the following
section, relationship between IL-1b and COX-2 is reviewed.
Several inflammatory functions of IL-1b are mediated via a potent lipid mediator called
prostaglandin (PG). PG are derived from arachidonic acid. The first committed step in their
synthesis is catalyzed by heme-containing bis-oxygenases, Cyclooxygenase (COX), officially
known as prostaglandin-endoperoxide synthase (PTGS). It controls a large spectrum of
functions, ranging from physiological activities, such as blood flow and gastric acid secretion to
pathophysiological functions as the primary mediators of innate immunity working as one of the
body’s first lines of defense against infection and allergy (Ricciotti and FitzGerald 2011).
Cyclooxygenases (COXs) are two isoforms, COX-1 and COX-2. COX-2 is one of the key
candidates in CNS with a multitude of functionalities involving neuroinflammation and
neurodegeneration including involvement in acute seizure and epilepsy (Hewett, Bell, and
Hewett 2006). COX-2 has been seen to work downstream of IL-1b signaling in systemic
inflammation including functions in CNS (Dinarello 2009; 2018). This section will describe the
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role of COX-2 in CNS in relevance to my dissertation study, discuss link between COX-2 and
IL-1b signaling and regulation of prostaglandin production via COX-2 downstream of IL-1b
signaling which may affect the neuronal E/I balance.
1.6.1

Cyclooxygenase-2 (COX-2)

COX enzymes catalyze cellular reactions by which Arachidonic acid plus two molecules of O2
are converted to ProstaglandinG2 (PGG2) and a peroxidase reaction via which PGG2 is reduced to
ProstaglandinH2 (PGH2).
Cyclooxygenase-1 (COX-1) is constitutively expressed throughout the body, whereas
constitutive COX-2 expression is limited to certain tissues. Constitutive expression of COX-2 in
CNS is found in certain subpopulations of glutamatergic neurons, but it is not constitutively
detected in glial population (Hewett, Bell, and Hewett 2006). For this study, the primary focus
will be on expression and functionalities of COX-2 in CNS particularly associated with neuronal
hyperexcitation.
1.6.1.1 COX-2 expression in CNS
Basal expression of COX-2 mRNA and protein are observed in number of brain region, with
higher expression levels in hippocampal and cortical neurons (Yamagata et al. 1993).
Constitutive COX-2 expression in rodent brain was characterized by Breder et al (Breder,
Dewitt, and Kraig 1995). It is primarily expressed by pyramidal neurons of the hippocampus,
cortical layers 2/3, lateral amygdala, certain hypothalamic nuclei and in spinal dorsal and ventral
horns and in the dorsal root ganglia, where it has been described to be present in the postsynaptic
dendritic spine (Kaufmann et al. 1996; Chen, Magee, and Bazan 2002). Constitutive neuronal
COX-2 expression is directly correlated with synaptic activity, thus suppressing glutaminergic
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activity reduces COX-2 expression (Yamagata et al. 1993; Stark and Bazan 2011; Hewett et al.
2016).
Prostaglandins, lipid mediators produced from AA in COX dependent manner are expressed in
different cell types of CNS, neurons (Taylor et al. 2008), astrocytes (Holgado et al. 2000;
Takemiya et al. 2006), microglia (Pinteaux et al. 2002) including endothelial cells of the brain
(Parfenova et al. 2002).
1.6.1.2 Role of COX-2 in CNS
COX-2 in CNS physiology has been implicated in the regulation of neuronal excitability,
synaptic plasticity, pain sensitization and learning and memory. On the other hand, it plays a
complex role in neuroinflammatory and neurodegenerative diseases including cerebral ischemia,
multiple sclerosis, Parkinson’s Disease, Alzheimer’s disease and encephalopathies. This has
been extensively reviewed by others (Hewett, Bell, and Hewett 2006; Yang and Chen 2008;
Rojas et al. 2014). In the following section, I reviewed its role in acute seizure to better
understand how IL-1b-COX-2 link may mediate E/I balance.
1.6.1.3 Role of COX-2 in acute seizure
Seizure activity increases COX-2 mRNA and protein in CNS (Okada et al. 2001; Takemiya et al.
2006; Tu and Bazan 2003; Voutsinos-Porche et al. 2004; Claycomb, Hewett, and Hewett 2011;
Gong and Hewett 2018). Selective inhibition of COX-2 in seizure and epilepsy have yielded
varied results, in some instances attenuating (Toscano et al. 2008) and in some other studies
enhancing seizure response (Tu and Bazan 2003; Dhir and Kulkarni 2006; Dhir, Naidu, and
Kulkarni 2006; Akula, Dhir, and Kulkarni 2008). Different inhibitors of COX-2 show different
seizure responses in PTZ induced acute seizure. Rofecoxib (selective COX-2 inhibitor) in diet
did not affect PTZ induced acute seizure but p.o rofecoxib treatment increased seizure severity in
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mice (Claycomb, Hewett, and Hewett 2011; 2012). Study done in rats with blood brain barrier
permeable COX-2 inhibitors, nimesulide (relatively COX-2 specific), celecoxib (selective COX2 inhibitor) or etoricoxib (selective COX-2 inhibitor) treatment given 1 hour prior to PTZ
injection showed only nimesulide attenuated PTZ induced seizure (Temp et al. 2017),
showing the varied effect of COX-2 inhibitors on acute PTZ- induced seizures are influenced by
timing and method of administration of drug.
Seizures are shown to induce prostaglandins within minutes in a COX-2 dependent manner (Zatz
and Roth 1975; Förstermann et al. 1982; Akarsu, Mamuk, and Comert 1998; Kim et al. 2008;
Yoshikawa et al. 2006) Many of these prostaglandins (PGE2, PGD2, PGF2) are shown to have
anticonvulsive properties (Förstermann et al. 1982; Akarsu, Mamuk, and Comert 1998; Kim et
al. 2008). On the other hand, non-neuronal cells also produce late-onset prostaglandin in kainic
acid-induced seizure model which when inhibited, blocked hippocampal neuron loss (Takemiya
et al. 2006). Anti-PGE2 antibodies attenuated PTZ-induced seizures in rats (Oliveira et al. 2008)
indicating the pro-convulsive effects of prostaglandins.
Previous results from my lab indicate that inhibition of COX-2 markedly increased susceptibility
of mice to seizure induction, suggesting that it may also contribute to the maintenance of the
innate seizure threshold (Claycomb, Hewett, and Hewett 2012) and COX-2 overexpression
increased seizure threshold (Gong and Hewett 2018). Role of COX-2 in seizure and epilepsy has
is paradoxical.
1.6.2

IL-1b as an upstream modulator of COX-2 In CNS

Early indication of IL-1b working upstream of COX-2 came from a study done in rats showing
that injection with recombinant IL-1b intra-peritoneally induced COX-2 mRNA in brain
vasculature (Cao et al. 1996). Subsequent studies showed that exogenous application of IL-1b
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increased COX-2 mRNA level and protein in primary hippocampal neuronal culture (Serou,
Decoster, and Bazan 1999), dorsal root ganglion cells (Ohnishi et al. 2019a), neuroblastoma cells
(Fiebich et al. 2000; Moolwaney and Igwe 2005), mice cortex (Moore, Olschowka, and
O’Banion 2004) and in blood vasculature of mice hypothalamus and cortex (Dunn et al. 2006).
IL-1b acting upstream of COX-2 has been shown to affect neuronal activity in cultured neurons
and slice preparation. For example, exogenous IL-1b stimulated the release of substance P from
cultured dorsal root ganglion (DRG) cells in a COX-2 dependent manner (Inoue et al. 1999).
Additionally, depolarization of hypothalamic parvocellular and magnocellular neurons and
hyperpolarization of GABAergic interneurons by exogenous IL-1b was blocked by selective
COX-2 inhibition, indicating a role of COX-2 in IL-1b dependent changes in neuronal
membrane potential (Ferri and Ferguson 2005). The effect of IL-1b on mEPSC amplitude was
blocked by selective COX-2 inhibition (Sang et al. 2005).
IL-1b stimulation caused induction of COX-2 and subsequent PGE2 synthesis in murine
astrocytes via Protein Kinase C and p38 and Extracellular signal-related Kinase (ERK1/2) of
MAPK pathway activation (Molina-Holgado et al. 2000). IL-1b-mediated increase in slow-wave
sleep (SWS) (hypothalamus driven sleep cycles) was blocked by the selective COX-2 inhibitors,
piroxicam, and NS-398 (Terao et al. 1998). IL-1b-dependent induction of COX-2 contributes to
hyperalgesia. In spinal cord neurons, central hyperalgesia due to peripheral inflammation was
mediated by COX-2-dependent increase in PGE2 which was blocked by intrathecal
administration of IL-1ra (Samad et al. 2001). Alongside, the anti-convulsive effects of IL-1b in
fully kindled rats were attenuated by the selective COX-2 inhibitor, piroxicam (Sayyah et al.
2005). Exogenous IL-1b induces COX-2 mRNA and PGE2 synthesis in cultured trigeminal
ganglia neurons and glia caused neuronal sensitization to pain (Neeb et al. 2011).
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Studies done till now and discussed here demonstrates role of exogenous application of IL-1b in
inducing COX-2 expression and function. As present study focuses on endogenous
neuromodulatory role of IL-1b, it is relevant to understand the difference between exogenous IL1b - COX-2 link v/s physiological role of IL-1b and any possible link to endogenous COX-2 in
CNS.
Rofecoxib, a selective inhibitor of COX-2, markedly enhanced the incidence of PTZ-induced
acute convulsive seizures, suggesting that its activity contributes to the maintenance of the innate
convulsive seizure threshold. Interestingly, rofecoxib did not enhance the susceptibility of IL1R1 KO mice to the pro-convulsive action of PTZ, raising the possibility that the two pathways
may be linked (Claycomb, Hewett, and Hewett 2012). No other studies are available to
demonstrate possible link between endogenous IL-1b and COX-2. It will be investigated in this
dissertation work.
1.7

Hippocampus – the region of interest

The hippocampal formation is a neuroanatomical structure of the limbic system of the brain
which consists of intricate connections between sensory and motor cortices. It is primarily
connected to the entorhinal cortex and is divided into the Dentate Gyrus(DG), the hippocampus
proper (subdivided in Cornu Ammonis (CA) 1, 2, and 3), and the Subicular complex (subiculum,
presubiculum, and parasubiculum). The hippocampus consists of unique and highly complex
projection patterns from one sub-region to another (Witter 1993). Classically it is described as
the unidirectional tri-synaptic excitatory neuronal circuit in the hippocampus. The primary input
to the hippocampus initiates from the entorhinal cortex, primarily to the granule cells of DG and
also to the pyramidal neurons of CA3 and CA1 via the Perforant Pathway. The granule cells
project to the CA3 subregion via the Mossy Fibers. The pyramidal neurons of CA3 projects via
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Association fibers to the contralateral CA3 and projects to the CA1 subfield via the Schaffer
collaterals (Witter 1993; Strange et al. 2014). The neurons in subicular formation are the target
for the pyramidal neurons of the CA1 subfield. The primary output from subiculum send
projection back to layers 5 and 6 of the entorhinal cortex. Studies have shown complex and
extensive networks of longitudinal and commissural projections are present in the hippocampus
(Witter 1993).
In addition to its role in spatial processing and episodic memory it also contributes to emotions,
motivation and in adult neurogenesis (Siebzehnrubl and Blumcke 2008; Knierim 2015).
Hippocampus is highly affected in neuroinflammatory conditions like ischemia and temporal
lobe epilepsy, neurocognitive deficit such as anterograde amnesia and vulnerable to
neuropsychiatric diseases such as depression and schizophrenia (Strange et al. 2014; Knierim
2015). For studies herein, hippocampus was selected as region of interest as it is the possible site
for studying neuromodulatory role of IL-1b in maintenance of seizure threshold. It also has
relevance in context of maintenance of seizure threshold.
1.7.1

Hippocampus – Its importance in the context of seizure threshold

This section will elaborate the importance of hippocampus in context of physiological function maintenance of seizure threshold and its relevance with seizure and epilepsy.
The hippocampus plays an important role in the process of seizure genesis and epileptogenesis as
reviewed by (Sloviter 1994; Sutula et al. 1998; Ang, Carlson, and Coulter 2006; Fujita et al.
2014; Sloviter 2005). The DG, in particular, is an important control point for much of the
information entering the hippocampus from the entorhinal cortex and it is thought to be involved
in the reduction in seizure threshold in the epileptic brain (Gloveli, Schmitz, and Heinemann
1998; Sutula and Dudek 2007; Houser et al. 2012). Positive fMRI-BOLD signal analysis showed
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that the DG was activated immediate prior to seizure onset (Brevard et al. 2006). Alongside,
extreme susceptibility of the hippocampus to PTZ induced seizure is shown with an early
immediate increase in c-Fos level and immediate increase in other neuropeptides (Yount,
Ponsalle, and White 1994).
1.7.2

Hippocampus - The possible site of endogenous IL-1b signaling and function in

murine brain
IL-1b is involved in several physiological activities or nervous system, particularly in regions of
hypothalamus (fluid and hormone regulation, sickness behavior), hippocampus (long term
potentiation, learning, and memory) and in spinal cord (pain sensitization and analgesia)
(Summy-Long et al. 2006; 2008; Watt and Hobbs 2000; Schneider et al. 1998; Goshen et al.
2007; Wolf et al. 2007; Goshen and Yirmiya 2009; Lynch 2014).
IL-1β ligand and its receptor is constitutively expressed in hippocampus (Lechan et al. 1990;
Kaneko et al. 2006; Viviani et al. 2014; French et al. 1999). P2X7R, the purinergic ATP
receptor, implicated in IL-1β release is expressed in several cell types of brain and spinal cord
(Sperlagh et al. 2006) and found to be involved in the physiological release of neurotransmitters
in the hippocampus (Kamei et al. 2005). COX-2, identified as a possible downstream candidate
for IL-1β in the maintenance of neuronal excitation, is constitutively expressed in CNS by CA3
neurons of the hippocampus (Yamagata et al. 1993) and induced in DG neurons via PTZ induced
convulsive seizure (Claycomb et al. 2011).
Together, these studies support the importance of understanding the molecular mechanisms
underlying the neuromodulatory roles of IL-1β in the hippocampus.
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1.8

Specific aims

Studies in this dissertation work are focused on the investigation of the molecular mechanism of
physiological IL-1b release in neurons and how it may contribute to the maintenance of the
excitatory/inhibitory balance in hippocampal neurons. The following specific aims are
hypothesized based on a previous study from our research group which showed neuromodulation
by IL-1b signaling in the maintenance of seizure threshold (Claycomb, Hewett, and Hewett
2012). The goal of Aim 1 is to confirm and extend previous studies implicating the role of
endogenous IL-1β signaling in acute seizures (Chapter 2). The goal of Aim 2 is to investigate the
molecular mechanism governing physiological IL-1β release in the hippocampus and its role in
the regulation of neuronal hyperexcitation. To investigate parallel aspects of this key question,
this aim is divided further into in vivo and in vitro studies (Chapter 3). The goal of Aim 3 is to
investigate the possibility of effect of excitatory neuronal activity on IL-1b expression and
signaling and subsequently analysis the possible link between neuromodulatory IL-1β signaling
and downstream cyclooxygenase-2 (COX-2) expression and/or activity in the neurons of the
hippocampus. This aim is also studied both in vivo and in vitro (Chapter 4). As primary
hippocampal neurons were utilized for in vitro studies as mentioned in Chapter 3 and 4, details
of the culturing procedure were documented in Chapter 5.
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1.8.1

Specific Aim 1: To demonstrate the reproducibility of the effect of IL-1RI gene

deletion on the acute PTZ seizure response (chapter 2).
For studies in Aim 1, the PTZ acute seizure model is used to corroborate the results
demonstrating an increased seizure severity and incidence of convulsions in mice lacking IL-1
signaling capability. The hypothesis is that IL-1β contributes to the maintenance of seizure
threshold and thus, more severe seizures will be elicited in mice lacking IL-1 signaling receptor.
The study will also assess the difference in latency to PTZ induced convulsion and mortality
associated with convulsions in between genotypes.
1.8.2

Specific Aim 2: To investigate the molecular mechanism governing IL-1β expression

and release in neurons of the hippocampus (chapter 3).
Canonical processing and release of IL-1β protein is known to be ATP-dependent via P2X7
receptor (P2X7R) activation. Although studied in other cell systems, the mechanism of IL-1β
release in neurons is yet to be understood. To assess this in mouse hippocampus, whether IL-1β
release occurs through a similar mechanism, the brain permeable P2X7R antagonist, JNJ47965567 will be given to CD-1 mice to determine if neuronal IL-1β release is blocked through
immunohistochemical analysis. Secondly, using in vitro system (cultured hippocampal neurons),
P2X7R dependent IL-1β release in the hippocampal neurons and its effect on excitatory neuronal
activity will be studied using P2X7R antagonism. This system will also be exploited to
investigate the subcellular location of IL-1β protein in the hippocampal neurons. Finally, seizure
threshold will also be compared between mice dosed with the antagonist and the vehicle.
Thus, these studies will allow us to determine i) whether P2X7R activation is required for
constitutive IL-1β release, ii) to determine which neuronal populations may be responsible for
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IL-1β production in hippocampus and iii) Role of P2X7R possibly via blocking of IL-1β release
in modulation of the excitatory-inhibitory (E/I) balance both in vivo and in vitro.
1.8.3

Specific Aim 3: To investigate the role of excitatory neuronal activity on IL-1β

expression/signaling function in neurons of the hippocampus: possible link between IL-1β
signaling and Cyclooxygenase-2 (COX-2) expression (Chapter 4).
Specific Aim 3.1:

To investigate if intensive neuronal excitation stimulates/alters IL-1β

expression/signaling components in the mice hippocampus/hippocampal neurons.
The possibility of IL-1b release regulating changes in neuronal activity will be investigated in
the prior chapters. This raises the possibility that excitatory neuronal activity may act as an
endogenous stimulus for IL-1β mRNA and protein induction. To assess this in vivo, changes in
IL-1β mRNA and protein, its signaling components in the hippocampus will be determined in a
time-course study following acute convulsive seizures in male CD-1 mice. The activitydependent changes in IL-1β protein expression will also be assessed in cultured hippocampal
neurons.
Specific Aim 3.2:

To investigate the possible link between IL-1β signaling and

cyclooxygenase-2 (COX-2) expression and/or activity in neurons of the hippocampus.
Secondly, to understand if constitutive IL-1b signaling regulates COX-2 expression and/or
activity in the hippocampal formation, constitutive/induced COX-2 expression and/or activity
will be studied in mice genetically lacking the receptor, IL-1R1. It is hypothesized, if IL-1b
signaling is involved in regulating neuronal COX-2 expression and/or activity in the
hippocampus, COX-2 expression and/or activity will be attenuated or ablated in the hippocampal
formation of mice lacking functional IL-1 signaling. Similarly, link between physiological IL-1b
and COX-2 will be assessed in vitro using IL-1R1 antagonism in hippocampal neurons.
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1.8.4

Culturing murine primary hippocampal neurons (Chapter 5).

A comparable system is required for the in vitro studies in chapter 3 and 4. Murine primary
hippocampal neurons are cultured and maintained as a system to assess the molecular
mechanisms associated with physiological IL-1β release and its neuromodulatory functions. As
this system will be introduced in our laboratory system, detailed characterization will be done to
understand and obtain comprehensive knowledge of this specific culture system and of the IL-1β
ligands and it’s signaling components in vitro to ensure success of the above-mentioned
experimentation.
1.9

Significance

Epilepsy is characterized by recurrent seizures that result from abnormal synchronous firing of
specific population(s) of neurons in brain (McNamara 1999; Hitiris 1996). Epilepsy is one of the
most important brain diseases that occurs due to imbalance in homeostatic E/I balance. It is often
associated with cognitive and learning deficits, psychosocial problems, and sudden unexplained
death (Aarts, Binnie and Smit 1984; Hermann et al. 2001; Beghi et al. 2006; Surges et al. 2009).
Although many current antiepileptic drugs affect excitatory or inhibitory neurotransmission
directly, their use can be limited by adverse side effects. Moreover, epilepsy in a large number of
patients is refractory to antiepileptic drug (Shorvon 1996; Löscher et al. 2009) making epilepsy
difficult to treat and manage (Loscher et al. 2006; 2011). Therefore, researchers are in a constant
look-out for new therapeutic targets. Along with several neurotransmitters in the brain which are
affected by seizure and epilepsy, several neuromodulators have been identified which plays a
role in the physiological regulation of these neurotransmitters and thus, indirectly in maintenance
of physiological E/I balance. Therefore, these neuromodulators can also be critical therapeutic
targets and should be well researched for their physiological and pathophysiological functions.
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IL-1β signaling pathway has been widely studied and well-characterized primarily in
neurodegenerative and neuroinflammatory diseases. Alongside, studies have also indicated
several physiological roles of IL-1β in the CNS that are independent of its role as an immune
modulator, including endogenous neuromodulatory role in the maintenance of E/I balance.
Previous studies from our lab showed IL-1β regulates the innate seizure threshold,
which arguably is a reflection of the homeostatic balance between excitation and inhibition
(E/I) in the brain. However, much is unknown about its physiological cellular source(s), release
mechanism and the functional significance of this release in maintenance of E/I balance. My
dissertation studies will focus on these aspects. A better understanding of this endogenous
neuromodulatory IL-1β signaling pathway in the brain that maintains the innate seizure threshold
(physiological excitatory/inhibitory balance) may facilitate the development of novel therapies
that may alter cellular pathways associated with seizures and epilepsy.
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1.10

Details of common and experiment-based reagents required for the study.

Name of reagent
(common)
Ultrapure water

Company

Catalog
no.

Invitrogen

10977-015

PharmacoAAPER
Avator
Performance

Ethanol
Methanol

111000200
3004-19

Storage

Final
conc.

0.5 %

0.02%

Room
temperature
Room
temperature
Room
temperature

Sodium azide (NaN3)
0.5% sol.

Aqua Solutions

8564

4℃

PBS (in vitro use)

Invitrogen

21-040-CV

Room
temperature

Recombinant murine IL-1β

Peprotech Inc.

211-11B

4℃

Name of reagent

Initial
Conc.

Company

Catalog no.

Storage

Henry-Schein Inc.

NDC11695-6776-2

Room temperature

ProMega Corporations

M7122

-20℃

ProMega Corporations

U1330

-20℃

DMSO

Fisher Chemicals

D128-500

Room temperature

MgCL2

ProMega Corporations

A351H

-20℃

GoTaq polymerase

ProMega Corporations

M300D

-20℃

Agarose

Invitrogen (LifeTech)

16500-500

Room temperature

Omnipure(Calbiochem)

4410

Room temperature

LifeTech (Ambion, RNA)

15596018

Room temperature

Isopropanol

Fisher Chemicals

BP2618-500

Room temperature

Chloroform

Fisher Chemicals

BP1145-1

Room temperature

1x M-MLV reaction buffer

ProMega Corporations

M1701

-20℃

oligo (dT) primers

ProMega Corporations

C110A

-20℃

dNTPs

ProMega Corporations

U1330

-20℃

Reverse transcriptase M-MLV
qPCR

ProMega Corporations

M1701

-20℃

Thermo Fisher

4304437

-20℃

Anesthesia
Isoflurane
Genotyping
5X Green GoTaq Flexi Buffer
(PCR reaction mix)
Deoxyribo-nucleotide triphosphate
(dNTP)

Ethidium Bromide
RNA isolation and cDNA synthesis
TriZol reagent

TaqMan™ Universal PCR Master
Mix
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Name of reagent

Company

Catalog no.

Storage

Concentration

Sucrose

EMD

SX1075

Room
temperature

Paraformaldehyde

EMD

19208

4℃

Acetone

Fisher
Chemicals

A18-1

OCT

TissueTek

4583

FisherBrand
Superfrost
Plus

12-550-15

BioRad

161-0407

Room
temperature

005-000-121

-20℃

60mg/ml

017-000-121

-20℃

60mg/ml

001-000-161

4℃

D-3571

-20℃

EMS

AF1

Room
temperature

Corning

2955-245

Room
temperature

Gibco

21-040-CV

Room
temperature

ThermoFisher

23225

Room
temperature

Roche

11836153001

Acros

12227-1000

Mini Protean TGX Gel(4-15%
gradient gel)

BioRad

456-1084

4℃

All blue precision marker

BioRad

161-0373

-20℃

Pink Blue precision marker

BioRad

161-0374

-20℃

Running buffer(10X
Tris/Glycine/SDS buffer)

BioRad

1610772

Room
temperature

Transfer buffer(10X
Tris/Glycine buffer)

BioRad

1610771

Nitrocellulose membrane

BioRad

162-0112

Immunofluorescence

glass slides
Triton X
Normal Goat serum
Normal Donkey serum
Bovine serum albumin
DAPI
Mounting media (Citifluor
mountant solution)
Coverslip

JAX Immuno
Research
JAX immuno
Research
JAX Immuno
Research
Life
technology

Room
temperature
Room
temperature

Protein estimation

1X PBS
BCA protein
estimation kit
Western Blot
Complete Protease
Inhibitor
IodoA
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4℃ (aliquoted in
-20℃)
4℃ (aliquoted in
-20℃)

Room
temperature
Room
temperature

10X
10X

LiCor Odyssey Blocking
buffer(TBS)

LiCor

927-50000

4℃

Tween 20

BioRad

170-6531

Room
temperature

Sodium dodecylsulphate

BioRad

161-0302

Room
temperature

MLB00C

4℃

895347

4℃

Sigma

18280

Room
temperature

PGE2 ELISA kit

Cayman
Chemicals

500141

-20℃

EDTA(0.5M pH 8)

Invitrogen

AM9260G

EMD

PX1565-1

ELISA
Quantikine IL-1β ELISA kit
Cell lysis buffer 2
Indomethacin

KH2PO4

Name of reagent

R&D
systems
R &D
systems

Room
temperature
Room
temperature

Company

Catalog no.

Storage

Sigma

P6500

-20℃

JNJ-47965567 (in vivo use)

Tocris Biosciences

5299

4℃ (dissolved in 30%
SBE)

JNJ-47965567 (in vitro use)

Tocris Biosciences

5299

-20℃ (stock solution)

Medchem

HY-17031

Room temperature

Bicuculline methobromide

Enzo Life Sciences

BMLE A109-0050

-20℃ (stock solution)

APV

Tocris Biosciences

106

-20℃ (stock solution)

Y-VAD-CHO

Cayman chemicals

10014

-20℃ (stock solution

NMDA

Sigma Aldrich

M3262

4℃ (stock solution)

MK-801

Research Biochemicals

M107

-20℃ (stock solution)

Pentylenetetrazol

Sulfobutylether-β-cyclodextrin

Table 1.2: List of reagents required for the dissertation research (with specifics).
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Primary
Antibody
(IHC)

Host

Companies

Catalog no.

RRID no.

Initial
Conc.

Dilution
factor

IL-1β (H-153)

Rabbit

Santa-Cruz
Biotechnology

sc-7884

AB_2124476

200 µg/ml

1:100

Hamster

BioRad Laboratories

MCA2352GA

AB_2125035

1 mg/ml

1:100

Rat

BioRad Laboratories

MCA4713GA

AB_10547604

1 mg/ml

1:100

Mouse
Rabbit
Rabbit
Rabbit

MilliporeSigma
Alomone Labs
Cayman Chemicals
Thermo-Fisher

MAB377
APR012
160106-1
PA5-38284

AB_2298772
AB_2040074
AB_10077935
AB_2816657

1 mg/mL
0.8 mg/ml.
500 µg/ml
1mg/ml

1:100
1:200
1:250
1:250

Primary
Antibody
(ICC)

Host

Companies

Catalog no.

RRID no.

Initial
Conc.

Dilution
factor

IL-1β (H-153)

Rabbit

sc-7884

AB_2124476

200 µg/ml

1:100

IL-1R1
P2X7R
NeuN

Hamster
Rat
Mouse

MAB7711
MCA4713GA
MAB377

AB_2125035
AB_10547604
AB_2298772

1:250
1:250
1:100

MAP-2

Mouse

M1406

AB_477171

Synaptophysin
Synaptophysin
(D-4)

Rabbit

ab14692

AB_301417

1 mg/ml
1 mg/ml
1 mg/mL
not
provided
0.65 mg/ml

sc-17750

AB_628311

200 µg/ml

1:500

MA1-046

AB_2092361

1mg/ml

1:500

ab12093

AB_298846

0.7mg/ml

1:500

sc-99031

AB_2125293

200 µg/ml

1:200

sc-8197

AB_2146726

200 µg/ml

1:200

ab33299

AB_732498

0.5mg/ml
Not
provided
500 µg/ml

1:500

IL-1R1
(JAMA147)
P2X7R
(Hano43)
NeuN
P2Y12
COX-2
p-IRAK-1

MyD88
(F-19)
GABAaa/1

Rabbit

Santa Cruz
Biotechnology
BioRad laboratories
BioRad laboratories
Millipore
Thermo-Fisher
Scientific
AbCam
Santa Cruz
Biotechnology
Thermo-Fisher
Scientific
AbCam
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
AbCam

GFAP

Mouse

Genetex

GTX73615

AB_378828

COX-2

Rabbit

Cayman Chemicals

160106

AB_10077935

Host

Companies

Catalog no.

RRID no.

Initial
conc.

Dilution
factor

Donkey

Jackson
ImmunoResearch
Labs

711-545-152

AB_2313584

7.5µg/ml

1:500

Goat

BioRad Laboratories

STAR104D405GA

AB_10846820

1 mg/ml

1:500

Goat

BioRad Laboratories

STAR104D649GA

AB_10845149

1 mg/ml

1:500

Goat

ThermoFisher
Scientific

A21049

AB_2535717

2mg/ml

1:500

Goat

Jackson
ImmunoResearch
Labs

115-095-146

AB_2338599

7.5µg/ml

1:500

Mouse

PSD-95

Mouse

PSD-95

Goat

IL-1RacP

Rabbit

Secondary
Antibody
(IHC)
Anti Rabbit
Alexa Fluor
488
Anti Hamster
DyLight 405
Anti Rat
Dylight 549
Anti Mouse
Alexa Fluor
350
Anti Mouse
Fluorescein
(FITC)

Goat
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1:1000
1:500

1:50
1:250

Secondary
Antibody (ICC)
Anti Rabbit
Alexa Fluor
488
Anti Mouse
Alexa Fluor
594
Anti Mouse
Alexa Fluor
488
Anti Goat
Alexa Fluor
594
Anti Rabbit
Alexa Fluor
488
Anti Hamster
DyLight 405
Anti Rat
Dylight 549

Antibody
(for WB)
IL-1β
β-actin
LiCor
Odyssey
Anti Mouse
IR dye 800
CW(for WB)
LiCor
Odyssey
Anti Rabbit
IR dye 680
LT (for WB)

Host
Donkey
Donkey
Donkey
Donkey
Goat

Companies
Jackson
ImmunoResearch
Labs
Jackson
ImmunoResearch
Labs
Jackson
ImmunoResearch
Labs
Jackson
ImmunoResearch
Labs
Jackson
ImmunoResearch
Labs

Catalog no.

RRID no.

Initial
conc.

Dilution
factor

711-545-152

AB_2313584

7.5µg/ml

1:500

715-585-150

AB_2340854

7.5µg/ml

1:500

715-545-150

AB_2340846

7.5µg/ml

1:500

705-585-147

AB_2340433

7.5µg/ml

1:500

111-545-144

AB_2338052

7.5µg/ml

1:500

Goat

BioRad

STAR104D405GA

AB_10846820

1 mg/ml

1:500

Goat

BioRad

STAR104D649GA

AB_10845149

1 mg/ml

1:500

Company

Catalog no.

RRID no.

Initial
conc.

Dilution
factor

AbCam

ab9722

AB_308765

1mg/ml

1:500

Sigma-Aldrich

A5441

AB_47644

Not
provided

1:4000

Goat

LI-COR
Biosciences

926-32210

AB_621842

1mg/ml

1:10000

Goat

LI-COR
Biosciences

926-68021

AB_10706309

1mg/ml

1:20000

Host
AntiRabbit
AntiMouse

Table 1.3. List of antibodies utilized in the dissertation study (with specifics).
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Reagents

Company

Catalog no.

Storage

Ara-C

Sigma

C-6645

4℃ (aliquoted in -20℃)

B-27(50X) (with AO)

Gibco

17504-055

-20℃

Beta-mercaptoethanol

Gibco

21985-023

4℃

Boric acid

EMD

BX0865-1

Room temp.

Corning

25-055-CV

Room temp.

Gibco

35050-06

room temp.

Corning

21-021-CV

Room temp.

Cell culture grade H2O
Glutamax
Hanks Balanced Salt
Solution
HEPES

Corning

25-060-CL

Room temp.

Horse serum

Gibco

26050-088

4℃ (aliquoted in -20℃)

L-glutamine

Gibco

25030-081

-20℃

Neurobasal A media

Gibco

10888-022

4℃

Penicillin

Gibco

15140-122

-20℃

Poly-L-lysine

Sigma

P9155

Room temp. (aliquoted in -20℃)

Sigma-Aldrich

221732

Room temp.

Gibco
Mediatech
Cellgro
Mediatech
Cellgro

15070-063

-20℃

25-900-CL

Room temp.

25-050-CL

-20℃

Sodium tetraborate
Streptomycin
Trypan Blue
Trypsin

Table 1.4: List of reagents required for the culturing neurons (with specifics).

qPCR probes(FAM-MGB)

Catalog no.

Company

Storage

IL-1β

Mm00434228_m1 Thermo Fisher Applied Biosystems

-20℃

IL-1R1

Mm00434237_m1 Thermo Fisher Applied Biosystems

-20℃

IL-1RaP

Mm00492638_m1 Thermo Fisher Applied Biosystems

-20℃

COX-2

Mm00478374_m1 Thermo Fisher Applied Biosystems

-20℃

P2X7R

Mm00440581_m1 Thermo Fisher Applied Biosystems

-20℃

Caspase-1

Mm00438023_m1 Thermo Fisher Applied Biosystems

-20℃

c-Fos

Mm00487425_m1 Thermo Fisher Applied Biosystems

-20℃

β-actin

Mm01205647_m1 Thermo Fisher Applied Biosystems

-20℃

Table 1.5: Details of qPCR probes for mRNA studies (with specifics).
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Specific Aim 1: To demonstrate the reproducibility of the effect of IL-1RI gene deletion on the
acute seizure response.

Synopsis
Previous results from this research laboratory demonstrated that inactivation of the genes for
interleukin-1β (IL-1β) or its signaling receptor sensitized mice to convulsant properties of
pentylenetetrazol (PTZ), suggesting that constitutive presence of this cytokine contributes to the
maintenance of the innate seizure threshold in the normal brain (Claycomb, Hewett, and Hewett
2012). This provided compelling evidence to support the premise of this dissertation that IL-1β
functions as an endogenous neuromodulator that modulates neuronal activity in the brain that is
associated with convulsive seizures. As this research investigated physiological localization of
IL-1b in the hippocampus of murine brain and to characterize the role of IL-1b release in the
regulation of the excitation/inhibition balance, it was essential to test the reproducibility of the
primary concept on which the central hypothesis of the specific aims (Aims 2 and 3) are based.
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Chapter 2
Effect of IL-1RI gene deletion on PTZ induced acute seizure
response: Neuromodulatory role of IL-1β in maintenance of E/I
balance - revisited.

Results from this chapter are part of the submitted manuscript: P2X7-dependent constitutive Interleukin-1β release from
pyramidal neurons of the normal hippocampus: Evidence for a role in maintenance of brain homeostasis. Spandita S.
Dutta, Torsten Wöllert, Sandra J. Hewett, and James A. Hewett. Manuscript submitted.
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2.1

Summary

Interleukin-1β (IL-1β) is well-characterized as a proinflammatory cytokine. Within the central
nervous systems (CNS), however, it is known to modulate certain physiological functions. In this
regard, function of physiological IL-1β signaling in acute seizure was re-examined using mice
with genetic disruption of IL-1β signaling receptor,IL-1R1, and modeling PTZ induced acute
seizure. In the PTZ induced acute seizure model, the severity and incidence of acute convulsive
seizures was higher in mutant Il1r1 (KO) mice compared to their respective wildtype littermates.
This result reconfirmed previous finding from this lab indicating IL-1β possesses anti-convulsant
properties and implying role of endogenous IL-1β in maintenance of seizure threshold.

2.2

Introduction

The role of IL-1β as a neuromodulator in seizure and epilepsy remains controversial. For
example, while some evidence suggests that IL-1β possesses pro-convulsant properties (A
Vezzani et al. 1999; 2000; Plata-Salamán et al. 2000; Heida, Moshé, and Pittman 2009; Mattia
Maroso et al. 2011), other studies are consistent with an anticonvulsive function of IL-1β (Miller
and Turner 1990; Sayyah et al. 2005). This may be related, at least in part, to the model or
approach used (Pinteaux, Trotter, and Simi 2009). Of particular relevance to this dissertation, our
previous results demonstrated inactivation of the genes for interleukin-1β (IL-1β) or its signaling
receptor, IL-1R1, sensitized mice to convulsant properties of pentylenetetrazol (PTZ), suggesting
that constitutive release of this proinflammatory cytokine contributes to the maintenance of the
excitatory-inhibitory (E/I) balance in the normal brain (Claycomb, Hewett, and Hewett 2012).
Thus, the goal here is to confirm and extend previous studies implicating endogenous IL-1β
signaling in acute seizures.
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2.3

Materials and methods

2.3.1

Mice

2.3.1.1 Maintenance: Colonies of mutant IL-R1 mice in C57BL/6J background (Maliszewski et
al. 1997) were established from breeders obtained from The Jackson Laboratory (Stock #003245).
All mice were housed on a 12-hour light/dark schedule in the AAALAC-accredited laboratory
animal care facility at Syracuse University. Cages contained Enrich-o’Cob bedding (The
Andersons Lab Bedding Products, Andersons Inc.) and provided one-pass, low-velocity, total
volume filtered air exchange under direct exhaust ventilation (OptiMICE®, Animal Care Systems,
Inc.). The environment of the facility was controlled for temperature and humidity and standard
mouse chow and water were provided ad libitum. Animal procedures were conducted in
accordance with the National Institute of Health (NIH) guidelines for the use of experimental
animals and were approved by the Syracuse University Institutional Animal Care and Use
Committee (IACUC). All mice were handled for mock injections for 7 days prior to the
performance of the actual experiment to habituate the mice to handling during injection
mechanism.
2.3.1.2 Breeding: Male (10-15 weeks old) wildtype (WT or +/+) and mutant (KO or -/-)
littermates for studies were derived from filial heterozygous (Het or +/−) breeding units that
were obtained from parental crossing WT females with male KO mice. Heterozygotic and female
offspring from these crossings were removed at weaning and male +/+ and -/- littermates were
housed 3-4 per cage until they reached adulthood, to have a similar representation in each cage.
The above breeding and caging strategy followed a previous study (Claycomb, Hewett, and
Hewett 2012) to control for potential non-specific differences in environmental or genetic
factors.
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2.3.2

Genotyping

2.3.2.1 Tail biopsies and DNA extraction: Mice pups were weaned between 21-28 days of birth
(Animal protocol submitted and approved by IACUC, Syracuse University, protocol no #14-013
and 17-010), their ear punched for identification and tail biopsied for genotyping. DNA from the
tail biopsies were extracted using 180µl lysis buffer (25mM NaOH and 2mM EDTA) at 95°C for
30 min and neutralized with 180µl neutralization buffer (40mM Trizma base) and stored at 4°C
for short term storage prior to use.
2.3.2.2 PCR: All genotyping was performed through PCR analysis of tail genomic DNA
samples using allele-specific primers [(50µM stock), Integrated DNA technologies)]. PCR was
run following Protocol 27489 (The Jackson Laboratory) with mixing 5µl DNA and 20µl PCR
master mix (Table 2.1). DNA sequence of the allele-specific primer were, common, 5’-CCG
AAG AAG CTC ACG TTG TCA AG-3’(forward) and wildtype specific 5’-GAG TTA CCC
GAG GTC CAG TGG-3’ (backwards) and knock out (KO) or mutant specific 5’-GAA TGG
GCT GAC CGC TTC CTC-3’ (backwards).
WT reaction
Master mix
Ultrapure H2O
PCR reaction
mix
Primers
(WT+all)
Deoxyribonucleotide
triphosphate
DMSO
MgCL2
Taq polymerase

Initial
conc.
5X

Amount in one
reaction (ml)
10
5

5mM
each
100mM

0.5

25mM
50 units/ml

0.25
2
0.2

KO reaction
Master mix
Ultrapure H2O
PCR reaction
mix
Primers
(KO+all)
Deoxyribonucleotide
triphosphate
DMSO
MgCL2
Taq polymerase

2

Table 2.1: Details of components of PCR Master Mix
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Initial conc.

5X

Amount in one
reaction (ml)
9.75
5

5mM
each
100mM

2
0.5

25mM
50 units/ml

0
2.5
0.2

2.3.2.3 Agarose gel electrophoresis: The PCR product was then visualized using agarose gel
electrophoresis. 2% agarose gel was made in 1X TAE buffer (50X TAE buffer stock was made
with 242g tris base, 14.6 EDTA, 57.1ml glacial acetic acid, and volume made up to 1-liter
ultrapure water) and 1µl ethidium bromide was added to the 50ml gel to detect DNA. 10µl of
DNA was loaded in each lane and ran with DNA Kb ladder and pre-determined known samples
of WT, KO, and het samples. Electrophoresis was conducted at 90V for 30 min and the gel is
photographed with the Licor documentation system LiCor Odessey Fc (OFC-0116) at 600nm.
2.3.3

Pentylenetetrazol induced acute seizure paradigm

Pentylenetetrazol is a Gamma amino butyl acid (GABA) A receptor antagonist that triggers
neuronal excitation indirectly through disinhibition. Pentylenetetrazol (PTZ) was aliquoted in
dark tubes and kept in -20°C freezer in boxes with desiccant for long term storage. Before use,
an aliquot of PTZ is brought to room temperature, weighed and dissolved in 0.9% saline, steriled
through syringe filter and administered intraperitoneally (i.p.) in a volume of 0.3ml/0.003kg and
seizure behavior scored using our 5 point severity scale as described previously: 0, normal
behavior; 1, hypo-mobility; 2, myoclonus; 3 and 4, convulsion without and with loss of righting,
respectively (Claycomb, Hewett, and Hewett 2011). Additionally, convulsion latency measured
in seconds (time for onset of convulsive behavior), the incidence of convulsion (% of mice
exhibiting convulsion, score ≥3), and mortality (% of mice exhibiting convulsion associated
death) were also quantified for this study.
2.3.3.1 Dose-response study: A limited dose-ranging study was performed in C57BL/6J wildtype male mice to determine the dose of PTZ for studies with this strain. Male wildtype
C57BL/6J mice were injected with a single dose of either 42, 43.5, or 45.5 mg/kg PTZ.
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2.3.3.2 Acute seizure paradigm: Based on results from the dose-response analysis performed,
acute seizure activity was induced by dose of 43.5 mg/kg PTZ (this dose yielded a spread of
seizure response in WT mice) on C57BL/6J IL-1r1 WT and KO mice. Studies were performed
without the genotype of the mice to ensure unbiased scoring (Fig.2.2).
2.3.4

Statistical analysis

All statistical analyses were performed using GraphPad Prism (ver. 8.0.2, GraphPad Software,
Inc.). All tests are indicated in the result section and/or legends to the figure. Statistical
significance was maintained at p<0.05. Behavioral data associated with scoring of seizure were
reported as median seizure score and incidence of a convulsive seizure. Latency to convulsion
after acute PTZ injection between genotypes was assessed using a two-tailed Mann–Whitney
test. ROUT method of outlier test was used to detect outliers for latency to convulsion after acute
PTZ injection between genotypes. Datasets representing proportions (incidence of convulsions)
were analyzed using a two-tailed Fisher’s exact test. Significance was set at p< 0.05. In figure
legends, p values were reported as their exact values whenever available.
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2.4

Results

2.4.1 Dose-response study
A dose-response study was performed to assess the acute PTZ-induced seizure response in
C57BL/6 mice prior to proposed experiments. Cohorts of wild-type male C57BL/6 mice were
treated with either of 3 different PTZ doses, 42, 43.5, or 45.5 mg/kg PTZ (Fig.2.1) and seizure
behavior were scored using our 5-point severity scale as described previously. The dose that
generated a spread of seizure response (23%) and the dose at which 100% mice had convulsive
seizure were 43.5 and 45.5 mg/kg PTZ, respectively (Fig. 2.1). The dose of 43.5 mg/kg PTZ with
a median score of 2 was selected for the study herein.

Fig 2.1.

PTZ elicits seizure behavior in a dose-dependent manner.

Dose-response analysis of C57BL/6J WT male mice were conducted by treating mice with either
42mg/kg (N=4), 43.5mg/kg (N=13) or 45.5mg/kg (N=6) b.w.
A. Seizure severity. Each point on the graph is the seizure score for each mouse. The median seizure
scores for 42mg/kg, 43.5mg/kg or 45.5mg/kg PTZ are represented by horizontal lines, respectively.
B. Incidence of convulsions. The number of mice exhibiting a convulsive seizure (PTZ seizure score≥3)
in A expressed as a % of total mice injected with PTZ for each treatment group (ratio in the bar is the raw
data).
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2.4.2

Effect of IL1R1 gene deletion on the innate seizure threshold

A previous study reported that mice lacking IL-1 signaling exhibited enhanced sensitivity to
pentylenetetrazol (PTZ) (Claycomb, Hewett, and Hewett 2012). To confirm this herein, wild
type (+/+, WT) and Il1r1 mutant (-/-, KO) littermate mice were challenged with 43.5 mg/kg PTZ
and seizure responses were assessed (Fig.2.2). This PTZ dose induced a median seizure severity
score of 2 in wild type mice and 4 in I1r1 mutant littermates (**, p= 0.0035, Mann Whitney Test,
two-tailed) (Fig.2.2A). KO mice showed corresponding higher incidence of convulsive seizure
(67%) having convulsive seizures compared to WT littermate controls (38%) (*, p= 0.0026, 2x2,
two-tailed Fisher’s exact test) (Fig. 2.2C).
The mutant mice exhibited a shorter latency to convulsion (Fig. 2.2B). A significant difference
was detected in mean latency to achieve convulsive seizures between the genotypes (*, p = 0.0094,
Mann Whitney Test, two-tailed). Finally, while the number of mice that succumbed to convulsions
was not significantly different between genotypes, it was nonetheless elevated in mutant mice (Fig.
2.2 D).
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Fig.2.2. The innate seizure threshold is reduced in mice lacking IL-1 signaling.
Wildtype (WT) (+/+, N = 52) and Il1r1 mutant (KO) (-/-, N = 58) mice were treated with 43.5 mg/kg PTZ
and seizure behavior was scored on a 5-point scale of increasing severity as described in methods (0 =
normal behavior).
A. Seizure severity. Each symbol shows the maximum seizure score for individual mice (*, p = 0.0035,
two tailed Mann Whitney Test). Horizontal line represents median seizure score.
B. Latency to convulsion. The ROUT method (Q = 1%) was performed to test for outliers and resulting
data are expressed as individual latencies from mice with convulsive seizure in A, superimposed over
a box and whisker plot. Analysis was performed on log transformed data (*, p = 0.0041, unpaired two
tailed t-test).
(continued)
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C. Incidence of convulsions. Data are expressed as the number of mice exhibiting convulsive seizure
responses (score ≥3) and non-convulsive seizure responses (score ≤2) from A. The incidence of
convulsions is expressed as % of the total population (*, p = 0.002, two tailed Fisher’s exact test).
D. Mortality. Data are expressed as the number of mice that survived or died from convulsive seizures.
The incidence of mortality is expressed as % of the total population (p = 0.77, two tailed Fisher’s
exact test).
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2.5

Discussion

The neuromodulatory role of IL-1β signaling in the maintenance of seizure threshold in the PTZ
model of acute seizure is confirmed. The previous study from our laboratory has demonstrated
that the PTZ dosing that elicited median seizure score of 1 (floor effect) was 24mg/kg and
median seizure score of 4 with PTZ causing a ceiling effect in seizure response was 43mg/kg
(Claycomb, Hewett, and Hewett 2012), compared to the study herein, where similar seizure
response was generated at 42 mg/kg and 45.5mg/kg, respectively. The median effective dose
(intermediate population response) for the current study generated median score of 2 with a
spread of seizure response is 43.5mg/kg which is higher than previously observed 36mg/kg PTZ.
Several factors may contribute to the shift in the acute PTZ dose responses. Firstly, to factor
differences in the physical environment, these mice were housed in a vivarium at Syracuse
University as compared to University of Connecticut vivarium, for the previous study. Though
mice are maintained on a similar light/dark schedule, specific conditions like caging, bedding
etc. differed in these two vivariums. Secondly, several recent studies have shown that the
sensitivity of mice to specific treatments varies between experimenters (Sorge et al. 2014;
Georgiou et al. 2018). These factors may have contributed to this shift in the responsiveness of
the mice towards higher concentrations of PTZ and a steeper dose-response curve compared to
the previous researcher in the seizure response study of the mice that genetically lacked IL1r1.
However, irrespective of dose used in either studies (36mg/kg v/s 43.5mg/kg), both studies show
an identical phenotypic behavioral response, and it eliminates any question of lack of
reciprocation of behavioral studies and strengthens this data which forms the basis of the overall
hypothesis of this dissertation work.
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Specific Aim 2: To investigate the molecular mechanism governing IL-1β expression and
release in neurons of the hippocampus.

Synopsis
While researchers have investigated about the cell types from which IL-1β is secreted and its
molecular mechanism release of at sites of inflammation both in peripheral system and in central
nervous system, nothing is known about its physiological release in the brain, specifically in the
hippocampus, although there are clear indications of its distinct physiological function in CNS.
The hypothesis of this aim is to investigate the molecular mechanism governing IL-1β release in
neurons of the hippocampus. Specifically, its purpose is to determine if physiological IL-1β
release may be dependent on the purinergic ATP receptor, P2X7R activation. It was reasoned
that the brain-permeable P2X7 receptor antagonist, JNJ-47965567 (Bhattacharya et al. 2013)
would result in IL-1β accumulation in the cells releasing it. If so, it would permit identification
of the cellular source in the hippocampus under physiological conditions. This process will also
be applied in vitro, to further examine the sub-cellular localization of IL-1β in hippocampal
neurons. Finally, it was posited that the P2X7 receptor antagonist may alter excitatory neuronal
activity in vitro and may produce a similar seizure phenotype in mice as seen in mice genetically
lacking IL-1 signaling which exhibited enhanced sensitivity to convulsive stimuli (demonstrated
in chapter 2) which will also be examined. Thus, studies from this section will assign an effort to
provide insight into the molecular mechanism of physiological IL-1β release and further support
for the notion that endogenous IL-1β contributes to the maintenance of the homeostatic
excitatory/inhibitory balance.

62

Chapter 3

P2X7-dependent constitutive Interleukin-1β release from pyramidal
neurons of the mouse hippocampus: Role in maintenance of E/I balance

This chapter is near duplicate of the submitted manuscript: P2X7-dependent constitutive Interleukin-1β release from
pyramidal neurons of the normal hippocampus: Evidence for a role in maintenance of brain homeostasis.
Spandita S. Dutta, Torsten Wöllert, Sandra J. Hewett, and James A. Hewett. Manuscript submitted.

63

3.1

Summary

Inactivation of the genes for interleukin-1β (IL-1β) or its signaling receptor, IL-1R1, sensitized
mice to convulsant properties of pentylenetetrazol (PTZ), suggesting that constitutive release of
this proinflammatory cytokine contributes to the maintenance of the excitatory-inhibitory (E/I)
balance in the normal brain. However, the cellular and molecular mechanisms that control this
homeostatic function remain to be clarified. This study focused the hippocampus because it is
known to be an important site of constitutive IL-1β release and function. The purpose of this
study was to determine whether the purinergic receptor, P2X7 is necessary for basal release of
IL-1β in the normal hippocampus, and to test its role in maintenance of E/I balance. This was
examined in vivo and in cell culture using JNJ-47965567 (JNJ), a highly selective antagonist of
P2X7. Focus was IL-1β immunoreactivity was not detectible in the normal hippocampal
formation under basal condition. However, an increase in immunoreactivity was observed in the
pyramidal cells of the CA3 and to a lesser extent in the CA1 regions 60 minutes after treatment
of mice with 30 mg/kg JNJ, suggesting that the antagonist blocked release IL-1β from these
cells. No immunoreactivity was detected in granule cells of the dentate gyrus without or with JNJ
treatment. In cultures of hippocampal neurons, IL-1β immunoreactivity was similarly increased
by JNJ treatment and this was paralleled by a concomitant increase in the excitation-coupled
genes, c-Fos and COX-2. Importantly, pretreatment with the P2X7 antagonist sensitized mice to
the PTZ-induced convulsive seizure response in a manner that resembled genetic deletion of IL1β signaling. Together, results from this report concludes that constitutive IL-1β release from
hippocampal pyramidal neurons contributes to the homeostatic balance between excitation and
inhibition in the normal brain. This function has implications for normal brain function and for
epilepsy, a neurological disorder in which the seizure threshold is compromised.

64

3.2

Introduction

Interleukin-1β (IL-1β) is a well-characterized cytokine signaling molecule of the innate and
adaptive immune systems (Dinarello 2009). It is expressed at high levels by infiltrating myeloid
cells at sites of tissue damage or infection where it serves as an important mediator in the
inflammatory response. Systemically, it is a mediator of the sickness behavioral response, thus
functioning as a link between the peripheral immune and central nervous systems (CNS) (Hansen
et al. 1998; Laye et al. 1995; Hosoi, Okuma, and Nomura 2000a; Wieczorek and Dunn 2006).
Within the CNS, IL-1β has been implicated in the pathogenesis of various disease states (Rothwell
and Luheshi 2000; Simi et al. 2007; Fogal and Hewett 2008), including cerebral ischemia,
traumatic brain injury, epilepsy, Alzheimer’s disease, and multiple sclerosis, although its function
appears to be complex (Shaftel, Griffin, and O’Banion 2008; Pinteaux, Trotter, and Simi 2009;
Hewett, Jackman, and Claycomb 2012). Remarkably, it is now clear that IL-1β modulates certain
physiological functions in the CNS that are independent of its role as an immune modulator
(Rothwell and Luheshi 2000; Hewett, Jackman, and Claycomb 2012). Among these are non-REM
sleep (Krueger et al. 1998; Fang, Wang, and Krueger 1998; Opp, Obal, and Krueger 1991), body
fluid regulation (Diana et al. 1999; Summy-Long et al. 2006; 2008) and long-term potentiation
and memory (Schneider et al. 1998; Ross et al. 2003; Goshen et al. 2007). Pertinent to the current
study, evidence suggests that constitutive IL-1 signaling contributes to regulation of the innate
seizure threshold (Claycomb, Hewett, and Hewett 2012), a property of the normal brain that
reflects the homeostatic control of neuronal excitation. Consistent with its modulatory role in the
normal brain, constitutive expression of IL-1β and its signaling receptor, IL-1 receptor type 1 (IL1R1), have been reported in the brain regions that subserve its physiological actions (Breder,
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Dinarello, and Saper 1988; Lechan et al. 1990; Cunningham et al. 1992; Deyerle et al. 1992;
Yabuuchi et al. 1994; Diana et al. 1999; Watt and Hobbs 2000; Friedman 2001; Liu et al. 2019).
IL-1β is produced as an inactive 31kD protein (pro-IL-1β) that requires cleavage to form the
active 17 kD peptide (Weber, Wasiliew, and Kracht 2010; Afonina et al. 2015). Since IL-1β
lacks a leader sequence, its secretion occurs via a non-classical mechanism (Anelli and Sitia
2008; Piccioli and Rubartelli 2013). The canonical release mechanism occurring under
inflammatory conditions requires two signals: an initial priming signal followed by a secondary
activation and release signal. Several exogenous and endogenous factors can prime cells for IL1β release, including bacterial products and pro-inflammatory cytokines, respectively. These
molecules induce the expression of pro-IL-1β and NLRP3, a key component of the IL-1β
processing inflammasome (Agostini et al. 2004; He, Hara, and Núñez 2016; Swanson, Deng, and
Ting 2019). The secondary activation signal induces assembly and activation of the
inflammasome leading to caspase-1-dependent (formerly Interleukin-1 Converting Enzyme)
processing and subsequent release of the active IL-1β peptide (Swanson, Deng, and Ting 2019).
Secondary signals are cellular stress factors that include extracellular ATP, an agonist of the
purinergic ionotropic receptor, P2X7 (Dubyak 2012). While much remains unknown about the
processing and release of IL-1β in the normal brain, some aspects may have similarities with its
release at sites of inflammation. In this regard, administration of a potent ATP analog directly
into the normal hippocampus induced the release of IL-1β, suggesting that its release in this
region can occur by an ATP-P2X7-dependent mechanism in the absence of neuroinflammation
(Bhattacharya et al. 2013).
P2X7 mRNA expression has been reported throughout the mouse brain in neurons as well as glia
(Metzger et al. 2017). Expression was particularly prominent in the CA3 region of the
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hippocampus, where it was localized to the excitatory pyramidal neurons. By comparison,
expression was much lower or not detected in the other primary neuronal populations of the
hippocampal formation, including the granule cells of the dentate gyrus. To confirm this
expression profile, Metzger et al. inserted a human P2X7 cDNA transgene into the mouse allele,
deleting all mouse transcript variants while retaining the innate transcriptional control
mechanisms to drive expression of the transgene. Expression of the human P2X7 mRNA
paralleled the innate mouse mRNA. This pattern of P2X7 expression in the hippocampus largely
agrees with the in situ hybridization analysis provided by the Allen Brain Atlas
[https://mouse.brain-map.org/experiment/show/81600560, Allen Mouse Brain Atlas, (Lein et al.
2007)]. P2X7R protein expression was studied for this report, which indicated its physiological
expression in both neuronal and non-neuronal cells of hippocampus (detailed in Appendix
section, Fig 7.2 & Fig. 7.3). Together with the evidence for P2X7-dependent release of IL-1β in
the hippocampus (Bhattacharya et al. 2013), these results raise the possibility that CA3 neurons
may be an important site of constitutive IL-1β release in the hippocampus. On the other hand,
other evidence suggests that P2X7 protein is expressed on the presynaptic terminals of the mossy
fiber synapses (Armstrong et al. 2002). This, together with the reported IL-1β immunoreactivity
in mossy fibers (Lechan et al. 1990), argues that the granule cell population may be the cellular
source of IL-1β in the hippocampus. Additional studies are necessary to distinguish between
these two possibilities.
The highly selective, brain permeable P2X7 antagonist, JNJ-47965567 [JNJ, (Bhattacharya et al.
2013)], was used herein to examine further the cellular source of IL-1β in the normal
hippocampus under basal conditions. It was reasoned that if IL-1β were constitutively released in
the hippocampus via a P2X7-dependent mechanism, the antagonist would result in its
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accumulation in the cells that release it. It was further posited that depletion of extracellular IL1β by the P2X7 antagonist would lower the seizure threshold much like disruption of IL-1 signal
transduction (Claycomb, Hewett, and Hewett 2012), thus further substantiating the role of basal
IL-1β release in maintenance of the normal excitatory-inhibitory balance in the brain.

3.3

Methods

3.3.1

Mice

3.3.1.1 CD-1 mice: Male 6-7-week-old CD-1 mice for in vivo studies were obtained from
Charles River Labs (Wilmington, MA) and housed three per cage for at least one week prior to
use. All in vivo studies were performed using 8-12-week-old male mice, which were handled
daily for seven days prior to treatments. For studies using hippocampal neuron cultures, pregnant
female CD-1 mice were purchased from Charles River Labs and housed singly upon arrival at
Syracuse University.
3.3.1.2 Animal housing: described in section 2.3.1.1 of chapter 2.
3.3.2 Mouse studies
3.3.2.1 JNJ-47965567 treatment: CD-1 mice were treated with the P2X7 receptor antagonist,
JNJ-47965567 (JNJ), either alone or 60 minutes prior to induction of acute seizures. JNJ was
dissolved in 30% Sulfobutylether-β-cyclodextrin (SBE) w/v water and injected subcutaneously at
a dose of 30 mg/kg (Bhattacharya et al. 2013). Comparisons were made to control mice treated in
parallel with the SBE-β-CD (SBE) vehicle solution.
3.3.2.2 Pentylenetetrazol induced acute seizure paradigm: Acute seizure activity was induced
with pentylenetetrazol, a GABAA receptor antagonist used previously to assess alterations in the
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innate seizure threshold in the brain of mice (Claycomb, Hewett, and Hewett 2011). PTZ
injection solutions preparation, injection and scoring was done following methods explained
section 2.3.3 of chapter 2. For studies in this chapter, 1 hour after s.c. injection of JNJ or its
vehicle, PTZ is given intraperitoneally. Doses of PTZ are mentioned in the result section.
3.3.2.3 Anesthesia: For studies using mice, fully anesthetized mice [with 120 mg/kg ketamine,
20 mg/kg xylazine, intraperitoneally in saline (1X)] were exsanguinated and perfused
transcardially with PBS. P0-P1 pups for hippocampal neuronal dissection were anesthetized
using isoflurane (1 ml on a gauze pad in a closed container for approximately 8 pups).
3.3.3

Primary hippocampal neuron cultures

3.3.3.1 Preparation: Cultures were established using a protocol that was derived from previous
reports (Ma et al. 2003; Uliasz et al. 2012; Beaudoin et al. 2012). The method of culturing
hippocampal neurons has been broadly discussed in chapter 5 of this dissertation thesis.
Tissue culture plates or 6-well glass bottom culture plates for higher resolution microscopy were
prepared by covering each well with 0.1M borate buffer (pH 8.5) containing 30µg/ml high
molecular poly-L-lysine. After at least one hour at room temperature, the plates were washed
thoroughly and dried under sterile conditions. Postnatal day 0-1 CD-1 mice were euthanized
using isoflurane, then placed on ice and dissected under aseptic conditions. Hippocampi from 8-9
brains were pooled in sterile calcium and magnesium-free Hank’s balanced salt solution
containing 2.5g glucose, 3.5g sucrose, 2.4g HEPES (pH 7.4) and 0.25% trypsin (dissection
medium, DM). After incubating briefly at 37oC, the tissue was triturated gently and the
dissociated cells pelleted and resuspended in Neurobasal A media containing 7% horse serum,
1% B27 supplement, 0.5mM L-glutamine, 1% of pen-strep and 5μM β-mercaptoethanol (2-ME).
The cell suspension was added to a PLL-coated 24 well plate (0.4ml/well) and incubated at 37oC
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under a humidified atmosphere of 5% CO2. The plating medium was replaced 12-16 hours later
with medium consisting of Neurobasal A media containing 3% horse serum, 1% B27
supplement, 0.5mM of L-glutamine, 1% pen-strep, and 5 μM β-ME. Finally, this was replaced 68 hours later with serum-free growth medium (Neurobasal A media containing only 2% B27
supplement, 0.5mM glutamine, 1% pen-strep, and 5mM β-ME). To reduce contamination by glia
and other non-neuronal cell types, the cells were treated with 6mM cytosine β-Darabinofuranoside hydrochloride from 3-6 days in vitro (DIV). Cells were fed twice weekly by
replacing 50% of the growth medium with fresh medium. This procedure yielded >90% enriched
neuronal cell cultures.
3.3.3.2 Cell culture studies: All studies with primary hippocampal neuron cultures were
performed at 14-15 days in vitro (DIV).
JNJ: For studies with JNJ, a stock solution of 2mM was prepared in DMSO and stored at -20°C.
This solution was diluted in growth medium and administered to cells at final concentrations of
0.1 or 0.3μM.
Bicuculline: For studies with bicuculline methobromide, a 100mM stock solution was prepared
in DMSO and frozen at -20oC. This was diluted in growth medium and administered to cells at a
final concentration of 100μM.
APV: For studies with 5-amino-phosphovaleric acid (APV), a 1.2mM stock solution was
prepared in water and frozen in aliquots at -20oC. This was diluted in growth medium on the day
of use and administered to cells at a final concentration of 30μM.
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3.3.4

Immunohistochemistry

3.3.4.1 Tissue collection, fixation and sample preparation: For studies using mice, fully
anesthetized mice were exsanguinated and sequentially perfused transcardially with phosphatebuffered saline (PBS) and 4% phosphate-buffered paraformaldehyde (PFA). The fixed brains
were excised from the cranium and post-fixed for several hours at 4oC in 4% PFA. The tissue
was then saturated with 20% sucrose solution at 4oC, immersed in OCT reagent, snap-frozen on
dry ice, and stored at -80oC until processing for IHC. Frozen brains were cut at -20oC on a
cryostat (Thermo Fisher Scientific Microm HM550) to obtain 14 µm coronal sections, which
were mounted on pre-coated slides and stored at -20oC.
3.3.4.2 Immunofluorescence: For staining, sections from treated mice were processed in
parallel with their respective controls. Sections were bathed in PBS containing 0.25% TritonX100 (PBST) and, depending on secondary antibody, incubated in 5% normal donkey serum
solution containing 1% bovine serum albumin. Subsequently, sections were incubated overnight
at 4°C with primary antibody in PBST containing 1% normal serum and 1% BSA, then washed
thoroughly with PBS and incubated with species-specific secondary antibodies at room
temperature in the dark. Sections were washed again with PBS, incubated for 5 min with PBS
containing 1µg/mL DAPI, and mounted with coverslips using anti-fade mounting solution
(Citifluor AF1). Images for each study were captured using an upright Zeiss Axio Imager A2
microscope fitted with an X-Cite 120Q fluorescence light source (Lumen Dynamics), AxioCam
MRc digital camera, and ZEN 2 software (Version 2.0.0.0, Carl Zeiss Microscopy GmbH). For
comparisons, images from each study were processed identically using Adobe Photoshop.
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3.3.5

Immunocytochemistry

3.3.5.1 Cell fixation and sample preparation: For studies using hippocampal cultures, media
was aspirated from culture wells and cells were incubated with 50/50 v/v methanol/acetone
solution for 15 min and washed with PBS.
3.3.5.2 Immunofluorescence staining: The PBS is aspirated out of the well and incubated for 7
min with 0.25% Triton-X100 in PBS (PBST). Next, cells were incubated with 10% normal
donkey in PBS for 1 hour at room temperature and subsequently incubated overnight at 4°C with
primary antibody in PBS containing 2% normal serum in PBS. Wells were washed thoroughly
with PBS and incubated with secondary antibodies for 30 min at room temperature in the dark.
Images were captured using an inverted IX50 Olympus microscope equipped with an X-Cite
120Q fluorescence light source (Lumen Dynamics), Olympus D73 digital camera, and CellSens
Standard software. For high resolution analyses, images were acquired with Zeiss Axio Observer
Z1 inverted microscope equipped with 40X/1.30 oil Plan-Neofluar objective illumination using
HAL100 12V 100W halogen lamp housed with microscope power supply (PhotoFluor LM-75,
89 North) and Hamamatsu CMOS ORCA-Flash4.0 LT CCD camera (C11440-42U30). For
comparisons, images from individual studies were processed identically using Adobe Photoshop.
3.3.5.3 Antibodies for IHC and ICC.
Primary: A rabbit polyclonal anti-IL-1β IgG was used at 1:100 for staining brain sections and
hippocampal neuron cultures (H-153, Santa Cruz Biotechnology, Cat #sc-7884, 200µg/mL,
RRID:AB_2124476). The specificity of this antibody was validated using an IL-1β blocking
peptide (Peprotech, Cat #211-11B) as described in Appendix, Fig.7.4 & 7.5 .
NeuN, MAP-2 (details are provided in table 1.3).
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Secondary: Donkey anti-rabbit Alexa Fluor 488 and donkey anti-mouse Alexa Fluor 594 (details
are provided in table 1.3).
3.3.6

Quantification of IL-1β immunoreactivity.

3.3.6.1 For IHC studies: All brain section images of subregions of hippocampi were converted
to 8-bit gray scale and fluorescent intensity was quantified using NIH FIJI (Image J2). The
maximum and minimum thresholds were set to 255 and 31, respectively, using the default auto
thresholding technique. Results from two images from each brain section were averaged and the
mean fluorescent integrated density was calculated in the hippocampal CA3 and CA1 pyramidal
cell layers using methods described previously (Gong and Hewett 2018).
3.3.6.2 For ICC studies: To quantify fluorescence intensity in cell bodies of hippocampal
neurons in culture, z-stack images were summed through z-project and displayed as 2D
maximum projection using ImageJ. For measuring fluorescence intensity of cell body, 6 steps
were summed for maximum intensity (1 step size =100nm). Using FIJI, an outline was drawn
around each cell (10 cells per field, 3 fields/well and 2replicates/treatment) and the area and
mean fluorescence intensity was recorded. Adjacent background readings/fields were also taken.
The corrected total cellular fluorescence (CTCF) = integrated density – (area of selected cell ×
mean fluorescence of background readings) was calculated and mean CTCF was compared
between treatments using a protocol that was derived from previous report (McCloy et al. 2014).
To measure fluorescent intensity in the neuronal processes, 8 steps were summed (MAP-2 costained) and displayed as 2D maximum projection using FIJI. Fluorescent intensity plot profile
was calculated for 31 pixels (1 µm) along the processes approximately 0.5 µm away from cell
body (10 neurites/microscopic field image, 5 field/well and 2 replicates/treatment), with point 0
being towards and 30 away from the cell body. Neurites arising from clearly identifiable neurons
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were selected for the dataset. Mean pixel intensity profile was plotted and compared between
treatments.
3.3.7

Quantitative PCR analysis

3.3.7.1 Sample collection: The growth medium was aspirated from 24 well culture plates and
0.250 mL of TriZol reagent was added to each well. Four wells were pooled per sample in
centrifuge tubes and frozen at -80oC until processing for quantitative PCR analysis.
3.3.7.2 RNA extraction: Centrifuge tubes containing samples in TriZol are thawed and 200ml of
chloroform was added and mixed well. The tubes were then centrifuged at 10000*g for 15 min at
4°C to separate the aqueous layer. 500ml isopropanol was added to the separated aqueous layer
and incubated for 10 min at room temperature. The mixture was then centrifuged at 10000* for
15 min at 4°C to pellet RNA. The RNA pellet was further washed in 75% ethanol to purify the
RNA. After that, the pellet was resuspended in 20ml ultrapure water and heated at 70°C for 5
min and placed on ice. RNA obtained was then quantified using a NanoDrop UV-Vis
Spectrophotometer (BioRad).
3.3.7.3 cDNA synthesis: cDNA synthesis was performed in a 21mL reaction mix containing
10ml 1mg/ml total RNA and 11ml master mix containing:
Reaction Master mix
Ultrapure H2O
1x M-MLV reaction buffer
oligo (dT) primers
dNTPs
Reverse transcriptase M-MLV

Amount in one reaction (µl)
2
4
2
1
2

Table 3.1: Reagents in cDNA synthesis master mix
The reaction mixture was heated to 42°C in a heat block for 1 hour and then stored at -20°C for
immediate use or -80°C for long term storage.
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3.3.7.4 Quantitative PCR: Expression of c-Fos and COX-2 was quantified with a real-time PCR
detection system (CFX Connect, BioRad Laboratories) using Applied Biosystems TaqMan
Universal PCR Master Mix and FAM-MGB dye gene expression assay probes. Relative
expression was quantified using the comparative cycle threshold method, ΔΔCt (Livak and
Schmittgen 2001), where individual Ct values were normalized to the β-actin Ct value from the
same sample then with a control sample Ct value (calibrator) to determine the relative fold
changes in mRNA. The Applied Biosystems Gene expression assay probes are cFos, COX-2 and
β-actin (details are provided in table 1.5).
3.3.8

IL-1β Immunoblot analysis

After aspirating growth medium from wells, cells were washed with PBS, harvested, then pooled
(4 wells/sample in PBS) and pelleted at 2000g for 5 min at 4°C. Pellets were resuspended in
RIPA buffer containing 50mM Tris, pH 7.5, 0.5% Na Deoxycholate, 0.1% SDS, 1%Nonidet
P40, 150mM NaCl, 0.5M Iodoacetamide and 1X Complete protease inhibitor for 30 min on ice,
after which lysates were cleared by centrifugation at 10,000*g for 20 min at 4°C. Total protein
concentration was determined using a commercially-available kit then adjusted to 1μg/μL protein
with 25% 4X SDS loading buffer and 30μg of lysate protein were separated on a 4-15% SDSpolyacrylamide gradient gel along with all Blue and Dual Color precision molecular size ladder.
The separated proteins were transferred to nitrocellulose membranes, which were blocked for 1
hour in LiCor Odyssey blocking buffer in Tris buffer saline and incubated with rabbit anti-IL-1β
polyclonal antibody, [Appendix, Fig.7.4 indicates this antibody detects both pro- and active IL1β] and mouse monoclonal anti-β-actin antibodies overnight at 4oC. The immunoblots were
washed with TBS containing 0.2% Tween20 and incubated with IRDye 680LT goat anti-rabbit
IgG and IRDye 800CW goat anti-mouse IgG. After incubating for two hours at room
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temperature on a rocker, the immunoblots were washed and imaged with a Licor documentation
system (Odyssey Fc OFC-0116). Antibody details were provided in table 1.3.
3.3.9 Statistical analysis
Data were analyzed using GraphPad Prism, Version 8.4.1 (GraphPad Software, Inc., La Jolla,
CA, U.S.A.). Statistical tests are described in figure legends. Statistical significance was set to
p<0.05.
Statistical tests are described in figure legends. Behavioral data associated with scoring of
seizure are reported as median seizure score and incidence of a convulsive seizure. Latency to
convulsion after acute PTZ injection between genotypes was assessed using a two-tailed Mann–
Whitney test. Datasets representing proportions (incidence of convulsions) were analyzed using a
two-tailed Fisher’s exact test. For q-PCR, statistics were performed on the logarithmic
transformation of 2-DDCT values, and analyzed with Kruskal Wallis test followed by uncorrected
Dunn’s test for JNJ study or one-way ANOVA followed by uncorrected Fisher’s LSD test for
bicuculline and APV treatment study. One-way ANOVA was followed by uncorrected Fisher’s
LSD test and two-way ANOVA test was followed by either Tukey’s multiple comparison or
Fisher’s uncorrected LSD test as deemed fit. For one-way ANOVA and two-way ANOVA test,
in addition to p values, F values were determined for equal variance. (F (DFn, DFd) where DFn
is the numerator of df (degree of freedom) and DFd is the denominator of df, in addition to p
values).
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3.4

Results

3.4.1

Effect of P2X7 antagonist on IL-1β release from mice hippocampus

Results in Chapter 2 imply that IL-1β is released constitutively in the normal brain to perform its
neuromodulatory functions. To assess the cellular source of IL-1β in the hippocampus, CD-1
mice were treated with the blood brain barrier permeable P2X7 antagonist, JNJ-47965567 (JNJ),
and results were compared to mice treated in parallel with its vehicle, SBE-β-CD (SBE). No
immunoreactive IL-1β was detected in any region of the hippocampal formation of vehicletreated mice (Fig. 3.1A-C). In contrast, it was detected in mice after exposure to the P2X7
antagonist for 60 minutes (Fig. 3.1 D-F). IL-1β immunoreactivity was strongest in pyramidal
neurons of the CA3 region (Fig. 3.1 A/D), where it was approximately 5 to 10-fold higher than
vehicle-treated controls (Fig. 3.2). Immunoreactivity was also detected in neurons of the CA1
region after antagonist treatment (Fig 3.1 B/E), albeit at much lower levels than the CA3 (Fig.
3.2). On the other hand, no immunoreactivity was detected in the granule neurons of the dentate
gyrus (Fig. 3.1 C/F).
This study provided evidence of physiological build-up of IL-1β in CA3 and CA1 sub-region of
hippocampus and also associating the requirement of P2X7R in its physiological release.
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Fig. 3.1.
IL-1β immunoreactivity is increased in hippocampal pyramidal neurons
after JNJ treatment.
Cohorts of CD-1 mice were treated with 30% SBE-β-CD (A, B, C) or 30 mg/kg JNJ-47965567 (D, E, F)
for 1 hour and brains were removed and processed for immunofluorescence microscopy as described in
Materials and Methods. Coronal brain sections were stained for IL-1β (green) and counterstained with
DAPI (blue). Representative photomicrographs are shown from the CA3 (A, D), CA1 (B, E) and DG (C,
F) sub-regions of the hippocampal formation. Scale bar = 100 µm.
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Fig.3.2.

Quantification of IL-1β immunoreactivity in the hippocampus.

Immunofluorescence intensity in duplicate sections from 3 vehicle- and 4 JNJ-47965567-treated mice was
quantified as described in Materials and Methods. A 2-way ANOVA followed by Tukey’s multiple
comparisons test was performed on log transformed data. a, significantly different from respective
vehicle-treated controls (*, p = 0.006); b, significantly different from the corresponding value in the CA3
subregion (*, p = 0.013).

3.4.2 Effect of P2X7 antagonist on IL-1β release from hippocampal neurons
IL-1β release was assessed further in cultures of hippocampal neurons. In contrast to the analysis
in vivo (Fig. 3.3), IL-1β immunoreactivity was detected under basal conditions in the soma of a
subset of hippocampal neurons in culture (Fig. 3.3 A), where it appeared as distinct perinuclear
puncta. Alongside, it was also expressed in the neuronal processes. This was elevated 30 min
after exposure to 0.1 or 0.3 µM JNJ (Fig. 3.3 B and C, respectively).
Immunoblot analysis of hippocampal neuronal cell lysates showed similar elevation in a 31kD
protein with increase in pro-IL-1b (Fig. 3.4 A & B). However, there was no evidence for the
17kD processed IL-1β in the cell lysates (Fig. 3.4 C).
Studies herein indicated, both in mice and in cultured hippocampal neurons, P2X7R moderated
constitutive IL-1β release, which when blocked pharmacologically, caused IL-1β accumulation
in hippocampal neurons.
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Fig.3.3.
IL-1β immunoreactivity is increased in cultures of hippocampal neurons
treated with JNJ.
Hippocampal neuron cultures (DIV 14) were treated with DMSO (A), 0.1 µM JNJ (B), or 0.3 µM JNJ (C)
for 30 minutes and processed for ICC using anti-IL-1β and without (green, left panel) and with anti-NeuN
(red, merged on right panel) as described in Materials and Methods. Scale bar = 25µm. Thick white
arrow within inset identifies IL-1β expression in cell body and thin white arrow within inset indicates its
expression in the neuronal processes.
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C.

Fig.3.4.
JNJ treatment cause an increase in a 31kDa protein in cultures of
hippocampal neurons.
Immunoblot analysis using anti-IL-1β and anti-β-actin antibodies was performed on cell lysates harvested
30 minutes following treatment with vehicle (DMSO) or JNJ (0.1 or 0.3 µM) as described in Materials
and Methods.
A. Representative immunoblot (Fig. 3.4 C shows complete blot). B. Quantification of immunoblot
results. Densitometric values for the 31kDa protein were normalized to the corresponding 42 kDa β-actin
band. Results were analyzed by ordinary one-way ANOVA (*, p = 0.0373) followed by uncorrected
Fisher’s LSD multiple comparisons test. *, indicates significant difference between DMSO vs. 0.1µM JNJ
(p = 0.0209) and DMSO vs. 0.3µM JNJ (p = 0.0294). (N = 4).
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3.4.3 Localization of IL-1b protein expression in cell bodies and neurites of hippocampal
neurons
The subcellular localization of IL-1β in cultures of hippocampal neurons was examined further
by higher resolution imaging. Two separate studies (either co-stained with MAP-2 or with
NeuN) (Fig. 3.5 and Fig.3.6 respectively) indicated significant elevated IL-1β immunoreactivity
in the cell body of neurons with either 0.1µM or 0.3µM JNJ treatment. Under higher resolution,
IL-1β expression was punctate and perinuclear in distribution. Although, there was a significant
increase in IL-1β immunoreactivity with P2X7R antagonist treatment, there was no change in
gross subcellular localization pattern of IL-1β.
IL-1β was also detected in the neuronal processes (Fig 3.7). High resolution images indicated
elevated level of IL-1β in neuronal processes proximal to the cell body, which tapered distally
along the length of the neurite in both control- and JNJ-treated cells. Quantitation of fluorescent
intensity showed that neurons treated with 0.3µM JNJ had significantly elevated IL-1β
immunoreactivity in processes compared to control or 0.1µM JNJ-treated cells.
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Fig.3.5. Subcellular localization of IL-1β immunoreactivity in cell bodies of cultured
hippocampal neurons.
i. Cultures were processed and imaged using high resolution microscopy as described in Materials and
Methods. Headings indicate treatments for each column of images. Top panel (A) show respective gray
scale images of anti-IL-1β and bottom panel (B) show cultures stained with anti-IL-1β (green) and NeuN
(red) antibodies. Scale bar = 25 µm. Images from insets demarcated are in top right corner of respective
images. Scale bar = 1µm. Arrows indicate cell bodies stained with anti-IL-1β antibody.

ii. Quantification of IL-1β in neuronal cell
body.
Total corrected cell fluorescent intensity of IL-1β
measured (as described in methods section) is
elevated with 0.1µM or 0.3µM P2X7R antagonist
treatment in neurons as determined by ordinary oneway ANOVA(*, p=0.0071) followed by uncorrected
Fisher’s LSD test for multiple comparison (*, p=
0.0017, DMSO vs. 0.1µM JNJ and p= 0.102, DMSO
vs. 0.3µM JNJ).
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Fig.3.6.
Subcellular localization of IL-1β immunoreactivity in cell bodies of cultured
hippocampal neurons.
i. Cultures were processed and imaged using high resolution microscopy as described in Materials and
Methods. Headings indicate treatments for each column of images. Top panel (A) show respective gray
scale images of anti-IL-1β and bottom panel (B) show cultures stained with anti-IL-1β (green) and antiMAP-2 (red) antibodies. Scale bar = 25 µm. Images from insets demarcated are in top right corner of
respective images. Scale bar = 1µm. Arrows indicate cell bodies stained with anti-IL-1β antibody.

ii. Quantification of IL-1β in neuronal cell
body.
Total corrected cell fluorescent intensity of IL1β measured (as described in methods) is
elevated with 0.1µM or 0.3µM P2X7R antagonist
treatment in neurons as determined by ordinary
one-way ANOVA (*, p=0.0154) followed by
uncorrected Fisher’s LSD test for multiple
comparison (*, p= 0.0093, DMSO vs. 0.1µM
JNJ and *, p= 0.0161, DMSO vs. 0.3µM JNJ).

84

Fig.3.7.
Subcellular localization of IL-1β immunoreactivity in neuronal processes of
cultured hippocampal neurons.
i. Cultures were processed and imaged using high resolution microscopy as described in Materials and
Methods. Headings indicate treatments for each column of images. Top panels (A) show cultures stained
with anti-IL-1β (green) and anti-MAP-2 (red) antibodies. Middle panels (B) show respective gray scale
images of anti-IL-1β staining from A. Scale bar = 25 µm. Bottom panels (C) are images from insets
demarcated in respective panels in B. Scale bar = 1µm. Arrows indicate processes stained with anti-IL-1β
antibody.
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ii.
Fluorescence intensity/pixel
of IL-1β in neuronal processes is
significantly higher in 0.3 µM JNJ
treatment compared to 0.1µM JNJ or
vehicle treatment.
Immunofluorescence intensity was
quantitated as described in Materials
and Methods. Significant differences
were analyzed using 2-way ANOVA
followed by uncorrected Fisher’s
multiple comparisons test (individual
pixel p values in appendix, table 7.1).

3.4.4 Effect of P2X7 antagonist on cFos and COX-2 gene expression
The reduction in seizure threshold observed in mice lacking IL-1 signaling suggests that IL-1
may dampen excitatory transmission in the normal brain [Fig. 1and (Claycomb, Hewett, and
Hewett 2012)]. This possibility was assessed in cultures of hippocampal neurons using the
immediate early genes, Fos (cFos proto-oncogene) and Ptgs2 (COX-2), as surrogate markers of
excitatory neuronal activity (Morgan et al. 1987; Yamagata et al. 1993). First, to demonstrate the
relationship between expression and neuronal excitation, cultures of hippocampal neurons were
treated with the GABAA receptor antagonist, bicuculline (Fig 3.8). Compared to vehicle-treated
cultures, bicuculline induced a 7-fold increase in cFos mRNA expression and a 6-fold elevation
in COX-2 mRNA expression (Fig. 3.8, panels A and B, respectively). However, there was a lack
of effect of NMDA receptor antagonist, APV, which is in agreement to what is expected, as APV
treatment suppresses expression mediated by excitatory activity (Fig. 3.8, panels A and B,
respectively).Next, the effect of JNJ on cFos and COX-2 expression was assessed (Fig. 3.8,
panels C and D, respectively). Although more modest than bicuculline, treatment with 0.1 and
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0.3 µM JNJ enhanced cFos expression by 1.86 and 2.16 fold and COX-2 mRNA expression by
1.68 and 1.81-fold, respectively.
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Fig.3.8.
cFos and COX-2 mRNA expression are increased in cultures of hippocampal
neurons after JNJ.
cFos (A, B) and COX-2 (C, D) mRNA expression was assessed by quantitative PCR analysis as
described in Materials and Methods. Cultures were exposed to 0 (DMSO), 0.1µM, or 0.3 µM JNJ for 30
minutes (A, C) and 30mM APV or 100 mM bicuculline for 90 minutes (B, D).
A.
c-Fos mRNA expression significantly increased with 0.3µM JNJ treatment (N=4) however, not
with 0.1M JNJ (N=4) as determined by Kruskal Wallis test (*, p= 0.0002) followed by uncorrected
Dunn’s test for multiple comparisons (*, p= 0.0017, DMSO vs. 0.3µM JNJ and p= 0.1160, DMSO vs.
0.1µM JNJ).
(continued)
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B.
COX-2 mRNA expression significantly increased with 0.3 µM JNJ treatment (N=4) however, not
with 0.1µM JNJ treatment (N=4) as determined by Kruskal Wallis test (p= 0.0876) followed by
uncorrected Dunn’s test for multiple comparisons ( *, p= 0.0307, DMSO vs. 0.3µM JNJ and p= 0.4320,
DMSO vs. 0.1µM JNJ).
C.
c-Fos mRNA expression significantly increased in hippocampal neuronal cells with 100µM
bicuculline treatment (N=4) but not with 30µM APV treatment (N=4) compared to control (N=4), as
determined by ordinary One-way ANOVA (*, p=<0.0001) followed by uncorrected Fisher’s LSD test for
multiple comparisons (*, p=<0.0001, control vs. Bicuculline and p= 0.6904, control vs. APV).
D.
COX-2 mRNA expression significantly increased in hippocampal neuronal with 100µM
bicuculline treatment (N=4) but not with 30µM APV treatment (N=4) compared to control (N=4), as
determined by ordinary One-way ANOVA (*, p=<0.0001) followed by uncorrected Fisher’s LSD test for
multiple comparisons (*, p=<0.0001, control vs. Bicuculline and p= 0.5717, control vs. APV).

3.4.5 Effect of P2X7 antagonist on PTZ-induced seizure activity
The effect of JNJ on basal IL-1b release together with its effect on cFos and COX-2 expression
(Fig.3.8) further suggest that constitutive IL-1β release serves to dampen excitatory
neurotransmission in the normal hippocampus. These results raise the possibility that JNJ will
enhance the sensitivity to PTZ, similar to that observed in IL-1R1 deficient mice (results from
chapter 2). To test this hypothesis, PTZ-induced seizure responses were assessed 60 min
following treatment with JNJ or its vehicle, SBE (Fig. 3.9). Seizure severity was significantly
increased in JNJ-treated mice relative to mice treated in parallel with the SBE vehicle (Fig.
3.9A). Although the incidence of convulsive seizures was increased two-fold in the JNJ
treatment group vs. the SBE control group (χ2 test for linear trend, p= < 0.0001), neither this nor
the latency to convulsions were significantly changed (Fig. 3.9 B and C). The effect on
convulsive seizure incidence was robust as it was also observed with higher doses of PTZ
(Fig.3.10 and 3.11). There was a dose-dependent increase in convulsive seizures with 46 and 50
mg/kg PTZ in the SBE-treated mice (40% and 50%, respectively). This nearly paralleled by
correspondingly higher incidences in the JNJ-treated mice (70 and 75% for 46 and 50 mg/kg
PTZ, respectively).
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Fig.3.9.
P2X7R antagonist lowers
seizure threshold.
Acute seizure activity was induced by PTZ
(42 mg/kg, i.p.) in vehicle and JNJ treated
mice and seizure behavior was scored on a 5point scale of increasing severity as
described in methods.
A. Seizure severity. Each point represents
the maximum seizure score for an individual
mouse. The median seizure scores for
between treatments (horizontal line) are
statistically different (*, p=0.0219, Mann
Whitney test, two tailed).
B. Latency to convulsion. There is no
significant difference between the treatments
(p =>0.999, two-tailed Mann-Whitney test).
Horizontal line indicates mean values.
C. Incidence of convulsions. The number of
mice exhibiting a convulsive seizure (PTZ
seizure score≥3) in A is expressed as a
fraction of total mice injected with PTZ for
each treatment group (ratio in the bar is the
raw data. (χ2 test for linear trend, *p= <
0.0001).
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Fig.3.10.
P2X7R antagonist
lowers seizure threshold.
A. For 46 mg/kg PTZ, seizure severity.
Each point represents the maximum
seizure score for an individual mouse. The
median seizure scores between treatments
(horizontal line) are not statistically
different (p=0.306, Mann Whitney test,
two tailed).
B. Latency to convulsion. There is no
significant difference between the
treatments (p=0.2121, two-tailed MannWhitney test). Horizontal line indicates
mean values.
C. Incidence of convulsions. The number
of mice exhibiting a convulsive seizure
(PTZ seizure score≥3) in A is expressed
as a fraction of total mice injected with
PTZ for each treatment group (ratio in the
bar is the raw data). (χ2 test for linear
trend, *p= < 0.0001).
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Fig.3.11.
P2X7R antagonist lowers
seizure threshold.
A. For 50 mg/kg PTZ, seizure severity. Each
point represents the maximum seizure score
for an individual mouse. The median seizure
scores between treatments (horizontal line) are
not statistically different (p=0.3622, Mann
Whitney test, two tailed). ).
B. Latency to convulsion. There is no
significant difference between the treatments
(p=0.6889, two-tailed Mann-Whitney test).
Horizontal line indicates mean values.
C. Incidence of convulsions. The number of
mice exhibiting a convulsive seizure (PTZ
seizure score≥3) in A is expressed as a fraction
of total mice injected with PTZ for each
treatment group (ratio in the bar is the raw
data). (χ2 test for linear trend, *p= 0.0141).
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3.5

Discussion

Evidence from this study supports three primary suppositions. First, pyramidal neurons, but not
granule cells of the dentate gyrus, are the primary cellular source of physiological extracellular
IL-1β release in the normal hippocampus. Second, basal processing and release of IL-1β from
these neurons is dependent on P2X7R activity. Third, P2X7R contributes to the homeostatic
balance of excitation and inhibition in the brain.
3.5.1

Cellular source of constitutive IL-1β release in the normal hippocampal formation

Several lines of evidence from previous studies support the contention that IL-1β expression and
release occur under physiological conditions in the brain. First, IL-1β transcripts have been
detected under basal conditions in RNA isolates from several tissues, including the
hypothalamus and hippocampus (Quan et al. 1996; Hosoi, Okuma, and Nomura 2000a), and this
was shown to fluctuate on a diurnal schedule (Taishi et al. 1997). Second, picomolar levels of
IL-1β protein have been reported in tissue homogenates from these regions indicating that the
cytokine is translated (Watt and Hobbs 2000; Hosoi, Okuma, and Nomura 2000b; Takemiya et
al. 2017). Third, tissue dialysis measurements suggest that IL-1β protein is released
constitutively into the extracellular space in vivo (Phelps et al. 1995; Summy-Long et al. 2008;
Frank et al. 2020) and immunohistochemical results showing physiological release of IL-1β from
the neurohypophysis is consistent with this (Watt and Hobbs 2000). Additionally, low picomolar
levels of IL-1β protein were detected in supernatants from hippocampal slice cultures under
basal conditions and this release occurred at 37 but not 20oC, demonstrating that IL-1β protein
secretion required normal cellular metabolic processes (Ross et al. 2003).
The identity of the cellular sources of IL-1β release is key to understanding its signaling in the
normal brain. In the hypothalamus, IL-1β protein expression has been localized to oxytocin- and
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vasopressin-containing neurons of the magnocellular and neurohypophysis suggesting a role in
regulation of normal physiological processes and behavior (Watt and Hobbs 2000). In the
hippocampus, results from one study showed that IL-1β mRNA was expressed in each of the
three major glutamatergic neuron populations of the rat hippocampal formation - the DG, CA3,
and CA1 (Bandtlow et al. 1990). Another study, however, reported prominent constitutive IL-1β
immunoreactivity in the mossy fiber axon terminals originating from the DG, but apparently did
not find evidence for expression in pyramidal neurons of the CA3 or CA1 (Lechan et al. 1990).
These results are at odds with the current study, which found IL-1β immunoreactivity in the
hippocampus only after treatment with the P2X7R antagonist, and under this condition, the
immunoreactivity was localized to CA3/CA1 pyramidal neurons but not granule cells of the DG.
The reason for the disparate findings between this and the Lechan study is not clear. However, it
could be due to species differences in IL-1β expression in the hippocampal formation since the
latter study was performed using tissue from rat brains. Possible species differences in IL-1β
function in the brain have been discussed previously (Vitkovic et al. 2000).
The cellular target of IL-1β action in the mouse hippocampal formation under basal conditions
remains to be elucidated. However, the location of IL-1R1 expression may provide hints. The
highest level of IL-1R1 mRNA expression is found in the granule cells of the DG and this
expression profile correlates well with the location of ligand binding sites, which are highly
concentrated in these cells as well (Ban et al. 1991; Cunningham et al. 1992; Deyerle et al.
1992). Given the evidence herein implicating CA3 neurons as a major source of IL-1β in the
hippocampus, this expression profile raises the possibility that CA3 may modulate DG function
via a pathway involving IL-1β-IL-1R1 signaling. A recent study using a novel transgenic
approach to map IL-1R1 protein expression in the hippocampal formation found prominent IL-
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1R1 protein in the cell soma and molecular layer of DG granule cells (Liu et al. 2015). The latter
is consistent with another study showing post-synaptic localization of IL-1R1 in hippocampal
neurons (Gardoni et al. 2011). Expression was also detected in the mossy fiber tract of the DG
neurons, suggesting a possible presynaptic function of IL-1 signaling as well.
3.5.2

Role of P2X7R in constitutive IL-1β release in the normal hippocampus

The detection of IL-1β immunoreactivity in hippocampal pyramidal neurons in the presence but
not absence of the P2X7R antagonist is consistent with the following conclusions: 1) IL-1β is
constitutively released by these neurons at very low levels in the normal hippocampus, 2)
blocking the function of P2X7R caused the cytokine to accumulate in these cells, and 3) P2X7R
functions as a trigger for IL-1β release from these cells under normal conditions in vivo. The
results from primary hippocampal neuron cultures showing an increase in IL-1β
immunoreactivity following treatment with the P2X7R antagonist provide additional support for
the role of P2X7R in constitutive release of IL-1β from hippocampal neurons. Evidence showing
high P2X7R mRNA expression levels in pyramidal neurons, and in particular CA3 pyramidal
neurons, is consistent with these conclusions [(Metzger et al. 2017) and Allen Mouse Brain
Atlas]. It should be recognized, however, that not all evidence agrees with this expression
pattern. For example, one study reported P2X7R mRNA expression in all primary cells of the rat
hippocampal formation, including the DG (Sperlágh et al. 2002). On the other hand, another
study reported presynaptic expression of P2X7R protein in the rat mossy fiber terminals of the
DG (Armstrong et al. 2002), which is interesting given the reported location of IL-1β ligand in
these same termini (Lechan et al. 1990). This draws further attention to the possibility that
species differences in IL-1β signaling could exist in the normal hippocampus. Alternatively,
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since the approach by Metzger et al. eliminated all splice variants of P2X7R, it is possible that
some differences in express patterns between studies may be due to splice variants.
It is intriguing that the immunostaining in hippocampal neuron cultures appeared most
prominently as perinuclear puncta. The nature and function of these puncta will require further
investigation. However, one possibility is that they are micro-vesicles that transport IL-1β from
the cell soma to remote sites of release, similar to what has been proposed in the hypothalamus
(Watt and Hobbs, 2000). The detection of small puncta in the proximal region of neurites herein
is consistent with this possibility. It is important to note that IL-1β release does not follow the
classical endoplasmic reticulum-Golgi apparatus secretory pathway (Rubartelli et al. 1990) and
that several alternative vesicle-mediated mechanisms have been proposed for its release from
activated inflammatory cells (Dubyak 2012). Among these pathways are microvesicle shedding
(Monteleone et al. 2018), secretory lysosome release (Rubartelli et al. 1990; Andrei et al. 1999)
or exosome secretion (Qu et al. 2007). Qu et al. argued that the exosome pathway is the primary
release mechanism from inflammatory cells. However, in addition to the puncta, a second
fraction of diffuse cytosolic IL-1β immunoreactivity was observed in cell soma and proximal
neurites of hippocampal neurons in culture. A non-vesicular fraction of IL-1β was also reported
in activated monocytes (Rubartelli et al. 1990; Andrei et al. 1999). The significance of this
fraction is not clear, although it would be consistent with release via micro-vesicle shedding
(Muralidharan-Chari et al. 2010).
Since the antibody used in immunocytochemical analysis herein detects both pro and active IL1β, it was not possible to determine whether the immunoreactivity was due to unprocessed/pro or
processed/active IL-1β. However, the results from the IL-1β immunoblot analysis may be
informative. The detection of an ~31-kDa band and absence of a 17kDa band in the culture
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lysates suggests that the immunoreactivity is due to unprocessed (pro) IL-1β and that the active
form is not stored but released upon processing. Additionally, the conspicuous absence of a
17kDa band and small increase the 31kDa band in cultures treated with the P2X7R antagonist
further supports this notion and implies that the increase in immunoreactivity in these cultures
was due to accumulation of the unprocessed peptide. An important implication of this result is
that processing as well as release of IL-1β occur in a P2X7R-dependent manner similar to what
has been reported in inflammatory cells (Piccini et al. 2008). The primary difference is that the
neuron cultures were not exposed to inflammatory stimuli. How IL-1β is process under noninflammatory conditions remains an open question. It is interesting to note that in addition to
expression of caspase-1, primary cultures of neurons from human embryonic brains
constitutively express several components of inflammasomes under normal conditions, raising
the possibility that neuronal IL-1β may be processed by an inflammasome-like process (Kaushal
et al. 2015). However, it is not known whether these factors are expressed in the normal adult
hippocampus. Alternatively, it is possible that processing occurs in an entirely novel manner. In
this regard, caspase-1 dimerization has been shown to be sufficient for IL-1β processing in the
absence of an inflammasome (Conos et al. 2016). In any case, IL-1β is presumed to be processed
by caspase-1 and there is evidence to support this in the hypothalamus (Tringali et al. 1996). In
this regard, a preliminary study performed with Caspase-1 inhibitor, Y-VAD-CHO for 1 hour,
showed a dose dependent, mild increase in pro-IL-1β level in hippocampal neurons with western
blot analysis (study described in appendix, Fig.7.8). Although further research needs to be
conducted to confirm role of Caspase-1 in cleavage and release of processed IL-1β in
hippocampal neurons, this data may indicate a role of Caspase-1 in this process.
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3.5.3

Role of P2X7R in modulation of the excitatory-inhibitory (E/I) balance

Two approaches were used to examine the role of constitutive P2X7R in maintenance of the
homeostatic balance between excitation and inhibition under physiological conditions. The first
examined the effect of P2X7R antagonist on the activity of the Fos and Ptgs2 genes in cultures of
hippocampal neurons. Because the transcriptional activity of these immediate early genes, which
code for cFos and COX-2, is coupled to NMDA receptor signal transduction (Morgan et al.
1987; Cole et al. 1989; Yamagata et al. 1993; Hewett et al. 2016), the increase in expression of
their mRNA expression in neurons after exposure to the antagonist is consistent with a
modulatory role of P2X7R on excitatory-inhibitory homeostasis in the normal hippocampus.
Specifically, the result suggests that constitutive P2X7R activity, likely driven by constitutive
ATP release, dampens excitation in the hippocampus under basal conditions. While the increase
is small, it is important to note that it occurred in the context of strong basal GABAA receptormediated inhibition in hippocampal neuron cultures, as indicated by the marked increase in cFos
and COX-2 expression induced by bicuculline in the neuronal cultures. On the other hand, the
lack of effect of APV by itself, which would be expected to suppress expression mediated by
excitatory activity, indicates that this basal inhibitory tone was sufficient to suppress to a large
extent excitatory activity in these cultures.
The second approach to assess the function of P2X7R in maintenance of E/I homeostasis
examined the effect of the P2X7R antagonist on the PTZ-induced convulsive seizure threshold.
As a GABAA receptor antagonist (Ramanjaneyulu and Ticku 1984; Huang et al. 2001), PTZ
shifts the homeostatic balance between excitation and inhibition in the brain to favor excitation.
This effect is dose-dependent and, if disinhibition is sufficiently strong, it can disrupt normal
brain function, triggering a seizure response. Results herein demonstrating that the P2X7R

97

antagonist enhanced sensitive to the excitatory properties of PTZ further suggests that
constitutive activity of P2X7R is involved in maintenance of the E/I balance in the normal brain.
Considering the effect of the antagonist on IL-1β release in the hippocampus, the result from
these studies are consistent with the hypothesis that the effect of the antagonist on cFos/COX-2
expression in neuronal cultures and PTZ seizure threshold in vivo is due to blocking IL-1β
release in the hippocampus. However, it is important to acknowledge that the effect of the
antagonist on IL-1β release and E/I balance are correlative, and as such, results herein cannot
directly address cause and effect. By virtue of its properties as a non-selective cation channel,
P2X7R could influence neuronal function independent of a role in IL-1β release. Moreover,
constitutive IL-1β expression has been reported in brain regions in addition to the hippocampus,
including the cortex, that could influence E/I balance. Thus, a relationship between P2X7R and
hippocampal IL-1β release in maintenance of E/I balance awaits more direct evidence.
Clearly, much remains unknown about the biochemistry of IL-1β in the normal hippocampus and
additional studies are necessary to answer questions related to its production, release, and
signaling. However, results from the current study will provide a foundation for further
investigation.
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Specific Aim 3: To investigate the role of excitatory neuronal activity on IL-1β expression/
signaling function in neurons of the hippocampus: possible link between IL-1β signaling and
Cyclooxygenase-2 (COX-2)
Synopsis
Aim 3 analyzed the possibility of whether alteration in expression of endogenous IL-1β ligand or
it’s signaling components expression and/or its signaling functionalities downstream may occur
due to excitatory neuronal activity. This aim parallelly investigated two sub-aims:
1. IL-1β release was found to be activity-dependent in the hypothalamus (Watt and Hobbs 2000)
or in hippocampal slice cultures (Ross et al. 2003), however, this has not been thoroughly
examined in the lights of seizure activity which is an outcome of uncontrolled neuronal activity.
These aims hypothesized IL-1β expression may be dependent on excitatory neuronal activity and
this idea would be explored in the first part of this chapter.
2. COX-2 has neuromodulatory role in maintenance of the innate seizure threshold (Claycomb,
Hewett, and Hewett 2012; Gong and Hewett 2018). Of importance to the present study,
exogenous IL-1β had been shown to induce COX-2 expression and prostaglandin production in
different CNS cells types (Samad et al. 2001; Sayyah et al. 2005; Neeb et al. 2011) suggesting
neuromodulatory pathway of COX-2 may function downstream of IL-1β. Furthermore, previous
study from our lab showed COX-2 inhibition elevated seizure severity in mice similarly in
wildtype mice and in mice with genetic deletion of Il-1R1. These studies together suggested a
possible contribution of COX-2 functioning downstream of IL-1β signaling, and this would be
explored in the second part of this chapter. Taken together, these two studies would investigate
effects of neuronal excitation on endogenous IL-1β expression and on its downstream signaling
possibly via COX-2.
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Chapter 4

Effect of neuronal excitation on endogenous IL-1β:
Possible contribution of COX-2
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4.1

Summary

Inactivating Interleukin-1β (IL-1β) or its signaling receptor (IL-1R1), genetically, or IL-1β release
from neurons, pharmacologically, sensitized mice to the convulsant property of pentylenetetrazol
(PTZ), implying its constitutive presence in maintenance the innate seizure threshold. Still,
whether changes in excitatory neuronal activity could simultaneously alter IL-1β synthesis and/or
downstream signaling function remains to be elucidated. This was examined in vivo using PTZ
induced convulsion and in hippocampal neuron culture with bicuculline. Effect of convulsion
transiently induced IL-1β mRNA in vivo. Although, low endogenous IL-1β protein could be
detected in mice hippocampus and in cultured neurons, excitatory neuronal activity had no
immediate effect on the basal protein level.
Secondly, purpose of this study was also to investigate if neuro-modulatory functions of
endogenous IL-1β is mediated via Cyclooxygenase-2 (COX-2). Therefore, this study determined
whether endogenous IL-1β affected basal and induced COX-2 expression and/or activity. Mice
with genetic deletion of IL-1R1 exhibited lower basal and PTZ induced COX-2 expression in
hippocampus. Parallelly, neutralizing IL-1R1 in cultured hippocampal neurons lowered basal and
bicuculline induced COX-2 immunoreactivity. As COX-2 is the rate limiting enzyme of
prostaglandin synthesis pathway, lower endogenous COX-2 expression in IL1r1 mutant mice
hippocampus also paralleled with altered basal PGE2 profile compared to wildtype littermates and
affected convulsion induced PGE2 production in mutants. This study will have implication in
understanding how endogenous IL-1β may maintain homeostatic excitation-inhibition balance via
COX-2.
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4.2

Introduction

Interleukin-1β (IL-1β) is a well-characterized cytokine of the innate and adaptive immune
systems (Dinarello 2009). Within the central nervous system (CNS), IL-1β has been implicated
in the pathogenesis of several neuroinflammatory and neurodegenerative diseases (Rothwell and
Luheshi 2000; Simi et al. 2007; Fogal and Hewett 2008; Shaftel, Griffin, and O’Banion 2008;
Pinteaux, Trotter, and Simi 2009; Hewett, Jackman, and Claycomb 2012). Several exogenous
(bacterial products) and endogenous factors (pro-inflammatory cytokines) causes increase in IL1β level and its release in brain (Rothwell and Luheshi 2000; Gibson, Rothwell, and Le Feuvre
2004; Simi et al. 2007). Parallelly, it’s function is also described in specific physiological
functions of the CNS independent of its role as immune mediator such as sleep (Krueger et al.
1998; Opp, Obal, and Krueger 1991), body fluid regulation (Diana et al. 1999; Summy-Long et
al. 2006; 2008), neuroprotection (Strijbos and Rothwell 1995; Mason et al. 2001), learning and
memory (Schneider et al. 1998; Barrientos et al. 2002; Ross et al. 2003; Avital et al. 2003). Very
low constitutive expression of IL-1β mRNA and protein have been reported in various regions of
the normal brain of rat: hypothalamus (Watt and Hobbs 2000), hippocampus (Lechan et al. 1990;
Kaneko et al. 2006; Viviani et al. 2014) and cortex (Quan et al. 1996), indicative of its
neuromodulatory functions. IL-1β signals through the canonical plasma membrane receptor
complex consisting of the ligand-binding chain, Interleukin-1 receptor 1 (IL-1R1), and its
accessory protein, IL-1RacP. Upon ligand activation, MyD88 is recruited to this complex, where
it serves as an adaptor for binding of Interleukin receptor-associated kinases (IRAKs) to
subsequently initiate downstream signaling cascade (Dinarello 2002; 2009). All components of
canonical IL-1 signaling are also expressed in the normal brain at the physiological level (French
et al. 1999; Nadjar et al. 2005; Cremona et al. 1998; Andre et al. 2005; Yabuuchi et al. 1994;
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Cunningham et al. 1992) and in cultured hippocampal neurons (Gardoni et al. 2011), implying
the likelihoods of neuromodulatory functions of constitutive IL-1β within the physiological
brain. Particularly to our interest, constitutive IL-1β is expressed in CA3 pyramidal neurons of
murine hippocampus (Chapter 3) and that blocking constitutive IL-1β signaling either genetically
or its release pharmacologically may lower the seizure threshold in mice [(Claycomb, Hewett,
and Hewett 2012) and Chapter 3]. These findings are indicative of neuromodulatory role of
constitutive IL-1β in regulating the homeostatic E/I balance. However, it is unclear whether
changes in neuronal activity (uncontrolled electrical activity which leads to the acute seizure)
could alter IL-1β expression and function. This study will focus on the effect of acute seizure on
IL-1β expression in normal hippocampus. Secondly, this study will also try to identify any
downstream effector candidate of IL-1β, which may play a role in moderation of E/I balance in
an IL-1β dependent manner.
In the present study, an interplay between constitutive IL-1β signaling and one of its known
downstream effectors, Cyclooxygenase-2 (COX-2) expression and/or activity in
neuromodulation is therefore investigated. Cyclooxygenases (COX) are enzymes that catalyze
the rate-limiting step of Arachidonic acid (AA) metabolism, producing lipid immune mediators
called prostaglandins (PGs) (Kaufmann et al. 1996). Unlike COX-1, COX-2 is constitutively
expressed by certain excitatory neurons of CNS (Förstermann et al. 1982; Yoshikawa et al.
2006). Constitutive COX-2 mRNA expression in cultured cortical neurons is NMDAR
dependent (Hewett et al. 2016). In relevance to this study, previous results from our lab indicated
overexpression of neuronal COX-2 in mice maintained elevated seizure threshold (Gong and
Hewett 2018) and inhibiting COX-2 markedly increased susceptibility of mice to seizure
induction (Claycomb, Hewett, and Hewett 2011), suggesting that COX-2 contributes to the
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maintenance of the innate seizure threshold. COX-2 is thus widely studied in CNS for its role in
several neuronal diseases as well as for its neuromodulatory functions, including seizure and
epilepsy (Hewett, Bell, and Hewett 2006).
Interestingly, inflammation mediated or exogenous IL-1β induces COX-2 expression and/or
prostaglandin (PG) production in different CNS cell types (Serou, DeCoster, and Bazan 1999;
Fiebich et al. 2000; Bazan and Lukiw 2002; Moolwaney and Igwe 2005; Favrais et al. 2007). Of
importance, a link between these two pathways has been demonstrated in central sensitization to
inflammatory pain in vivo (Samad et al. 2001; Sayyah et al. 2005) and in rat trigeminal nerve
ganglia (Neeb et al. 2011). However, it is unclear whether constitutive IL-1β in brain may
influence basal COX-2 expression and thus its neuromodulatory effects. Earlier studies from this
group showed inhibition of COX-2 lowered the acute convulsive seizure threshold in wild-type
mice and in mice lacking IL-1 signaling similarly, indicating the possibility of COX-2
functioning downstream of IL-1 signaling (Claycomb, Hewett, and Hewett 2012). These
evidences led us to hypothesize that constitutive IL-1β might regulate the innate seizure
threshold via COX-2.
Expression of IL-1β receptor, IL-1R1 is highly concentrated in the hippocampus (French et al.
1999) and P2X7R, the purinergic receptor which may be required for physiological IL-1β release
is also expressed in the hippocampus (Metzger et al. 2017). Constitutive IL-1β accumulates in
CA3/CA1 pyramidal neurons and in certain populations of hippocampal neurons in culture
(studied in chapter 3). Within CNS, COX-2 is constitutively expressed in certain glutaminergic
neuronal population including pyramidal cells of CA3 and is induced in granule cells of DG post
seizure (Claycomb, Hewett, and Hewett 2011; Gong and Hewett 2018). Therefore, our study will
focus on hippocampus as the site of action for neuromodulatory IL-1β expression and function.
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4.3

Materials and Methods

4.3.1

Mice

CD-1 mice: Male 6-7-week-old CD-1 mice for in vivo studies were obtained from Charles River
Labs (Wilmington, MA) and housed three per cage for at least one week prior to use. For studies
using hippocampal neuron cultures, pregnant female CD-1 mice were purchased from Charles
River Labs and housed singly upon arrival at Syracuse University.
IL-1R1 mutant mice: Mutant C57BL/6J mice lacking a functional gene for IL-1R1 (Il1r1) were
obtained from The Jackson Laboratory [Stock #003245,(Glaccum et al. 1997)] and maintained as
a breeding colony in the Syracuse University vivarium as described previously (Claycomb,
Hewett, and Hewett 2012). Details of breeding and genotyping procedures are provided in section
2.3.1 of Chapter 2. Brains of the mice used for PTZ study from Chapter 2 were utilized for
immunohistochemical and prostaglandin study herein.
4.3.1.1 Animal housing: as described in section 2.3.1.1 of chapter 2.
4.3.1.2 Anesthesia: Mice for all in vivo studies were anesthetized with 120 mg/kg ketamine, 20
mg/kg xylazine, intraperitoneally in saline (1X). P0-P1 pups for hippocampal neuronal dissection
were anesthetized using isoflurane (1 ml on a gauze pad in a closed container from
approximately 8 pups).
4.3.2

Pentylenetetrazol (PTZ) induced acute seizure paradigm

Detailed functioning, usage, and injection technique for the acute seizure paradigm have been
described in section 2.3.3 of Chapter 2. All acute seizure study used mice injected with saline
(1X) as control.
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4.3.2.1 Dose-response study: Separate cohorts of CD-1 mice were treated with a single dose of
either 50,55 or 60 mg/kg PTZ and seizure behavior scored using our 5 point severity scale as
described previously: 0, normal behavior; 1, hypo-mobility; 2, myoclonus; 3 and 4, convulsion
without and with loss of righting, respectively (Claycomb, Hewett, and Hewett 2011).
Additionally, the incidence of convulsion (% of mice exhibiting convulsion, score ≥3) was also
quantified for this study. The dose with spread of seizure response and maximally effective doses
( >90% mice had convulsive seizure) for male CD-1 mice were 55mg/kg and 60 mg/kg
respectively (Fig 6.1).
4.3.2.2 Acute seizure paradigm: To model neuronal excitation uniformly within all mice, a
dose which effectively generated convulsive seizure was chosen. Based on results from the doseresponse analysis performed; acute seizure activity was induced by a single dose of 60 mg/kg
PTZ on CD-1 mice as it induced convulsive seizure in >90% of mice.
4.3.3

Primary hippocampal neuron cultures

4.3.3.1 Preparation
The method of culturing hippocampal neurons has been broadly discussed in chapter 5 of this
dissertation thesis. Primary hippocampal neurons were cultured following the method discussed
briefly in the section 3.3.2 of chapter 3.
4.3.3.2 Cell culture studies
All studies with primary hippocampal neuron cultures were performed at 14-15 days in vitro
(DIV). For studies with bicuculline methobromide, a 100mM stock solution was prepared in
DMSO and frozen at -20oC. This was diluted in growth medium and administered to cells at a
final concentration of 100μM.
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For IL-1R1 neutralization, 1µg/µl neutralizing IL-1R1 Ab (details in table 1.3) (stock conc.
1mg/ml) was diluted in growth medium and administered to the wells designated for
neutralization treatments. To study effect of neuronal excitation in absence of/lowered IL-1
signaling, bicuculline (100μM) was administered following 2 hours neutralizing antibody
treatment for two hours. Wells were replaced with fresh medium prior to the studies.
4.3.4

Quantitative PCR analysis

4.3.4.1 Sample collection (in vivo): Mice with seizure score of 3 or 4 and their saline controls
were included in this study. Fully anesthetized mice were exsanguinated and perfused
transcardially with cold phosphate-buffered saline (PBS) and the hippocampi from both
hemispheres were removed and stored in -80°C immediately. Before RNA extraction, one
hippocampal side (studies primarily was done with left hemisphere, right was kept on reserve)
for each mouse sample was homogenized in 250µl PBS on ice, aliquoted into two tubes and each
dissolved in 1mL TriZol Reagent in labelled centrifuge tubes and immediately stored at -80°C
prior to RNA extraction.
4.3.4.2 RNA extraction and cDNA synthesis: As described in the sections 3.3.7.2 and 3.3.7.3
of chapter 3.
4.3.4.3 Quantitative PCR: Total RNA was purified and reverse transcribed as described
previously (Hewett et al. 1999) and expression of c-Fos, IL-1β, IL1R1,IL1RacP, Caspase-1 and
P2X7R was quantified with a real-time PCR detection system (Mastercycler ep RealPlex2 RealTime PCR System, Eppendorf)) using Applied Biosystems TaqMan Universal PCR Master Mix
and FAM-MGB dye gene expression assay probes. Relative expression was quantified using the
comparative cycle threshold method, ΔΔCt (Livak and Schmittgen 2001), where individual Ct
values were normalized to the β-actin Ct value from the same sample then with a control sample
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Ct value (calibrator) to determine the relative fold changes in mRNA. To assess primer
efficiency for each analysis, qPCR reactions were performed on a dilution series of known
cDNA concentrations (12.5, 25, 50, 100, and 200 ng/reaction, cDNA generated from salinetreated CD-1 mice hippocampus). Efficiency across all input concentrations was confirmed
(slope of relative efficiency plot <0.1) between all primer pairs and housekeeping gene (β-actin)
primer pair. The expression assay probes (Thermo Fisher Scientific) were cFos, IL-1β, IL1r1,
IL1RaP, Caspase-1, P2X7R, COX-2 and β-actin (details in table 1.5).
4.3.7

Immunofluorescence analysis of protein

4.3.7.1 Immunohistochemistry: As described in the section 3.3.4 of chapter 3.
4.3.7.2 Immunocytochemistry: As described in the section 3.3.5 of chapter 3.
4.3.7.3 Antibodies for IHC and ICC.
Primary: IL-1β, IL-1R1, NeuN, MAP-2, COX-2.
Secondary: Donkey anti Rabbit Alexa Fluor 488, Donkey anti-Mouse Alexa Fluor 594, Goat anti
Hamster DyLight 405. Details of antibodies and their usage are provided in table 1.3.
4.3.7.4 Quantification of immunoreactivity.
All brain section images of subregions of hippocampi were converted to 8-bit gray scale and
fluorescent intensity was quantified using NIH FIJI (Image J2). For COX-2 immunoreactivity, the
maximum and minimum thresholds were set to 26 and 255, using the auto thresholding technique.
Results from two images from each brain section were averaged and the mean fluorescent
integrated density was calculated in the hippocampal sub-regions using methods described
previously (Gong and Hewett 2018).
To quantify fluorescence intensity in hippocampal neurons in culture, maximal and
minimal threshold was set similarly for individual study using auto thresholding technique and the
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total fluorescent integrated density for each field was calculated. Alongside total number of
neurons in each field were counted using cell counter plugin in FIJI (3 fields/well, 3 wells/plate X
2 replicates). Total fluorescence integrated density was divided by the number of neurons for
individual fields which was then quantitatively represented as fluorescence intensity per neuron.
For visual representation, images from individual studies were processed identically using Adobe
Photoshop.
4.3.8

IL-1β Immunoblot analysis: As described in section 3.3.8 of chapter 3.

4.3.9

Enzyme linked Immunosorbent Assay (ELISA)

4.3.9.1 IL-1β ELISA
4.3.9.1.1

In vivo sample collection: Mice with seizure score of 3 or 4 and their saline

controls were included in this study. Prior to brain dissection, all mice were fully anesthetized
with 100/10mg/kg ketamine/xylazine, respectively, i.p. For time-course analyses of IL-1b
protein expression, CD-1 mice, were exsanguinated 15, 30, 60, and 120 minutes following PTZ
injection by transcardial perfusion with ice-cold PBS and the hippocampi were removed.
Hippocampal tissue was homogenized in Cell Lysis Buffer 2 (Part#895347, R & D Systems) and
the supernatant was collected after centrifuging at 13000*g for 30 minutes and stored at -80°C
prior to using.
4.3.9.1.2

ELISA: A commercially available ELIZA kit was used to quantify IL-1β in

hippocampal tissue of mice brain (Quantikine mouse IL-1β ELISA). Total protein concentration
was quantified using commercially available kit (BCA) and supernatant were adjusted to 1μg/μL
protein with lysis buffer. IL-1β concentrations were determined from a standard curve
(1.25pg/ml- 80pg/ml) by diluting the known concentration provided by the manufacturer.
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4.3.9.2 Prostaglandin (PGE2) assay
4.3.9.2.1

Impeding endogenous COX-2 production due to surgery: Saline or PTZ treated

mice were immediately anesthetized after injection or after PTZ induced convulsion, respectively.
Peritoneal cavity of anesthetized mouse was opened via surgery and injected with indomethacin
(10mg/kg) diluted in PBS into the inferior vena cava. After 3 minutes, transcardial perfusion was
conducted with 12-15 ml ice-cold 1X PBS followed by 10 ml indomethacin (20mM diluted in 1X
PBS). The hippocampi were quickly removed and snap-frozen in liquid nitrogen.
4.3.9.2.2

Homogenization of hippocampal tissue: Hippocampal tissue was homogenized

in 100-150µl homogenization buffer (containing 10% v/v 10mM EDTA, 0.1% v/v 10mM
Indomethacin and 1mM KH2PO4 in ultrapure water) and supernatant was collected after
centrifuging at 12000*g for 20 minutes and stored at -80oC prior to use.
4.3.9.2.3

PGE2 ELISA: Total protein concentration was quantified using commercially

available kit (BCA) and supernatants were adjusted to 0.25μg/μL protein with homogenization
buffer. PGE2 concentrations were determined using workbook provided by manufacturer from a
standard curve (31.25pg/ml- 4000pg/ml) by diluting the known concentration provided by the
manufacturer.
4.3.10 Statistical analysis
Data were analyzed using GraphPad Prism, Version 8.4.1 (GraphPad Software, Inc., La Jolla, CA,
U.S.A.). Statistical tests are described in figure legends. Statistical significance was set to p<0.05.
Statistical tests described in figure legends. Behavioral data associated with scoring of seizure
are reported as median seizure score and incidence of a convulsive seizure. Latency to
convulsion after acute PTZ injection between genotypes was assessed using a two-tailed Mann–
Whitney test. Datasets representing proportions (incidence of convulsions) were analyzed using a
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two-tailed Fisher’s exact test. For q-PCR, statistics were performed on the logarithmic
transformation of 2-DDCT values, and analyzed with Kruskal Wallis test followed by uncorrected
Dunn’s test. For t-test, one-way ANOVA, two-way ANOVA, in addition to p values, F values
were determined for equal variance. (for ANOVA, F (DFn, DFd) where DFn is the numerator of
df (degree of freedom) and DFd is the denominator of df and for unpaired t-test, t values and df,
in addition to p values). In case this p-value was significant, the Welch t-test was done instead of
unpaired t-test and Brown Forsythe test was done instead of one-way ANOVA to account for
this variance. For in vivo studies comparing immunofluorescence , two-way ANOVA were
followed by Bonferroni’s multiple comparison test. For comparing PG levels in mice
hippocampus and for in vitro studies, one-way or two-way ANOVA were followed by Fisher’s
uncorrected LSD test.
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4.4

Results

4.4.1

PTZ induced acute seizure: Dose-response study

PTZ elicits seizure and convulsion in a dose-dependent manner (Claycomb, Hewett, and Hewett
2011). The threshold and maximally effective doses for my studies was assessed in a doseresponse analysis of CD-1 mice by treating the mice with either 50 mg/kg (N=14), 55 mg/kg
(N=6) or 60 mg/kg (N=16) b.w. of PTZ and seizure behavior was scored using our 5-point
severity scale as described in methods. The threshold (dose with intermediate population
response) (33%) and maximally effective doses [PTZ dose inducing convulsive seizure in >90%
mice) determined for male CD-1 mice were 55mg/kg and 60 mg/kg respectively (Fig. 4.1).
60mg/kg PTZ was chosen for the following seizure studies in mice because it induced
convulsions in with an incidence of >90%.

Fig.4.1.

Identification of PTZ dose for acute convulsive seizure threshold analyses.

Dose response analysis of CD-1 mice were conducted by treating mice with either 50mg/kg (N=14),
55mg/kg (N=6) or 60mg/kg (N=16) b.w.
A. Seizure severity. Each point represents the maximum seizure score for an individual mouse,
horizontal line represents median seizure score for that dose.
B. Incidence of convulsions. The number of mice exhibiting a convulsive seizure in A is expressed as a
% of total mice injected with PTZ for each treatment group (ratio in the bar is the raw data).
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4.4.2

Effect on IL-1β ligand and signaling components in mice hippocampus with PTZ

induced seizure activity
To test whether intensive neuronal activity in mice induced or altered IL-1β mRNA and protein
level, CD-1 mice were challenged with 60mg/kg PTZ and their seizure response were assessed.
IL-1β mRNA levels at different time points post injection in hippocampal tissue was compared
to saline treated mice tissue (15-, 30-, 60- and 120-min post PTZ injection). IL-1β mRNA level
elevated significantly in hippocampus immediately after convulsion (4.5 times compared to
saline treated hippocampus 15 min post injection). IL-1β mRNA restored to basal level in
hippocampus by 60 mins following injection (Fig.4.2). This transient increase in IL-1β mRNA
level was consistent with elevated c-Fos mRNA level, used as surrogate marker of excitatory
neuronal activity (Morgan et al. 1987). However, no immediate significant changes were
identified in the mRNA levels of IL-1β receptor, IL-1R1 and its accessory protein, Il-1RacP
(Figure 4.3 A and B) and in P2X7R (the purinergic receptor required for IL-1β release) mRNA
level (Figure 4.3 C). However, Caspase-1 mRNA, the proteolytic enzyme required for cleavage
of IL-1β to its functional form and for its secretion, elevated 4 times by 60 mins and remained
elevated at 120 mins (Figure 4.3 D).
To test if the increase in IL-1β mRNA translated to change in protein level, IL-1β level was
measured using ELISA in hippocampal tissue of mice having PTZ induced convulsion in a time
course study (15-, 30- and 60-min post injection). ELISA analysis demonstrated constitutive IL1β protein in low pico-gram level indicating physiological presence of IL-1β in hippocampal
tissue. Time course study showed no immediate alteration in IL-1β protein levels with intensive
neuronal activity; however, it did not affect the basal levels (Fig 4.4).
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Fig. 4.2.
IL-1b mRNA level in hippocampus changes in parallel to basal excitatory
neuronal activity.
Time course (15 min (N=6), 30 min(N=6), 60 min(N=5) and 120 min (N=4)) of IL-1b and c-Fos mRNA
expression following PTZ induced convulsive seizures in mice (60mg/kg b.w.) compared to saline treated
control mice (N=6) . A 2-way ANOVA followed by uncorrected Fisher’s LSD comparisons test was
performed on log transformed data showed significant difference in mRNA levels with treatment from
respective vehicle-treated controls (*, p = 0.0021).
(For IL-1b mRNA, *, p = 0.0041, Kruskal-Wallis test with multiple comparison by uncorrected Dunn’s
test. Significance denoted by “a” ,*, p= 0.0141, saline vs. 15 min, p = 0.8319, saline vs. 30 min, p=
0.4663, saline vs. 60 min and p=0.2547, saline vs. 120 min.
For c-Fos mRNA, *, p = 0.0198, Kruskal-Wallis test with multiple comparison by uncorrected Dunn’s
test. Significance denoted by “b”, *, p= 0.0144, saline vs. 15 min, *, p = 0.0068, saline vs. 30 min, p=
0.1674, saline vs. 60 min and p=0.8252 and saline vs. 120 min.)
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Fig.4.3.
Effect on IL-1b signaling components’ mRNA in mice hippocampus with
acute convulsive seizure.
A. Time course (15 min (N=7),30 min (N=7), 60 min (N=4) and 120 min (N=5)) of IL-1R1 mRNA
expression following PTZ induced convulsive seizures in mice (60mg/kg b.w.) compared to saline-treated
control mice (N=6).
For IL-1R1 mRNA, p = 0.1444, Kruskal-Wallis test with multiple comparison by uncorrected Dunn’s
test, p= 0.6278, saline vs. 15 min, p = 0.3323, saline vs. 30 min, *, p= 0.0186, saline vs. 60 min and
p=0.9379 saline vs. 120 min.
B. Time course (15 min (N=6),30 min (N=5), 60 min (N=4) and 120 min (N=5)) of IL-1RaP mRNA
expression following PTZ induced convulsive seizures in mice (60mg/kg b.w.) compared to saline-treated
control mice (N=5).
For IL-1RaP mRNA, p =0.833, Kruskal-Wallis test with multiple comparison by uncorrected Dunn’s test,
p= 0.548 saline vs. 15 min, p = 0.2441, saline vs. 30 min, p= 0.4159, saline vs. 60 min and p=0.49, saline
vs. 120 min.
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C. Time course (15 min (N=3),30 min (N=3), 60 min (N=3)) of P2X7R mRNA expression following PTZ
induced convulsive seizures in mice (60mg/kg b.w.) compared to saline-treated control mice (N=3).
For P2X7R mRNA, p = 0.6255, Kruskal-Wallis test with multiple comparisons by uncorrected Dunn’s
test, p= 0.2097, saline vs. 15 min, p = 0.3048, saline vs. 30 min and p=0.2542 saline vs. 60 min.
D. Time course (15 min (N=4),30 min (N=4), 60 min (N=3)and 120 min (N=4)) of Caspase-1 mRNA
expression following PTZ induced convulsive seizures in mice (60mg/kg b.w.) compared to saline treated
control mice (N=4).
For Caspase-1 mRNA, *, p = 0.0135, Kruskal-Wallis test with multiple comparison by uncorrected
Dunn’s test, p= 0.8007, saline vs. 15 min, p= 0.0583, saline vs. 30 min and *, p=0.0035, saline vs. 60 min
and *, p=0.0373, saline vs. 120min.
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Fig.4.4.

IL-1b protein expression is not altered by acute convulsive seizure.

IL-1b level was quantified by ELISA in hippocampal homogenates of mice either treated with saline
(N=5) or with PTZ injection [15min (N=5), 30 min (N=4), and 60 min (N=5)]. IL-1b level between time
points were compared by Brown-Forsythe ANOVA test #
(p=0.9815, F*(DFn, DFd)=0.05496 (3, 6.025) followed by unpaired t with Welch correction (p= 0.9068,
saline vs. 15 min, p = 0.8648, saline vs. 30 min and p=0.07965, saline vs. 60 min).
#

Brown-Forsythe ANOVA test was done instead of one-way ANOVA as significant difference was found
in variance Brown-Forsythe test (**, p= 0.0096, F(DFn, DFn)=5.484 (3,15)).

4.4.3

Effect on IL-1β ligand in cultured hippocampal neurons with bicuculline induced

neuronal excitation
To assess this in vitro, cultured primary hippocampal neurons were treated with bicuculline to
shift E/I balance to favor excitation by disinhibition. Previous study in chapter 3 have shown
constitutive IL-1β immunoreactivity in subset of cultured neurons where IL-1β is expressed in
cell body as perinuclear puncta and in neuronal processes. Similar IL-1β immunoreactivity

117

pattern was observed in vehicle treated cells and this level remained same with 4 hours
bicuculline treatment (Fig.4.5).
Immunoblot analysis of hippocampal cell lysates showed corresponding results. Constitutive
presence of only 31kD pro-IL-1β protein in cultured hippocampal neurons was seen whose level
did not alter with bicuculline induced neuronal activity. Alongside, there was no evidence of
17kD processed IL-1β peptide in both vehicle and bicuculline treated cells (Fig.4.6).

Fig.4.5A

(continued)
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Fig.4.5B
Fig.4.5.
IL-1b protein expression is not
altered by neuronal excitation in cell bodies and
neuronal processes of hippocampal neurons.
Representative photomicrographs of cultured
hippocampal neurons in culture (DIV 14)
demonstrating IL-1β (green) immunoreactivity costained with A. neuronal marker NeuN (red) and B.
neuronal processes MAP-2 (green) in control and
bicuculline treatments. (20X objective). Scale bar =
25µm. White arrows show IL-1β immunoreactivity in
the neuronal processes.

Fig.4.5C

C. IL-1b fluorescence intensity per neurons was
quantified in hippocampal neuronal cells as described
in materials and methods for control and bicuculline
treatment after 4 hours treatment and analyzed using
unpaired t test (p=0.0626, t=1.992, df=36).
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i.
ii.

Fig.4.6: IL-1b protein expression is not altered by neuronal excitation in vitro.
Immunoblot analysis using anti-IL-1β and anti-β-actin antibodies was performed on cell lysates harvested
after 4 hours following treatment with vehicle (DMSO) or Bicuculline as described in Materials and
Methods.
i. Representative blot. ii. Fluorescence intensity of IL-1β in cell lysate treated either with bicuculline
(N=3) or its vehicle (DMSO) (N=3) for 4 hours was quantified, normalized to β-actin fluorescence
intensity and analyzed by unpaired t test (p=0.9815, t=2.277, df=6). Equal variance was validated by the F
test.

4.4.4

Effect of IL-1R1 gene deletion on basal and induced COX-2 expression in mouse

hippocampus
My studies have shown, P2X7R antagonism (possibly through blocking of IL-1β release)
elevates basal COX-2 mRNA in hippocampal neurons (Fig. 3.8, Chapter 3). In mouse with
genetic deletion of IL-1 signaling, it was reasonable to test if this altered signaling may affect
COX-2 mRNA level. No genotype dependent changes in COX-2 mRNA level in hippocampus
was observed between genotypes (Fig.4.7).
As suggested in the introduction, neuronal COX-2 expression and/or activity has been shown to
be regulated via exogenous IL-1β treatment indicating COX-2 may function to downstream of
IL-1β signaling. However, it is unknown if constitutive IL-1β affects basal COX-2 expression
and/or activity. To test this hypothesis, COX-2 immunoreactivity was observed in saline treated
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wild type and IL1r1 mutant littermate mice. Constitutive neuronal COX-2 expression is observed
in glutaminergic neurons of cortex and in subsets of CA3 pyramidal neurons of mice (Claycomb,
Hewett, and Hewett 2011; Gong and Hewett 2018). The current study was consistent with this
result in the wild type littermates. Furthermore, constitutive COX-2 immunoreactivity was 36%
lower in CA3 subregion of KO mice compared to the WT littermates (Fig.4.8), indicating
absence of functional IL-1 signaling affected basal COX-2 expression in mice hippocampus.
To test the effect of IL-1r1 gene deletion on neuronal activity induced COX-2 expression, wild
type and IL1r1 mutant littermate mice were given 43.5mg/kg PTZ and its seizure behavior was
observed (studies in section 2.4.2 of Chapter 2). To understand effect of IL1r1 deletion on
induced COX-2 expression, only wild type and mutant mice having convulsive seizure (seizure
score of 3 or 4) were considered which kept the effect of PTZ stimulus similar across genotype.
Immunohistochemical analysis of WT mice brain showed immediate elevated expression (by 1
hour) in CA3 sub-region of hippocampus and induced expression in DG and CA1 sub-regions
(Fig.4.9). KO mice, on other hand, had significantly lower induced COX-2 expression in CA3
(~70% lower) and DG (~65% lower) sub-regions of the hippocampus compared to their WT
littermates and no observable expression in the CA1 region (Fig.4.9 i and fluorescence intensity
quantification in Fig. 4.9 ii).
Similarly, elevated COX-2 level was seen in CA3 compared to basal state and remained induced
in DG sub-region of the hippocampus of WT mice following 3 hours of the convulsive seizure
which is consistent with previous findings (Claycomb, Hewett, and Hewett 2011; Gong and
Hewett 2018), however, activity dependent COX-2 level in IL-1r1 KO mice was significantly
lower in these sub-regions compared to the WT littermates (~ 76% lower in CA3 and ~ 75%
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lower in DG subregion of KO mice) (Fig.4.10 i and fluorescence intensity quantification in Fig.
4.10 ii).
Therefore, these results conclude both basal and induced COX-2 expression in absence of
functional IL-1β signaling was lower.

Fig.4.7. Basal COX-2 mRNA expression in the hippocampus of mice brain in mice.
Relative normalized COX-2 mRNA expression in WT and KO mice (N=3,each genotype) was compared
with two-tailed, unpaired t-test (p= 0.4127, t=0.9135, df= 4). Fold change from one WT sample was used
as calibrator and set to 1.Equal variance was validated by F test (F=6.303, DFn, DFd= 2,2).
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Fig.4.8.
IL-1R1 gene deletion alters basal neuronal COX-2 expression in mouse
hippocampus.
i. WT or KO (N= 5, each) brain sections were stained for COX-2 immunoreactivity (green),
counterstained with DAPI (blue) and photomicrographs were acquired from coronal section (10X
objective). Representative photomicrograph shows COX-2 immunoreactivity in (A & D) CA3, (B & E)
CA1 and (C & F) DG subregion of hippocampus. Headings indicate IL-1r1 genotype for each column of
images. Scale bar =100 µm.

123

ii. COX-2 fluorescent intensity was quantified and compared by a two-tailed unpaired t-test between the
genotype for CA3 sub-regions of the hippocampus. (***, p=0.001, t=6.764, df=8 for CA3 subregion).
Equal variance was validated by F test (F, DFn, DFd= 1.036, 4, 4). No COX-2 expression was detected
in CA1 and DG sub-region of the hippocampus in both the genotype.
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Fig.4.9.
IL-1R1 gene deletion alters activity dependent neuronal COX-2 protein
expression in mouse hippocampus.
One hour following PTZ injection, WT or KO (N= 5,each) mice brain sections were stained for COX-2
immunoreactivity (green) and DAPI (blue) and photomicrographs were acquired from coronal section
(10X objective). Representative photomicrograph shows COX-2 immunoreactivity in (A, D) CA3, (B, E)
CA1 and (C, F) DG subregion of hippocampus. Headings indicate IL-1r1 genotype for each column of
images. Scale bar = 100 µm.
(continued)
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ii.
COX-2 fluorescent intensity was quantified for all three sub-regions of hippocampus and
were analyzed using 2-way ANOVA followed by Bonferroni’s multiple comparisons test.
Significant differences (a, between genotypes (***,p<0.001) and b, from the corresponding
value in the subregions (***, p <0.001)) were observed. No COX-2 expression was detected in
CA1 sub-region of hippocampus in KO mice brain. Equal variance was validated by F test.

Bonferroni's multiple comparisons tests
WT - KO
CA3
CA1
DG
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Significant?

Summary

Adjusted
p-Value

Yes
Yes
Yes

**
**
**

<0.0001
0.0005
<0.0001

Fig.4.10.
IL-1R1 gene deletion alters activity dependent neuronal COX-2 protein
expression in mouse hippocampus.
Three hours following PTZ injection, WT or KO (N= 3) brain section was stained forCOX-2
immunoreactivity (green) counterstained with DAPI (blue) and photomicrographs were acquired from
coronal section (10X objective). Representative photomicrograph shows COX-2 immunoreactivity in (A,
D) CA3, (B, E) CA1 and (C, F) DG subregion of hippocampus. Headings indicate IL-1r1 genotype for
each column of images. Scale bar = 100 µm.
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ii.

COX-2 fluorescent intensity for was quantified for the CA3 and DG sub-regions of hippocampus
and were analyzed using 2-way ANOVA followed by Bonferroni’s multiple comparisons test. Significant
differences (a, between genotypes (*, p=0.0409) and b, from the corresponding value in the subregions (*,
p <0.001)) were observed. No COX-2 expression was detected in CA1 sub-region of hippocampus of
either genotype. Equal variance was validated by F test.
Bonferroni's multiple
comparisons tests
WT-KO
DG
CA3

4.4.5

Significant?

Summary

Adjusted pValue

Yes
Yes

**
**

0.0037
0.0007

Effect of excitatory neuronal activity on COX-2 mRNA and protein expression in

hippocampal neurons.
Section 3.4.4 in chapter 3 demonstrated the relationship between COX-2 mRNA expression and
neuronal excitation. Cultures of hippocampal neurons were treated with the GABAA receptor
antagonist, bicuculline (Fig 3.8 D). Compared to vehicle-treated cultures, bicuculline induced a
6-fold elevation in COX-2 mRNA expression alongside 7-fold increase in cFos mRNA
(surrogate marker for neuronal excitation) expression (Fig. 3.8 B, respectively).
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Similarly, a different set of cultured hippocampal neurons either pretreated (for 30 mins) with or
without MK-801(non-competitive NMDA antagonist) and were then treated with bicuculline
(GABAA antagonist) or its vehicle for 60 min. MK-801 treatment, similar to APV treatment, did
not change basal COX-2 or c-Fos level. Compared to the culture which received no or MK-801
treatment, COX-2 and c-Fos MRNA were elevated approximately 4 and 3.5 folds, respectively in
neurons treated only with bicuculline. However, cultures which received bicuculline following
MK-801 pre-treatment significantly attenuated COX-2 and c-Fos mRNA level, implying
elevation in COX-2 mRNA level due to excitatory neuronal activity was NMDA receptor
dependent (Fig. 4.11).
Certain population of hippocampal neurons in culture expressed COX-2 endogenously (Fig 4.12
A, Control). Alongside elevation in COX-2 mRNA level with excitatory neuronal activity,
hippocampal neurons also showed an elevation in COX-2 protein expression following
bicuculline treatment (2 hours and 4 hours, Fig. 4.12 A). Induced COX-2 immunoreactivity was
significantly elevated within 2 hours of treatment which lowered gradually to basal level by 4
hours (as quantified in Fig. 4.12 B). Alongside, significant elevation in total COX-2 intensity, %
of neurons expressing COX-2 was also significantly higher at 2 hours post bicuculline treatment
(Fig. 4.12 C).
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Fig. 4.11
Expression of COX-2 and excitation-coupled gene, cFos increases in
hippocampal neuron cultures after Bicuculline treatment but attenuated with MK-801
treatment.
Cultures were treated with 0 (Control) or MK-801 (10 µM, 30 min pre-treatment), followed by 0
(DMSO) or Bicuculline(100µM, 60 min treatment) (N=3). Normalized mRNA levels were
compared between treatments using 2-Way ANOVA followed by Uncorrected Fisher’s LSD test
(*, significantly different between treatments, p < 0.001). Annotations for this graph were used to
designate individual significance between treatments and described in the following table
containing individual p values.
Uncorrected Fisher's LSD
Significant? Summary Individual P Value
COX-2
control vs. MK-801
No
Ns
0.1405
control vs. Bicuculline
Yes
*
<0.0001
control vs. MK-801+Bicuculline
No
Ns
0.5430
MK-801 vs. MK-801+Bicuculline
No
Ns
0.3667
Bicuculline vs. MK-801+Bicuculline
Yes
#
<0.0001
c-Fos
control vs. MK-801
No
ns
0.2177
control vs. Bicuculline
Yes
•
0.0002
control vs. MK-801+Bicuculline
No
ns
0.5051
MK-801 vs. MK-801+Bicuculline
No
ns
0.5559
Bicuculline vs. MK-801+Bicuculline
Yes
<0.0001
F
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Fig.4.12.
COX-2 expression is elevated
with bicuculline treatment in hippocampal
neurons.

*

A. Representative photomicrograph (20X
objective) demonstrates COX-2 protein expression
(green) colocalized with neuronal marker, NeuN
(red) in hippocampal neuronal cells for bicuculline
treatment compared to untreated neurons after 2and 4-hours post-treatment. Scale bar = 25µm.
B. Quantification of mean COX-2 fluorescence
intensity per neuron between control and
bicuculline treated cells were analyzed by one-way
ANOVA, (*,p=0.0293, followed by Fisher’s
uncorrected LSD test for multiple comparison, *,
p= 0.0108, Bic (2hours) vs. Control and p= 0.502,
Bic (4hours) vs. Control). The equal variance was
validated by the F test.

*

C. Quantification of % neurons expressing COX-2
was compared between control and bicuculline
treated cells. % of neurons expressing COX-2
protein by one-way ANOVA. (*,p=0.0437,
followed by Fisher’s uncorrected LSD test for
multiple comparison, , p= 0.0658, Bic (2hours) vs.
Control and p= 0.3439, Bic (4hours) vs. Control).
The equal variance was validated by the F test.
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4.4.6

Effect of IL-1R1 receptor neutralization on basal and induced COX-2 expression in

hippocampal neurons
Both basal and neuronal activity dependent COX-2 expression were significantly lowered in
hippocampus of mice with genetic deletion of IL-1R1. To test if this observation recured in vitro,
IL-1R1 neutralizing antibody was utilized to block the IL-1R1 receptor function in cultured
primary hippocampal neurons. Constitutive COX-2 immunoreactivity in distinct neuronal
population of hippocampus was elevated by excitatory neuronal activity (Fig 4.12 & 4.13 C).
Basal COX-2 expression (Fig. 4.13, Panel A) was significantly lowered (52%) in hippocampal
neurons following 120 mins of IL-1R1 neutralizing antibody treatment (Fig 4.13, panel B).
Secondly, IL-1R1 neutralization antibody pretreatment caused significantly lower (72.5%)
activity dependent COX-2 expression (Fig. 4.13, Panel D), compared to bicuculline induced
COX-2 immunoreactivity in hippocampal neurons (Fig. 4.13, Panel C).
Basal and induced COX-2 expression was lower with IL-1R1 neutralization treatment in vitro, and
this study showed corresponding outcomes as seen in vivo with IL-1r1 mutant mice, indicating
modulation of COX-2 expression when IL-1 signaling is not functional, both in vivo and in vitro.
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Fig.4.13.
IL-1 receptor neutralization lowers constitutive and activity dependent
COX-2 expression in vitro.
i.
Representative photomicrographs of hippocampal neurons in culture with following treatments
exhibited COX-2 immunoreactivity (green) co-stained with DAPI (blue) (20X objective).
A. Constitutive COX-2 immunoreactivity in hippocampal neurons, B. with 120 min IL-1R1 neutralizing
antibody treatment, C. with 120 min bicuculline treatment, and D. 120 min pretreatment with IL-1R1
neutralizing antibody followed by 120 min of bicuculline treatment. Scale bar = 25µm.

(continued)
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ii. COX-2 fluorescence intensity per neurons was quantified, compared between treatments and analyzed
using Ordinary one-way ANOVA, followed by Fisher’s uncorrected LSD test for multiple comparison (*,
p<0.0001). Equal variance was validated by F test.

Uncorrected Fisher's LSD

Significant?

Summary

- IL-1R1 Ab v/s +IL-1R1 Ab
- IL-1R1 Ab v/s +Bicuculline
+ Bicuculline v/s +IL-1R1 Ab + Bicuculline

Yes
Yes
Yes

**
****
****
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Individual
p-Value
0.0089
<0.0001
<0.0001

4.4.7

Effect of IL-1R1 gene deletion on basal and induced PGE2 level

COX-2 is the rate-limiting enzyme required for prostaglandin synthesis from arachidonic acid.
Being the key enzyme of this biochemical pathway, alteration in availability of COX-2 may
skew physiological and neuronal activity dependent prostaglandin production and function. To
test the hypothesis whether lowered basal and induced COX-2 may also affect prostaglandin
production, constitutive (naive) and intensive neuronal activity dependent (43.5mg/kg PTZ
treated) PGE2 levels were measured in wild type and mutant IL1r1 littermate mice hippocampi.
PGE2 measured via indirect ELISA demonstrated genotype and neuronal activity dependent
variation (Fig. 4.14). Wild type mice hippocampi generated 130.3±3.9 pg/ml PGE2 in basal state.
However, immediately following a convulsion, the PGE2 level increases approximately 4 times
of its basal level (514±32.4 pg/ml) in the hippocampi of PTZ treated WT mice. Hippocampi of
WT mice have approximately 50% lower constitutive PGE2 level compared to their KO
counterparts.
Following a convulsion, WT mice hippocampi generated 4 times higher PGE2 than what it
produced basally and 2.81 times more PGE2 produced in the KO hippocampi following a
convulsion. In contrast, the level of PGE2 in KO hippocampi remained same after a convulsion
in KO mice hippocampi (Fig.4.14). Thus, basal and induced PGE2 production was mediated by
IL-1 signaling in mice hippocampi.
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Fig.4.14.
IL-1 signaling affects basal and activity-dependent PGE2 levels in the
hippocampus of mice brain.
PGE2 levels were measured through ELISA in WT (N=3, for each treatment group) or KO (N= 3, for each
treatment group) hippocampi treated with either saline or with 43.5mg/kg PTZ injection inducing
convulsive seizure and analyzed using 2-way ANOVA followed by Fisher’s uncorrected LSD test.
Significant differences ( p<0.001), a, between genotypes (p=0.008) and b, between treatments (p <0.001)
were found. Annotations in this graph were used to designate individual significance between treatments
and/or genotype and is described in the following table containing individual p values.

Uncorrected Fisher's LSD Significant? Summary Individual p-Value
WT: Saline vs. WT: PTZ
Yes
***
<0.0001
WT:Saline vs. KO:Saline
Yes
*
0.0204
WT: PTZ vs. KO: PTZ
Yes
#
<0.0001
KO: Saline vs. KO: PTZ
No
ns
0.3182
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4.5

Discussion

Evidence from this study supports two primary suppositions. First, excitatory neuronal activity
does not alter immediate IL-1β protein levels in the normal hippocampus. Second, this report
particularly draws merit in determining the role of endogenous IL-1β signaling in modulating
basal and neuronal activity dependent COX-2 in hippocampus of mice brain, as role of
endogenous IL-1β in mediating COX-2 have not been investigated prior to this study .
Constitutive IL-1β moderates basal and neuronal activity dependent COX-2 expression and its
function.
4.5.1 Effect of excitatory neuronal activity on IL-1β ligand and its signaling components.
IL-1β is a secretory protein which is produced and released primarily in cells of
monocyte/macrophage lineage by stimuli either exogenous (like bacterial toxin, LPS or gamma
radiation) or endogenous (pro-inflammatory cytokines) (Dinarello 2009). Endogenous IL-1β is
expressed in hippocampal neurons and its physiological release is indicated to be dependent on
ATP receptor P2X7R dependent, as studied in chapter 3. However, studies in previous chapter
do not shed light upon the specific endogenous stimuli that may trigger IL-1β production and
release from neurons.
Firstly, this study reports intensive excitatory neuronal activity (PTZ induced convulsion)
causing a transient increase in IL-1β mRNA immediately following PTZ induced convulsion
which recedes to basal level by 2 hours. Previous literatures have also shown induction of IL-1β
gene expression due to different kinds of neuronal activity. Both in vivo and in vitro, IL-1β gene
expression was elevated in the hippocampus with long term potentiation (induced at 1 hour
following LTP and was highest at 3 hours post LTP in slices and 8 hours following LTP in
hippocampus of rat brain) in NMDA dependent manner (Schneider et al. 1998). Fear
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conditioning induced about 2.4 times more IL-1β gene expression after 24 hours in hippocampus
of mice (Goshen et al. 2007) and spatial recognition memory task similarly elevated IL-1β
mRNA in hippocampus but not in hypothalamus of mice within 90 min of task completion
(Labrousse et al. 2009). Particularly in relevance to this result, 50mg/kg PTZ injection in rats
showed similar immediate elevation in IL-1β (in 30 min) in hippocampus following PTZ induced
seizure and declines by 3 hours (Minami et al. 1990). Altogether, these studies account for fact
that altering excitatory neuronal activity may serve as an endogenous non-inflammatory stimulus
in brain to induce IL-1β gene, specifically in hippocampus. Intensive neuronal activity did not
induce either its receptor, IL-1R1 mRNA or its receptor accessory protein, IL-1RacP mRNA
within first 2 hours of PTZ administration, irrespective of inducing IL-1β mRNA in
hippocampus. Alteration in excitatory neuronal activity may not require IL-1R1 mRNA
induction in parallel to induction of IL-1β mRNA as very few surface IL-1R1 is sufficient to
elicit biological response within a cell (Bankers-Fulbright, Kalli, and McKean 1996).
Endogenous IL-1R1 expression is mostly concentrated in DG neurons of hippocampus (Parnet et
al. 2002; Liu et al. 2019) and may be sufficient to propagate IL-1β signals. Yet, Caspase-1
mRNA is induced at 1 hour following convulsive seizure in hippocampus of mice brain. As
Caspase-1 is required for processing of inflammatory IL-1β (Pétrilli, Papin, and Tschopp 2005;
Dinarello 2009), its induction may seem relevant in this scenario. As discussed in section 3.5 of
chapter 3, requirement of Casapase-1 in processing endogenous IL-1β will require further
investigation to understand the relevance of its mRNA induction following PTZ treatment in
mice hippocampus.
It is known that endogenous IL-1β is produced, processed and released for several
neuromodulatory functions in normal brain. The current study did not find any immediate change
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in IL-1β ligand in hippocampus tissue following convulsion. Consistent with results in chapter 3,
saline treated hippocampus showed very low basal level of IL-1β (40pg/ml). This level of IL-1β
did not change following PTZ induced convulsion within an hour. It can be hypothesized that
constant level of endogenous IL-1β protein in hippocampus between treatment time points as
seen here may occur if excitatory neuronal activity dependent IL-1β production and release
occurs simultaneously, maintaining a constant basal level of IL-1β. Alternatively, IL-1β protein
may translate after 1 hour of PTZ induced convulsion. The current study differs from studies
done by Temp et al. 2017, where IL-1β protein doubled its endogenous level in hippocampus of
mice brain within 20 min of PTZ injection (50mg/kg, i.p.) (Temp et al. 2017).
In cultured inflammatory cells, IL-1β mRNA is stable up to 4 hours of induction before it is
degraded by intrinsic mechanism (Fenton et al. 1988). Studies herein showed mRNA elevation
upto 30 min before it went back to basal level by 2 hours. Therefore, a caveat in this study
remains in observing IL-1β levels only for one hour. Extending the time point can suggest a
different result. Further experimentation will be required to test these hypotheses.
PTZ was utilized to model intensive excitatory neuronal activity without causing excitotoxic
insults in mice brain (Claycomb, Hewett, and Hewett 2011). This model is unique as it provided
an opportunity to study if IL-1β is induced by alterations in neuronal activity independent of
immune reactions initiated by excitoxicity as seen in kainic acid (KA) model of acute seizure.
KA causes excitotoxic insults within 1-3 hours of administration (Eriksson et al. 1999) and
induces IL-1β mRNA within 2.5 hours of administration (Minami et al. 1990) followed by
elevated IL-1β protein by 5 hours of administration (Eriksson et al. 1999). However, IL-1β
induction in this case occurs in microglia (Eriksson et al. 1999) and is associated with excitotoxic
insults and neuronal cell loss (Eriksson et al. 1999; Claycomb, Hewett, and Hewett 2012)
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indicating an immunological effect rather than neuronal. However, cellular site of IL-1β mRNA
induction by PTZ in mice hippocampus will require further study.
Similarly, in cultured hippocampal neurons, no changes in level of IL-1β protein were observed
after 4 hours of bicuculline treatment. Correspondingly, no gross differences in subcellular
localization of IL-1β were observed between treatments (compared to Fig. 3.3). Furthermore, IL1β expression in cell lysates as seen through western blot expressed only 31kD pro- IL-1β band.
As IL-1β processing is associated with its release, this observation seems to be recurring
occurrence across CNS cell types [studies in chapter 3 with cultured neurons with or without JNJ
treatment, Fig 3.4 and in mixed glial culture (Kim, Smith, and Van Eldik 2004)]. Measuring IL1β in cell media post treatment will be able to shed light upon constitutive production,
processing and release of IL-1β induced by excitatory neuronal activity. It can be summarized
herein that PTZ mediated intensive excitatory neuronal activity did not markedly elevate IL-1β
protein immediately in mice hippocampus or in cultured neurons. The logical next step is to look
into changes in expression or function of any effector molecules downstream of IL-1β signaling.
Preliminary results on phosphorylated IRAK-1 immunoreactivity (Section 7.5, Appendix)
showed, it immediately elevated following PTZ induced convulsive seizure stimuli (Fig 7.9). As
IRAK-1 is phosphorylated by IRAK-4 which in turn is self-phosphorylated after its association
with MyD88 adaptor protein, it can be an indication of activation of IL-1β signaling (S. Li et al.
2002; Neumann et al. 2007). To test if IL-1β signaling initiated IRAK-1 phosphorylation due to
intensive neuronal activity, p-IRAK-1 immunoreactivity was tested in IL1r1 mutant mice, which
showed significantly lowered p-IRAK-1 immunoreactivity (Fig 7.10 s). IRAK-1 is a key kinase
to NF-kB signaling, possibly downstream of IL-1β signaling (Kishi et al. 2016). These
preliminary studies indicate, firstly, IL-1β signaling may be triggered by intensive neuronal
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activity (immediate phosphorylation of downstream kinase), and secondly, this phosphorylation
is dependent on functional IL-1β signaling. Further studies will be required to understand the
IRAK phosphorylation in this aspect in detail. Also, it can help identify IRAK-1 phosphorylation
as a biomarker for acute seizure activity.
Another effector candidate of IL-1β signaling whose expression and function was investigated in
detail was COX-2.
4.5.2 Effect of endogenous IL-1 signaling on basal and activity dependent COX-2
expression
COX-2 is the rate limiting enzyme in arachidonic acid pathway which produces lipid
inflammatory mediators (prostaglandins) by metabolizing membrane phospholipids. COX-2 is
generally induced by inflammation and its physiological expression is present only in very few
specific cells of CNS including glutaminergic neurons of hippocampus (Kaufmann et al. 1996).
In relevance to this report, numerous studies have identified COX-2 mRNA, protein and COX-2
dependent PG production is induced by exogenous IL-1β in CNS (Blom et al. 1997; Inoue et al.
1999; Molina-Holgado et al. 2000; Samad et al. 2001; Morioka et al. 2002; Parker et al. 2002;
Hein et al. 2007; Neeb et al. 2011; Ohnishi et al. 2019b).Some studies have also shown effect of
IL-1ra in moderating COX-2 (Inoue et al. 1999), however, both IL-1β and IL-1ra was provided
to the system exogenously.
Endogenous COX-2 expression in neurons in CA3 region of hippocampus is lower in absence of
IL-1 signaling. However, basal COX-2 mRNA levels is similar in both WT and IL-1R1 mutant
mice [(Claycomb 2011) and current data] implying firstly, knocking out IL-1R1 in mice did not
affect basal COX-2 transcription and secondly, absence of IL-1 signaling affected COX-2
expression in post transcriptional manner.
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Post transcriptional modification in COX-2 is receiving research importance owing to its
relevance in neuromodulatory roles (Hewett et al. 2016; Gong and Hewett 2018). 3’UTR region
of COX-2 contains Adenylate-uridine Rich Element, which mediates post-transcriptional
regulation of COX-2. No evidence as far directs towards role of endogenous IL-1β in moderating
3’UTR elements of COX-2 mRNA. However, a study done on human endometrial stromal cell
show exogenous IL-1β mediated post-transcriptional modification of COX-2 mRNA by
enhancing mRNA stability and sustaining COX-2 mRNA production (Tamura et al. 2002). IL1Ra treatment on other hand lower COX-2 mRNA stability (Tamura et al. 2002). Although this
study is done in different tissue type with exogenous IL-1β, this may provide clue as to how IL1β may moderate COX-2 mRNA in hippocampal neurons and its absence (in mice with IL-1r1
deletion) can alter mRNA stability and not its production, lowering basal expression of COX-2
protein. Secondly, even though COX-2 immunoreactivity is significantly lower in mutant mice,
COX-2 expression is not completely abrogated indicating parallel mechanism on which basal
COX-2 production may be dependent, alongside IL-1 signaling.
PTZ induced neuronal activity mediates the following changes in COX-2 expression in mice
hippocampus, i) both in wildtype and mutants, PTZ induced acute convulsive seizure induces
COX-2 expression in DG subregion and elevates activity dependent COX-2 expression in CA3
subregions by 1 hour, alongside, it also induces COX-2 expression in CA1 sub-region but only in
the wildtypes, ii) at three hour following PTZ injection, COX-2 expression remains elevated in
CA3 and DG region, which is consistent with previous findings (Claycomb, Hewett, and Hewett
2011; Gong and Hewett 2018) and iii) Activity dependent COX-2 expression is lower in the
mutant mice in CA3 and DG regions at both time points, however, is absent in CA1 region.
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Firstly, role of endogenous IL-1 signaling is implied in activity dependent COX-2 expression.
Like its basal expression, activity dependent COX-2 is not completely dependent on IL-1
signaling as COX-2 expression lowered but was not completely abolished. Secondly, this study
demonstrates COX-2 protein induction occurs very quickly in all three regions of hippocampus
in WT type however, only DG and CA3 but not in CA1 of mutant mice at a lower rate. IL-1β
needs to be secreted and bind to cell membrane receptor, IL-1R1for signaling. Studies from
chapter 3 have indicated endogenous IL-1β may be located in CA3/CA1 pyramidal neurons. IL1R1 localization in hippocampus therefore should suggest cells involved in IL-1 signaling. In
mice, IL-1R1 protein is shown to concentrated in the cell soma and molecular layer of DG
granule cells (Parnet et al. 2002; Liu et al. 2015), however expressed throughout CA1-CA4
(French et al. 1999). Although, whether endogenous IL-1β release from neuron is synaptic or
extra-synaptic, is not yet investigated, this report is indicative of an autocrine signaling
mechanism within CA3/CA1 neurons and paracrine signaling in DG neurons of hippocampus via
which IL-1β signaling may regulate COX-2 function.
Lastly COX-2 is induced in CA1 neurons of hippocampus of wild type mice within one hour,
which completely abolishes by 3 hours post injection. COX-2 is induced in CA1 neurons of rat
hippocampus in sub-convulsive electric stimulation model of kindling after 24 hours (Chen,
Magee, and Bazan 2002), but no previous report mentions rapid COX-2 induction followed by
rapid abolition in CA1 region in any acute seizure paradigm. However, no expression of COX-2
in CA1 neurons of mutant mice may indicate COX-2 induction in these CA1 neurons to be
moderated specifically by IL-1β signaling, however, further study will be required to confirm
this notion and its relevance.
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Using cultured hippocampal neurons, it was once again shown endogenous COX-2 mRNA is
induced by glutaminergic signaling [Fig 3.8 & (Yamagata et al. 1993; Stark and Bazan 2011)].
MK-801 treatment by itself lowered COX-2 induction however not significantly. The deficiency
in effect of MK-801 by itself, which is expected to suppress expression mediated by excitatory
activity, indicates that this basal inhibitory condition is sufficient to suppress to a large extent of
basal excitatory activity in these cultures as seen also with APV treatment (Fig. 3.8, Chapter 3) .
However, bicuculline mediated elevation in both c-Fos and COX-2 mRNA which is significantly
suppressed with pretreatment with MK-801, confirms COX-2 mRNA induction to be NMDA
dependent in cultured hippocampal neurons. Bicuculline induces COX-2 protein by two hours of
treatment. It is utilized to model and test if COX-2 induction was IL-1 signaling dependent.
Basal and activity dependent COX-2 immunoreactivity is lower with IL-1R1 neutralization in
cultured hippocampal neurons which corroborates with the in vivo studies. Simultaneously, it
indirectly confirms the source of IL-1β which moderates COX-2 expression to be neuronal.
Cellular signaling mechanism connecting endogenous IL-1β and COX-2, however, will need
further investigation.
4.5.3

Effect of endogenous IL-1 signaling on basal and activity dependent PGE2 level

Prostaglandin level elevates after convulsive stimuli (Förstermann et al. 1982). Among the
prostaglandins expressed in CNS, PGE2 is highly studied in CNS owing to its neuroinflammatory roles (Lima et al. 2012). Moreover, exogenous IL-1b elevates PGE2 in COX-2
dependent manner in CNS in rat hippocampus (Hein et al. 2007) or in cultures like murine
astrocytes (Blom et al. 1997; Molina-Holgado et al. 2000), mixed glial culture (Parker et al.
2002), in neurons and astrocytic mixed culture from trigeminal ganglia (Neeb et al. 2011). It also
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induces COX-2 dependent prostaglandin synthesis in neurons of spinal cord (Samad et al. 2001)
and dorsal root ganglia (Inoue et al. 1999; Morioka et al. 2002).
Constitutively, there is low constitutive level of prostaglandins expressed in brain (Förstermann
et al. 1982). Low level of PGE2 in saline treated WT hippocampus which elevates immediately
after convulsive stimuli is consistent with this finding (Berchtold-Kanz et al. 1981; Förstermann
et al. 1982). Convulsive stimuli did not induce PGE2 levels in IL-1r1 KO mice but did not affect
the basal level. As PGE2 was measured in hippocampus immediately after convulsion, this
observation can be attributed to reduced endogenous COX-2 in the mutant mice. However,
elevated level of PGE2 in KO hippocampi can be indicative of compensatory COX-1 dependent
PGE2 production due to lowered constitutive COX-2. Exogenous IL-1b is shown to elevate both
isoforms of PGE synthase (enzyme ), COX-2 dependent membrane associated mPGES and
COX-1 dependent cytosolic cPGES/p23 (Moore, Olschowka, and O’Banion 2004). But role of
endogenous IL-1b in mediating PGESs are not known yet. As, COX-1 is basally expressed in
CNS and link between endogenous IL-1b and COX-1 is not studied herein, it may be premature
to comment on compensatory role of COX-1 mediated PGE2 synthesis in IL-1R1 mutant mice
hippocampus without further study.
Prostaglandins generated from convulsive stimuli have shown several protective properties
against acute seizure (Förstermann et al. 1982). Further studies will be required to understand if
elevated PGE2 in WT mice following convulsion provides any neuroprotection which may be
lower or absent in the mutants due to absence of PGE2 synthesis by convulsive stimuli . To
summarize, this study indicated role of endogenous IL-1 signaling in moderating endogenous
and convulsive stimuli induced PGE2 levels in COX-2 dependent manner. Thus, this report
identifies PTZ induced convulsion (or intensive neuronal activity) as an endogenous non-
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inflammatory stimulus to induce endogenous IL-1b mRNA in mouse hippocampus. It also
reports a novel link between endogenous IL-1 signaling and COX-2 in hippocampal neurons.
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Chapter 5
Development and maintenance of murine primary hippocampal
neuronal culture.
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5.1

Summary

Optimized cell culture systems have been applied for an array of biochemical and imaging
studies to complement and model biological systems. For this dissertation, murine hippocampal
neuronal cultures were cultured and maintained as a research tool. Murine hippocampal neuronal
cultures were prepared and maintained utilizing a standardized protocol which includes isolating,
successful culturing and upkeep of these neurons in tissue culture plates without astrocyte feeder
layers from postnatal mouse pups. Alterations within established protocols were made to
maintain this working culture system. This chapter will describe the standardization of the
culture protocol in the Hewetts’ lab and how it differed in certain aspects from already published
protocols. Firstly, this chapter enlisted the changes made within the established protocol to
formulate this working procedure and justified the changes made for growing neurons in vitro.
Secondly, the study also characterized endogenous expression of key IL-1 signaling components
in the murine hippocampal neuronal culture to further strengthen its relevance in context of this
dissertation research.

5.2

Introduction

The detailed process of how primary hippocampal neuronal culture was developed and
maintained as a working protocol in this lab will be discussed in this section. As this culture
system was a new model system in our laboratory, it required development of a standardized
protocol for successful culture of murine hippocampal neurons.
Prior to delving deeper into the description of the procedure for this culture system, it was
important to shade light on the relevance of hippocampal neuronal culture system in lights of the
dissertation. Using P2X7R antagonism, it was seen IL-1b accumulated in CA3/CA1 pyramidal
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neurons of hippocampus in mice brain (Chapter 3, Fig 3.1). Based upon this result, it was
hypothesized that constitutional IL-1b release is neuronal as opposed to glial IL-1b release and
functioning in neuroinflammatory or neurodegenerative processes. Culturing hippocampal
neurons would directly able us to test the hypothesis that constitutive IL-1b is neuronal without
confound. Studies discussed until now (in chapter 3 & 4) have shown constitutive IL-1b to be
neuronal and required for the maintenance of excitation/inhibition balance. Utilizing both in vivo
and in vitro approaches, release of IL-1b from hippocampal neurons was indicated to be P2X7R
mediated (studies in chapter 3). This study also paved way for a novel approach in studying in
detail the sub-cellular localization of IL-1b, functional relevance of its physiological expression
and release (Chapter 3 and 4) and its possible downstream signaling mechanism in
neuromodulation (Chapter 4). To successfully execute these studies, in vitro approaches were
considered alongside utilizing mice as model for investigation. Thus, the goal of this chapter was
to describe in detail, a working protocol developed in this lab to culture and maintain of nearpure, primary murine hippocampal neurons which was utilized for studying role of constitutive
IL-1b in neuromodulation.
This chapter will firstly describe how this protocol differs from some of the established protocols
in details and secondly, describe some of the characterization studies done to rationalize the
potential of this culture system to study role of constitutive IL-1b release and functioning in
neuronal excitation.

5.3 Culturing murine Hippocampal Neurons
Cells in vitro requires specific media for its culture and growth depending on its cell and tissue
types, origin and methods of culture. For culturing hippocampal neurons, initially, all media and
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reagents were prepared as described in (Beaudoin et al. 2012) and was applied to the culture
system, however, it did not yield viable neurons in culture. After reviewing multiple research
protocols for this culture system, procedures from few protocols were combined to yield viable
hippocampal neurons in vitro. Hippocampal neuronal cultures were prepared from postnatal day
0-1 CD-1 mouse pups using a protocol established from several previous studies (Ma et al. 2003;
Uliasz et al. 2012; Beaudoin et al. 2012). The following section will broadly describe the
changes and alterations made in these studies.
5.3.1

Materials

5.3.1.1 Mice: Post-natal day 0 (P0) or post-natal day 1(P1) pups were taken from time pregnant
CD-1 mice (Charles River Laboratories).
5.3.1.2 Reagents for culturing neurons: are described in detail in table 1.4 of chapter 1.
5.3.1.3 Preparation of media and reagents
Changes made into the media preparation for the current procedure is enlisted within the report.
The plating and growth media were prepared following Ma et al. 2003, the dissection media was
prepared following Uliasz et al. 2012.
•

10X Dissection Media (DM)- 10X dissection media was made as described in (Uliasz et
al. 2012). In short, 25 g glucose, 35 g sucrose, and 24 g HEPES was diluted in 500 ml
10X Hank’s Balanced Salt Solution (HBSS) without calcium and magnesium and pH was
adjusted to 7.4 and filtered through a 0.22µM cellulose nitrate filter system (Corning) for
sterilization and stored at room temperature of 4°C. 1X DM was used during dissection
and was made by diluting it in sterile water 1:10 and stored at 4°C.

•

Hippocampal Plating Media A (PMA) used for this culture was prepared following
(Ma et al. 2003). In short, 7% v/v heat inactivated Horse Serum, 1% v/v B27 Supplement
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(50x) , 5 μM β-mercaptoethanol (2-ME), 0.5mM glutamine, 10ml/l Penicillin/
streptomycin (100x, final conc.) were dissolved in Neurobasal A Medium. 100-200ml
media were made, sterile-filtered through 0.22μm cellulose nitrate filter system (Corning)
and stored in 4ºC for up to 2-3 weeks. The primary difference from already established
protocol referred above was the use of lower concentration of 2-ME (5μM) compared to
25μM mentioned in Ma et al. 2003.
•

Hippocampal Plating Media B (PMB) used for this culture was prepared following (Ma
et al. 2003). Briefly, 3% v/v heat inactivated Horse Serum, 1% v/v B27 Supplement
(50x), 5μM 2-ME, 0.5mM glutamine, 1% v/v Penicillin/streptomycin (100x) were
dissolved in Neurobasal A Medium. 100-200ml media were made, sterile-filtered through
0.22µm cellulose nitrate filter system (Corning) and stored in 4ºC for up to 2-3 weeks.

•

Maintenance Media (MM) used for this culture was prepared following (Ma et al.
2003). 2% B-27 (50x), 5μM 2-ME, 0.5mM glutamine, 10ml/l Penicillin/streptomycin
(100x) were dissolved in Neurobasal A medium. 300ml media were prepared, filtered
through a 0.22µm cellulose nitrate filter system (Corning) and was stored in 4ᵒC for 2-3
weeks.

•

Ara-C (Cytosine Arabinoside) used for this culture was prepared following (Uliasz et
al. 2012). In short, 20 mg Cytosine Arabino-furanoside were dissolved in 125 ml sterile
Mediatech Cellgro H2O, sterile filtered through 0.22µM cellulose nitrate filter system
(Corning) to make 8µM stock of Ara-C and stored as 1 ml aliquots in -20°C. For this
culture system, 6µM Ara-C was used by diluting it in MM.
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5.3.1.4 Coating culture plates
Initially, cultures plates were lined with Poly-D-Lysine (PDL) coated coverslips (Neuvitro, Cat#
GC-12-PDL) – 12 mm diameter (can be stored in -20°C for 6 months) (Ma et al. 2003). Sterile
forceps were used to place one coverslip/well 1 hour before plating cells. Due to variation in
viability of cells observed in cells plated on different batches of PDL coated coverslips, culture
plate coating were switched to Poly-L-lysine following the protocol described by (Beaudoin et
al. 2012). In short, to make 100µg/ml stock solution of PLL, the bottle containing 5mg of PLL is
brought to room temperature by keeping it in room temperature for 30 min and dissolved in 50
ml borate buffer (made with 1.24g boric acid and 1.9g Sodium tetraborate dissolved in 400ml of
sterile H2O, maintained to pH 8.5 and sterile filtered through 0.22µM cellulose nitrate filter
system). The bottle was left undisturbed for 40min-1 hour to ensure PLL had dissolved
completely in borate buffer. It was mixed well prior to aliquoting and stored at -20°C. To coat
the plates, on the day of dissection, 100 µg/ml stock solution (thawed) was dissolved in borate
buffer in a 3:7 ratio to obtain a final concentration of 30µg/ml. Culture plates were coated at
room temperature for at least 1 hour prior to dissection. The unbound PLL solution were
aspirated, plates were washed thoroughly with cell culture grade water (3 times) and allowed to
air-dry in the hood with plate lids off (dried at least for one hour).

5.3.2

Mouse pup brain dissection for hippocampal neuronal culture

Hippocampal neuronal cultures were prepared from the hippocampus of postnatal pups (P0/P1
days old). Equipment were set up before dissection, sterile euthanasia of postnatal pups and
isolating pup brains for dissection were done primarily following (Uliasz et al. 2012). For each
set of hippocampal dissection, (1 set of dissection yielded cells to be plated in one 24 well cell
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culture plate/one 6 well culture plate) 8-9 pups were euthanized, and their brains dissected for
obtaining hippocampi.
The pup brains were isolated after setting up the dissection tools in sterile manner as follows:
Four #3C Dumont Forceps, one #4 Dumont Forceps, one Rat Tooth stainless-steel Forceps (1 x 2
teeth), one curved Metzenbaum Dissecting Surgical Scissor (5 ½"L) were placed in 70% ethanol
and soaked for > 15 min to be used for dissection. Parallelly, the dissecting hood was wiped with
70% ethanol and the airflow system was turned on approx. 15-20 min prior to use. Two 150 mm
Petri dish bottoms (to act as ice container) and four 150 mm Petri dish lids (tool and dish trays)
were wiped with 70% ethanol and placed in the dissecting hood. Ice was placed on both 150mm
dish bottoms, one of them covered with 150 mm lid over one plate of ice to act as a tray for
media dishes. The other plate of ice was placed on the dissecting scope stage. Ethanol-soaked
tools were carefully laid out on the sterile pads on the petri dish inside dissection hood. Four 60
mm dishes with 3ml and one 35 mm dish with 1 ml DM were kept on the ice tray to avoid
cellular degradation of the dissected tissue. 2.5 ml-3 ml dissection media containing final
concentration of 0.25% trypsin was prepared and kept on ice to dissociate the dissected
hippocampal tissue. Once the set-up was complete, 8 pups/dissection were euthanized,
decapitated and their heads were cleaned in ethanol and in dissection media following (Uliasz et
al. 2012).
To dissect hippocampi from pup brain, visual guides were used as described in (Seibenhener and
Wooten 2012; Beaudoin et al. 2012).The dish containing sterile heads was then placed in the
center of the ice bath on the dissecting scope stage are brains were teased out of the skull using
two Durmont #3C forceps after the skin from the top of the skull were carefully peeled away,
while remaining cognizant of the entire dissection process is being done in cold temperature to
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avoid tissue disintegration. All of the brains were transferred to a new clean dissection media
containing dish. Next, using fresh set of Durmont #3C forceps, the brains were placed with
dorsal side up (under 2 to 2.5X magnification) and carefully the cortex from the left hemisphere
was flipped open as described in (Seibenhener and Wooten 2012; Beaudoin et al. 2012). Once
the hippocampus was identified under the dissecting scope, it was slowly separated from the
cortex and the meninges on top of the hippocampus were removed very carefully without
disturbing or cutting through the hippocampus in the process. Once the meninges were removed,
the hippocampus was removed by snipping it along the edges. The isolated hippocampus was
then transferred to a 35 mm dish containing DM. Similarly, the hippocampus from the right
hemisphere was also dissected. Once 16-18 hippocampi are dissected out, they were minced
using Durmont #4 forceps and transferred to the dissection media containing trypsin (3 ml) and
incubated for 12 min. at 37°C (water bath).

5.3.3

Plating and growing neurons in culture

Neurons were plated as described by (Beaudoin et al. 2012). However, the procedure published
by Beaudoin et al. primarily varied from the current technique used are in usage of different
media to plate and grow neurons (which were prepared following Ma et al. 2003), different
timing for which cells were incubated in those media (designed after few rounds of problem
solving to yield viable neurons) and in few key plating techniques as described below.
Plating medium A was warmed to 37°C parallelly (10 ml/ plate was required, therefore ~12 ml
was warmed) while the hippocampal tissue was trypsinized. For triturating the cells, in the
laminar flow hood, a flame was used to reduce the bore size of one cotton plugged pipette to
~3/4 of normal (medium bore) and another to ~1/2 of normal (small bore). Rubber bulbs were
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attached, and the set-up was set aside on a pipette rack with tips up as described in (Beaudoin et
al. 2012).
After the tissue in trypsin containing DM is incubated for 12 min in 37°C, the tube containing
hippocampal tissue was removed from the water bath and spun in a centrifuge at low speed for 3
min (700xg). This step differed from the original protocol which allotted wait time for tissues to
settle and not centrifuge. The current study however accounted for the same total time in trypsin
containing media (15 min). Post centrifugation, the dissociated hippocampal tissue pieces which
settled at the bottom of the tube was collected using the regular bore pipette into a 15 ml tube
containing 1.5 ml of plating medium A in the tissue culture hood and triturated for 4-6 times.
Next, using the medium bore pipette, the tissue was gently triturated 5-7 times to suspend the
neurons. Lastly, it was triturated 5-6 times with the small-bore pipette. Although, the overall
technique was adopted from Beaudoin et al. 2012, 15 ml tube were used instead of petri dish to
ensure minimal surface area for the process and to avoid formation of bubbles in the media while
trituration. Number of times the tissue was triturated were also reduced to avoid excessive cell
breakage.
After waiting for 30-40 seconds for the bigger visible tissue debris to settle, the cell containing
media was pipetted and transferred to a new tube containing about 1.5 ml plating medium,
swirled gently to mix and the volume made up to 5ml without forming bubbles.
Approximately 300,000 cells/ml can be obtained in plating media (standard cell counting
procedure using hemocytometer and Trypan blue staining as described in (Beaudoin et al. 2012)
and was done initially to plate similar number of cells/plate. Prior to plating the cells, 200µl of
plating media A is added to each well for 24 well plates (or 800µl for 6 well plates). Next, 200µl
of cell suspension were added to each well for 24 well plates (or 800µl for 6 well plates). Plates

155

were then covered and placed in a humidified incubator with 5%-6% CO2/air at 37°C. (Few
hours after the cells were plated, to check if cells have attached to plates, the plates were swirled
gently a couple of times under the hood and immediately observed under the scope to see if any
cells were still floating. The media were not switched if cells were not attached to the bottom of
the plate and still floating).
After 12-16 hours of plating, plating media B was warmed to 37°C and the cells are switched
from PMA to PMB. However, the technique to switch the media were different from Beaudoin et
al. 2012, which aspirated the entire media gently prior to adding new media. To ensure the cell
layer were never exposed to air to avoid oxidative damage, in this current method, 200µl/well
new media were added (for 24 well plates or 800µl/well for 6 well plates), swirled gently for 1-2
times to ensure any settled debris to float and then 400µl media were removed from the well (or
1.6ml for 6 well plates). 200µl fresh media/well (or 800µl for 6 well plates) were immediately
added. Longer exposure (12-16 hours compared to 4-6 hours in PMA as described in Beaudoin et
al. 2012) in media ensured no sudden changes in cell environment and longer exposure to serum
for their growth.
The cells were then switched to maintenance media 6-8 hours later (warmed to 37°C before use)
using the above-mentioned media changing procedure. The procedure to use two plating media
with different serum concentrations, prior to use of maintenance media was followed as
described by (Ma et al. 2003) and alterations in their exposure time was determined after few
trails which differed from one plating media followed by growth media described in Beaudoin et
al. 2012. The current technique had two crucial advantages- firstly, two plating media containing
7% horse serum (PMA) followed by 3% (PMB), ensured gradual decrease in concentration of
serum, thereby ensuring no rapid changes in the cell environment. Secondly, longer exposure to
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serum containing media allowed cell growth without disturbances and showed better viability
and cell growth compared to exposure of shorter duration.
Cells were treated with Ara-C (6µM final concentration) on DIV 3 for an incubation duration of
3 days, after which the media is changed and was replaced with fresh MM. Cells were fed every
three days by replacing 50% of the maintenance medium with fresh medium. The growth of the
cells was observed daily under the scope. Cells for experiments were typically used between
DIV14/15.

5.3.4

Troubleshooting and optimization of Hippocampal neuronal culture

Noticeable problems, their possible reasons and solutions faced during culturing murine
hippocampal neurons were discussed by Beaudoin et al. 2012. Troubleshooting section, in detail,
discussed commonly faced problems and how to avoid these difficulties (or their possible
solutions). While working on this current protocol, all relevant points from that section were
taken into consideration and carefully taken care of. In this section, few more areas of
troubleshooting and their process of optimization (if applicable) have been discussed.
5.3.4.1 Use of P0-P1 pups
On contrary to the use of E15 fetal pups for dissection of cortical neurons, hippocampal neurons
are cultured from E18.5 to P5 (Kaech and Banker 2006; Nunez 2008; Kaar, Morley, and Rae
2017). Current study utilized P0-P1 pups. Utilizing neonatal pups were beneficial than using
fetal pups yielded benefit for the following reasons: firstly, the female could then be further bred
to generate more pups. Secondly, hippocampal neuronal development coincides with late fetalearly neonatal period indicating that neonatal pups would likely yield more neurons than fetal
pups. These were some advantages of utilizing neonatal pups (Beaudoin et al. 2012).

157

One study utilized P2-P5 pups to generate hippocampal neurons successfully and characterized
them (Kaar et al. 2017). In my hands, this process was not successful, although initially the
neurons from two cultures progressed similarly (Fig.5.1 A). Neurons from P2-P3 pups did not
extend axons and dendrites to a similar extent compared to neurons cultured from P0-P1 pups
with progression in days in vitro (Fig. 5.1 B & C). Also, with age, there were much higher glial
contamination even after similar treatment of Ara-C [consistent with findings from (Beaudoin et
al. 2012), troubleshooting section].
Neurons from P0-P1 pups

Neurons from P2-P3 pups

A. DIV 3

B. DIV 14

C. DIV 14

Fig.5.1.
Difference in progression between hippocampal neurons cultured from P0P1 pups v/s P2-P3 pups.
Hippocampal neuronal cell culture (10X objective) in vitro in DIC images demonstrated A. progression
between neurons cultured from P0-P1pups (left) v/s P2-P3 pups (right) on DIV 3, and B & C. at DIV 14,
neurons from P0-P1 pups (on left) and from P2-P3 pus (on right). Scale bar = 50 µm.
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5.3.4.2 Use of Neurobasal A media
Most culture protocols utilize Neurobasal media or MEM eagle’s with Earle’s BSS for plating
and maintaining hippocampal neurons (Beaudoin et al. 2012; Seibenhener and Wooten 2012).
Initial studies utilized Neurobasal media for making growth media for the cells (Beaudoin et al.
2012). However, we switched to the Neurobasal A medium used in (Ma et al. 2008) as plating
and growth media were made following (Ma et al. 2003; Ma et al. 2008). Although no parallel
tests were run comparing Neurobasal Media with Neurobasal A media, according to Thermo
Fisher Scientific research resource page, the difference lied in the concentration of NaCl,
(4000mg/L in Neurobasal A media v/s 3000mg/L in Neurobasal media) which changed the
osmolarity of the media to 260±10 mOsm.
5.3.4.3 Use of different coating media/pH
Different studies utilize different plate coating media. For ICC studies, using coated glass
coverslips are a standard process. Such commercially available coated coverslips can be used,
however, variations in coating between batches may exist. Initially, the present protocol utilized
commercially available PDL coated coverslips to grow hippocampal neurons. However, few
batches of cells died within hours of plating. When coating media was changed from PDL to PLL
and rest of the procedure was kept consistent, these sudden deaths of cells were avoided.
Secondly, the pH of coating media became very important factor for cell viability. Diluting PLL
or PDL in sterile H2O as suggested by manufacturer may work for other types of adherent cell
types but failed to grow hippocampal neurons in culture. Diluting PLL in a slightly basic buffer
[borate buffer pH 8.5 used for the studies (Beaudoin et al. 2012)] kept cells viable, hence borate
buffer was used to dilute PLL for coating plates for neurons to attach and grow in culture.
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5.3.4.4 Use of Ara-C
As mentioned earlier, hippocampal neurons were typically cultured from either E18.5 days or
P0-P1 pups. One disadvantage of this system is the development period of hippocampal neurons
coincides with the development of glial cells, unlike cortical neurons which develop earlier
(Beaudoin et al. 2012). Thus, there needs to be a fine balance to treat hippocampal neurons in
culture in such a period of development that it restricts glial cell growth and division without
hurting neuronal cell development in culture. As primary neurons are very delicate cells in
culture, care was taken to determine the right time to treat the cells with Ara-C (Beaudoin et al.
2012), which would restrict glial cell division and its growth, eventually making the culture a
near-pure neuronal cell culture. Following (Beaudoin et al. 2012), we initially cultured neurons
with 3 µM Ara-C on DIV-2, which initially restricted astrocyte growth as seen in Fig. 5.2 A.
DIV 7 cell culture showed no astrocytes in the culture (undetectable GFAP immunoreactivity)
however, with maturity, by DIV 14, the culture system showed substantial number of astrocytes
in the cell culture (Fig.5.2 B) and the glial number increased with progression of days in vitro
(Fig.5.2 C) as seen through increase in GFAP positive cells. As Ara-C was washed from the
media on DIV 4 [following (Beaudoin et al. 2012)], astrocytes which were still viable left in
those culture, rapidly grew and proliferated without Ara-C in media and contaminated pure
neuron culture.
Glial cell growth was controlled using a higher concentration of Ara-C (6 µM). This restricted
glial cell growth as seen in Fig.5.2 D and generated a near pure hippocampal neuronal culture
with <10% glial cell contamination (Fig.5.6). We still observed microglia in the culture;
however, we cannot treat neuronal culture with LME to eliminate microglia as it will be toxic to
neurons and kill them.
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Alongside transitioning from usage of two plating medias (Ma et al. 2003) from use of one
plating media (Beaudoin et al. 2012), we also delayed the treatment of Ara-C from DIV 2 to DIV
3 and from 2 days of Ara-C treatment to 3 days of Ara-C treatment. Cultures were replenished
with fresh media on DIV 6. This process ensured healthy growth of neurons without glial
contamination in culture.

Fig.5.2. Glial contamination in culture increases with DIV with low Ara-C concentration.
Hippocampal neurons in culture showing GFAP (green) immunoreactivity in cells counterstained with
DAPI at A. DIV 7, B. DIV 14, and C. DIV 21 (20X magnification) after being treated with 3µM Ara-C.
Scale bar = 25µm.

D. Glial contamination in culture is lowered with revised Ara-C treatment.
Hippocampal neurons at DIV 14 in culture showing GFAP (green) immunoreactivity in cells
counterstained with DAPI (20X objective) when treated with 6µM Ara-C for 3 days. Scale bar = 25µm.
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5.3.4.5 Use of β-mercaptoethanol (2-ME)
Protocol by Beaudoin et al 2012 did not use 2-ME to culture hippocampal neurons (Beaudoin et
al. 2012). However, following Ma et al 2003, using 2-ME in all of the mediums increased the
survival rate and viability of the cells in the culture (Ma et al. 2003). 2-ME has been widely used
for culturing neurons and its benefits in maintenance of the culture for several days are reviewed
in (Ishii et al. 1993). However, the dosage of 2-ME should be tested prior to the culturing of
neurons. Although the recommended dosage for culturing neurons is 10-50µM (Ishii et al. 1993;
Ma et al. 2003), for my study the dosage of 2.5-5µM was adequate to maintain a healthy culture
system.

5.4

Characterization of cultured hippocampal neurons

The culture of hippocampal neurons is widely used and hence, well characterized. Neurons in
culture undergo distinct stages of development, starting with extension of neuronal processes,
followed by specification of axon and dendrite alongside their extension. Synapse formation and
maturation follows with progression of days in vitro. This system was also characterized to
understand if the neuronal growth and development occurred similar to cultured neurons
developed via previously established protocol. Herein, endogenous expression of key IL-1
release and signaling components in cultured murine neurons were also looked into, to justify its
use for this dissertation research.
5.4.1 Methods
5.4.1.1 Microscopy
Live cells were imaged for monitoring growth using an inverted IX50 Olympus microscope
equipped with Olympus D73 digital camera, and CellSens Standard software. Care was taken to
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monitor sterility when cultured plates are taken out and into the incubator, before and after
imaging.
5.4.1.2 Immunocytochemistry
Described in section 3.3.5 of chapter 3.
5.4.1.2.1

Antibodies:

Primary antibodies: NeuN, β-III-tubulin, Synaptophysin (Rabbit anti-Mouse), PSD-95 (Goat
Anti-Mouse), PROX-1, GAD65/67, GABAa/α1, GFAP, P2X7R, IL-1R1, IL-1RacP, MyD88,
Synaptophysin (mouse monoclonal used for counterstaining experiment with IL-1RacP) and
PSD-95 (Mouse monoclonal used for counterstaining experiments with MyD88).
Secondary antibodies: Donkey anti Rabbit Alexa Fluor 488, Donkey anti-Mouse Alexa Fluor 488,
Donkey Anti-mouse Alexa Fluor 594, Donkey Anti Goat Alexa Fluor 594, Goat anti-Rat DyLight
549, Goat anti Hamster DyLight 405. Details of antibodies are provided in table 1.3.
5.4.1.2.2

Microscopy: Images from standard epifluorescence microscopy were captured

using an inverted IX50 Olympus microscope equipped with an X-Cite 120Q fluorescence light
source (Lumen Dynamics), Olympus D73 digital camera, and CellSens Standard software. For
high-resolution analyses, images were acquired using Zeiss Axio Observer Z1 inverted microscope
equipped with 40X/1.30 oil Plan-Neofluar objective illumination using HAL100 12V 100W
halogen lamp housed with microscope power supply (PhotoFluor LM-75, 89 North) and
Hamamatsu CMOS ORCA-Flash 4.0 LT CCD camera (C11440-42U30). For comparisons, images
from individual studies were processed identically using Adobe Photoshop.
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5.4.2

Results

5.4.2.1 Days in vitro (DIV) characterization
The growth of hippocampal neurons in culture under this protocol were observed and matched
with observation noted in anticipated result section of (Beaudoin et al. 2012).
Within DIV 2, cultured neurons started developing lamellipodia, which increased in length with
progression of days in culture gradually initiating connections with other cells and processes. By
DIV 7, neuronal processes formed a well-developed network with other neurons. By DIV 10, the
culture demonstrated well-formed and mature neurons with structured web of the neuronal
processes which has developed complex network with each other with time. Post DIV 17, the
neurons formed tight aggregates or clusters connected through a tightly formed bridge of
neuronal processes. By DIV 21, within some of the wells, empty spaces with no cells were
noticed. Alongside loosening of the attachment caused floating of the cell bed from the sides of
the well. Cell growth as observed with the current protocol (Fig. 5.3) was consistent as described
in the literature (Beaudoin et al. 2012). Alongside observing live culture to understand
development of neurons in culture, immunocytochemical staining with specific neuronal markers
were performed to demonstrate neuronal growth and maturity.
b-III-tubulin, a neuron-specific intermediate filament, is present in the cytoskeletal structure of
neuronal processes. Cultured cells were stained for b-III-tubulin immunoreactivity. As seen in
Fig. 5.4, b-III-tubulin immunoreactivity allowed study the gradual growth and complexity of
neuronal processes in vitro and validated the maturity of neurons.
Likewise, as neurons mature and develop, synapses are formed for functional neurotransmitter
release and developing synaptic connections between neurons, expression of specific proteins
gradually increase in neuronal synapses. As seen through Fig. 5.5, the immunoreactivity of
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Synaptophysin (left column- marker for the synaptic terminal) and PSD-95 (right columnmarker for post synaptic region) gradually increased through days in vitro. Fig. 5.4 and 5.5 thus
confirmed through use of these neuronal markers that neuronal maturity is attained by DIV 10.
All studies with primary hippocampal neuron cultures (studies in chapter 3 & 4) were performed
at 14-15 days in vitro (DIV).

165

Fig. 5.3.
Development of near pure hippocampal neurons grown on PLL coated
culture plates.
Representative photomicrographs of cultured hippocampal neurons at A. DIV 2, B. DIV 3, C. DIV 5, D.
DIV 7, E. DIV 10, H. DIV 14, G. DIV17, and H. DIV 21 demonstrated an increasing order of complexity
with growth and maturity of hippocampal neurons in culture (10X objective). Scale bar = 50µm.
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DIC image

ICC with b-3-tubulin

A. DIV 7

B. DIV 10

C. DIV 14

D. DIV 17

E. DIV 21

Fig.5.4.
Increasing complexity of b-III-tubulin immunoreactivity in cultured
hippocampal neurons with progression of days in vitro.
Panel (A-E) are representative photomicrographs of hippocampal neuronal cell culture in vitro, DIC
images (on left) with b-III-tubulin immunoreactivity (in green) demonstrated increasing order of
complexity with progression of days in vitro (10X objective). Scale bar = 25µm.
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Synaptophysin

PSD-95

A. DIV 7

B. DIV 10

C. DIV 14

D. DIV 17

Fig. 5.5.
Increasing Synaptophysin and PSD-95 immunoreactivity in cultured
hippocampal neurons with progression with days in vitro.
Panel (A-D) are representative photomicrographs of hippocampal neuronal cell culture in vitro, with
neuronal cell culture demonstrating immunoreactivity of pre-synaptic marker, Synaptophysin (on left)
and post-synaptic marker, PSD-95 (20X objective). Scale bar = 25µm.
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5.4.2.2 Culturing near pure hippocampal neurons
Cell cultures were stained for NeuN immunoreactivity (neuronal marker) and counterstained
with DAPI (which stains every nucleated cell) and using cell counter plugin in FIJI, cells stained
with NeuN and DAPI were counted across microscopic fields. Result demonstrated >90% of the
total cells stained with DAPI also showed NeuN immunoreactivity, indicating this culture to be
near pure neuronal culture. This result is consistent with neurons cultured through protocol
discussed by Beaudoin et al. 2012. Fig. 5.6 demonstrates cell culture with NeuN staining
counterstained with DAPI (DIV 14). As shown in the right panel marked with white arrowhead,
there are presence of few non-neuronal cells.

Fig. 5.6. Primary hippocampal neuronal culture may contain few non-neuronal cell types.
Representative photomicrographs of hippocampal neuronal culture (DIV 14) stained with neuronal
marker NeuN (red, left panel) counterstained with DAPI(blue, right panel) (20X objective). Scale bar =
25µm. White arrowheads indicate the non-neuronal cells only stained blue on the right panel.

5.4.2.3 Certain population of hippocampal neurons are inhibitory in nature
Previously published protocols identified majority of the neurons in these preparations as
excitatory neurons, with inhibitory neurons representing about 18–20% of these population.
GAD 65/67 immunoreactivity is commonly used to identify inhibitory neurons. Hippocampal
culture maintained using the current protocol similarly showed fairly similar percentage of
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inhibitory neurons (Fig. 5.5). GABAa/α1 is another commonly utilized marker of inhibitory
hippocampal neurons of all sub-regions [Hippocampome.org, (Wheeler et al. 2015; Hamilton et
al. 2017)]. Culture established with the present protocol also showed a heterogeneous
distribution of neurons expressing GABAa/α1(Fig 5.6). c-Fos levels measured with APV or MK801 treatment (chapter 3 and 4) indicated strong basal GABAA receptor-mediated inhibition in
hippocampal neuron cultures, possibly mediated by these GAD 65/67 positive neurons in the
culture.

Fig. 5.7.
culture.

GAD65/67 immunoreactivity identifies inhibitory neurons in hippocampal

GAD65/67(green) immunoreactivity identified inhibitory neurons in hippocampal neuronal culture (DIV
14) counterstained with DAPI (on the right column). A. Higher distribution of inhibitory neurons in one
microscopic field v/s B. Fewer GAD65/67 positive neurons demonstrated heterogeneity in the distribution
of inhibitory neurons in culture. (20X objective). Scale bar = 25µm.
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Fig. 5.8.
culture.

GABAa/α1 immunoreactivity detects inhibitory neurons and synapses in

GABAa/α1 (green) immunoreactivity in specific hippocampal neurons and their processes (DIV 14)
counterstained with NeuN (red, right column) to recognize all neurons in the field. To understand
heterogeneity in the distribution of neurons expressing GABAa/α1, two microscopic fields are shown
here (A and B) (20X objective). Scale bar = 25µm.

5.4.2.4 Endogenous expression of IL-1 signaling components in primary hippocampal
neurons
IL-1b functions through its functional receptor, IL-1R1. IL-1R1 is constitutively expressed
primarily in the postsynaptic regions of cultured rat hippocampal neurons, alongside the
expression of the receptor accessory protein, IL-1RacP, and the signaling adapter protein MyD88
(Gardoni et al. 2011). IL-1R1(Fig. 5.9), IL-1RacP (Fig. 5.10), and MyD88 (Fig.5.11)
immunoreactivity were seen in primary mouse hippocampal neurons in the current study was
consistent with previous findings (Gardoni et al. 2011).
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P2X7R immunoreactivity was also observed in cultured hippocampal neurons (Fig. 5.12). Subcellular localization of IL-1R1 appeared to be in the cell membrane. P2X7R immunoreactivity
was concentrated in the cell membrane as well as in neuronal processes.
In vivo, physiological IL-1b is present in the hippocampus of mice brain as seen through ELISA
studies (Fig. 4.4). However, IHC studies on the saline-treated mice brain section were not
capable of detecting endogenous expression in hippocampus (Fig.3.2, SBE treated brain
sections). Unlike absence of immunoreactivity in tissues, ICC staining on hippocampal cells
showed endogenous expression of IL-1b in the certain cell population of hippocampal neurons in
culture (Fig. 3.3). The IL-1b immunoreactivity was detected in both cell bodies and neuronal
processes. Together, these results showed hippocampal neurons in culture endogenously express
IL-1b and its signaling components and justified utilization of cultured hippocampal neurons for
further characterization of neuromodulatory function of IL-1b (which were done in chapter 3 and
4).

Fig.5.9.

Localization of IL-1R1 immunoreactivity in cultured hippocampal neurons.

Photomicrograph of hippocampal neurons (DIV 14) show A. IL-1R1 immunoreactivity in green and B.
gray scale images with IL-1R1 immunoreactivity (40X objective). Scale bar = 25 µm.
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Fig.5.10.
neurons.

Localization of IL-1RacP immunoreactivity in cultured hippocampal

Photomicrograph of hippocampal neurons (DIV 14) show accessory protein of IL-1 receptor, IL-1RacP
immunoreactivity (green) counterstained with A. presynaptic marker, Synaptophysin (red) and B.
postsynaptic marker PSD95 (red) (20X objective). Scale bar = 25 µm.

Fig.5.11.

Localization of MyD88 immunoreactivity in cultured hippocampal neurons.

Photomicrograph of pure hippocampal neurons (DIV 14) show adaptor protein of IL-1 receptor, MyD88
immunoreactivity (red) counterstained with A. presynaptic marker, Synaptophysin (green) and B.
postsynaptic marker, PSD95 (green) (20X objective). Scale bar = 25 µm.
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Fig.5.12.

Localization of P2X7R immunoreactivity in cultured hippocampal neurons.

Photomicrograph of hippocampal neurons (DIV 14) show A. P2X7R immunoreactivity (red) and B. gray
scale images with P2X7R immunoreactivity (40X objective). Scale bar = 25 µm.

5.5 Concluding remarks
This culture was prepared with a modest level of difficulty and care. Once the protocol was
standardized, it was used for a variety of studies, discussed in chapter 3 and 4. Alongside
offering a great insight into neuronal physiology and function, this model established itself to be
an effective model for this dissertation research.
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Chapter 6
Main findings, conclusions and future direction
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6.1

Main findings
•

IL-1b has role in maintenance of brain homeostasis:
-

Genetic deletion of IL-1R1 in mice lowers seizure threshold – studies from
(Claycomb 2011) revisited.

-

Role of P2X7R in modulation of excitatory-inhibitory balance favoring excitation in
hippocampal neurons – possibly by blocking IL-1b release.

-

Role of P2X7R in maintaining seizure threshold in mice – possibly blocking IL-1b
release.

•

There is a presence of endogenous IL-1b protein in neurons of the hippocampus:
-

Endogenous IL-1b expression is present in pyramidal neurons of CA3 and CA1
subregion of the hippocampus.

-

Within hippocampal neurons, IL-1b is present in cell bodies and neuronal processes.

•

Constitutive Interleukin-1β release from hippocampal neurons seems P2X7-dependent.

•

Intensive neuronal excitation may serve as endogenous stimuli for IL-1b mRNA
induction following convulsive stimuli.

•

Endogenous IL-1b has potential link to COX-2 expression and functions in modulation of
excitatory-inhibitory balance.
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6.2

Summary and conclusions : Limitations of current study

6.2.1

IL-1b has role in maintenance of brain homeostasis.

Previous findings from our laboratory research demonstrated how genetic deletion of the IL-1b
ligand or its receptor, IL-1R1 lowered the seizure threshold indicating a regulatory nature of IL1b in maintenance of excitation/inhibition balance. This evidence formed the fundamental basis
of this dissertation research. Therefore, as mentioned in chapter 2, prior to characterizing some
of key aspects of IL-1b’s role in brain homeostasis or delving deeper in endogenous IL-1b
biology, this concept was revisited. Convulsant property of PTZ was used to model shift or
change E/I balance. PTZ was utilized as it generates intensive excitatory neuronal activity
without excitotoxic insults in mice brain (Claycomb, Hewett, and Hewett 2011). Studies herein,
showed role of endogenous IL-1b in maintenance of seizure threshold via two independent ways.
As it was hypothesized that physiological IL-1b may mediate E/I balance, genetic deletion of IL1R1 in mice and treating mice with P2X7R antagonist (possible via blocking IL-1b release)
demonstrated similar results, proving the hypothesis.

6.2.1.1 Genetic deletion of IL-1R1 in mice lowers seizure threshold – studies from (Claycomb
2011) revisited
One primary concern shown by previous reviewers was developmental defects in these knock
out lines generating alterations in their seizure threshold. This may contribute to their seizure
phenotype. Deficiency or alterations in phenotypes in mutant mice line is common. Genetic
knock-out mice lines may generate alternative phenotypes perhaps due to compensatory changes
(Barbaric, Miller, and Dear 2007). However, similar seizure phenotype was observed in IL-1b
KO and IL-1R1 KO mice lines (Claycomb, Hewett, and Hewett 2012). Firstly, researchers
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developing these lines did not characterize any unusual phenotype in their findings (Zheng et al.
1995; Maliszewski et al. 1997). Secondly, similar phenotypic alterations in two distinct mutant
mouse line seem highly unusual. Yet, these proteins belong to the same cytokine signaling
pathway and therefore, these lines may generate the similar altered seizure phenotype. Mice lines
deficient either the ligand or its receptor, and IL-1 signaling has been implicated in neurogenesis
and neuronal development (discussed in chapter 1). Alteration in seizure phenotype may happen
due to altered neuronal development and this can pose concern.
6.2.1.2 Role of P2X7R in modulation of excitatory-inhibitory balance – possibly by blocking IL1b release
Role of P2X7R dependent release of IL-1b in neurons and how it may affect E/I balance was
studied and discussed in chapter 3. Utilization of pharmacological inhibitor of P2X7R opened an
interesting avenue for studying endogenous neuronal localization of IL-1b and some specific
aspects of IL-1b release mechanism which was discussed in section 3.5 of chapter 3.
Inhibiting P2X7R activation displayed accumulation of IL-1b both in vivo and in vitro (Chapter
3). This indicated role of P2X7R in endogenous IL-1b release from neurons. P2X7R antagonism
study demonstrated altered neuronal excitation in vitro and lowered seizure threshold in vivo. Of
interest to this section, following P2X7R inhibition, PTZ induced seizures were more severe in
mice (Chapter 3). Alongside, connected to the topic of IL-1b’s role in maintenance of seizure
threshold, pharmacological inhibition of P2X7R activation yielded similar results to PTZ
induced seizure studies with genetic deletion of IL-1b ligand (Claycomb, Hewett, and Hewett
2012) or its receptor [(Claycomb, Hewett, and Hewett 2012) and chapter 2].
Lowered seizure threshold by pharmacological inhibition of P2X7R possibly happens via
blocking IL-1b release, therefore, this study may provide additional evidence for role of
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endogenous IL-1b in the maintenance of E/I balance and may bypass some concerns associated
with utilization of mutant mice lines. As the effect of this drug was acute, it can be argued that
developmental effects did not likely account for the seizure phenotypes seen with IL-1b ligand or
the receptor knock out mice. In this aspect, the genetic and pharmacological approach together
provided compelling evidence to support the contention of IL-1 signaling in the maintenance of
seizure threshold.

Fig. 6.1. Physiological IL-1b in CNS maintains seizure threshold.
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6.2.2

Endogenous IL-1b expression in neurons of the hippocampus.

6.2.2.1 Cellular localization: CA3/CA1 pyramidal neurons
Localization of IL-1b in CNS have been classified in literature based on different sub-regions of
the brain where it is either expressed [endogenous expression in the hypothalamus (Breder,
Dinarello, and Saper 1988) and hippocampus (Lechan et al. 1990; Deak, Bellamy, and
D’Agostino 2003) or whether its condition of release is physiological (primarily neuronal) (Watt
and Hobbs 2000) or pathophysiological (primarily microglial) (Liu and Quan 2018). The
localization or source of endogenous IL-1b have been discussed in chapter 1 and section 3.5.1 of
chapter 3. Few explanations were also discussed to justify the incongruency between findings
from different researchers on the cellular sources of IL-1b in mice hippocampus.
In CNS, microglia are the primary source of IL-1b in neuroinflammatory and neurodegenerative
conditions. Several reviews over the years have tied information from literatures and helped in
better understanding of cellular sources of IL-1b in pathophysiological conditions (Allan,
Tyrrell, and Rothwell 2005; Dinarello 2009; Hewett, Jackman, and Claycomb 2012; Liu and
Quan 2018). During neuroinflammation, initial source of IL-1b is microglial, however, with
continuation of inflammatory and subsequent reparative processes, IL-1b is also sourced from
reactive astrocytes, neurons and even from endothelial cells (Boutin et al. 2003).
On the other hand, information on the physiological source of IL-1b seem to be
compartmentalized as the researchers till now have only described their region of interest in
CNS. Two areas of brain has been widely studied in respect to endogenous role of IL-1b,
hypothalamus, particularly in hormone regulation and central stress axis (Watt and Hobbs 2000;
Goshen and Yirmiya 2009) and in hippocampus primarily with LTP and learning and memory
processes (Schneider et al. 1998; Curran, Murray, and O’Connor 2003; Ikegaya et al. 2003;
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Viviani et al. 2014). Therefore, most information available on cellular localization of
endogenous IL-1b have been derived from these two regions of the brain. Finally, most studies
done to explore role of IL-1b physiology utilized an exogenous trigger (like LPS) or exogenous
IL-1b (Ross et al. 2003; Goshen et al. 2007). Although these studies claimed exogenous IL-1b
level were at physiological range, it is challenging to conclude if it actually mimicked the
physiological condition. Along the same line of thought, most physiological roles of IL-1b was
initially identified alongside specific disease conditions such as memory impairment due to
fever, sickness behavior or neurodegenerative conditions (Spulber and Schultzberg 2010), for
which pinpointing the cellular source of IL-1b was made further difficult.
Studies done in rat brain to measure IL-1b level in different regions indicated its low
physiological level in hypothalamus, hippocampus and in posterior cortex of the brain (Deak,
Bellamy, and D’Agostino 2003; Porterfield et al. 2012). Study herein similarly showed very low
(picogram level) IL-1b in the hippocampus of mice brain via ELISA study (Fig.4.3, Chapter 4).
As IL-1b level was low, it remained undetected with IHC study, hence the localization still
remained unclear. Only when P2X7R was inhibited, endogenous IL-1b accumulated in
pyramidal neurons of CA3 and CA1 sub-region of hippocampus (Fig.3.1).
Firstly, as discussed in section 3.5.1 of Chapter 3, variation of expression between species can
owe to differential expression found between physiological IL-1b expression in rats v/s current
result obtained here in mice. However, it still does not explain for the fact as to why there are
different expression pattern seen by different researchers in the same species (rat) (Lechan et al.
1990; Kaneko et al. 2006; Viviani et al. 2014). Secondly, observation in the current study is
based on accumulation caused by P2X7R inhibition. Studies herein showed similar expression
pattern in CA3 and CA1 region as seen in Viviani et al, however, no IL-1b expression was seen
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in DG. Although P2X7R was indicated to be involved in endogenous IL-1b release from
neurons, further investigation is required to understand if any other parallel release mechanism
exists which may explain absence of IL-1b expression in DG.
Hippocampal neurons in culture also showed IL-1b immunoreactivity, however, unlike in brain
section, where IHC was unable to detect any immunoreactivity, certain populations of
hippocampal neurons in culture showed endogenous IL-1b immunoreactivity. The hippocampal
neuron culture system served as a tool to better understand the subcellular localization of IL-1b
within neurons.
6.2.2.2 Sub-cellular localization of IL-1b in neurons of hippocampus
The expression pattern of IL-1b immunoreactivity in pyramidal neurons of CA3 and CA1
neurons was consistent to the IL-1b expression as seen with CA3 neurons in normal
hippocampus of rats (Viviani et al. 2014) and IL-1b immunoreactivity seen in hypothalamic
neurons (Watt and Hobbs 2000). The CA3/CA1 pyramidal neurons showed similar perinuclear
punctate profile similar to neurons of hypothalamus (Watt and Hobbs 2000). However, the
current study was lacking any IL-1b presence in neuronal processes in vivo as observed in
neuronal fibers (Watt and Hobbs 2000). A caveat of the current study lies in not conducting
colocalization studies with marker for neuronal processes. Colocalization study with MAP-2 or
b-III-tubulin in brain section treated with JNJ may provide answer, whether IL-1b is localized in
neuronal processes.
Using higher resolution microscopy, sub-cellular localization of hippocampal neurons was
investigated.
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6.2.2.3 Sub-cellular localization of IL-1b in cultured hippocampal neurons
Epifluorescence microscopy study on cultured hippocampal neurons showed IL-1b
immunoreactivity in both cell bodies (similar to in vivo observation) and in neuronal processes in
similar punctate profiles as discussed above (Watt and Hobbs 2000; Lechan et al. 1990). Subcellular localization of IL-1b was further examined in primary hippocampal neuron culture
using high resolution microscopy. Higher-resolution microscopy study showed IL-1b having a
punctate profile in the cell body and neuronal processes, alongside some diffused
immunoreactivity. Endogenous cytosolic expression of IL-1b in cultured neurons was consistent
with sub-cellular localization pattern of IL-1b found in cultured murine macrophage, showing
similar perinuclear cytosolic expression (Brough and Rothwell 2007). Although, different cell
types utilize variant form of IL-1b production and release mechanism (chapter 1), it was found
cytosolic IL-1b localization pattern across cell types remained consistent.
Few interpretations can be made based upon the sub-cellular localization of IL-1b in neurons.
Vesicle like structures seen herein may be IL-1b packaged in microvesicles, required for IL-1b
release (Rubartelli et al. 1990; Monteleone et al. 2018). Further experimentation will be required
to understand the mechanism clearly.
It is also important to investigate whether endogenous IL-1b release occurs synaptically or extrasynaptically. A recent study using a novel transgenic approach to map IL-1R1 protein expression
in the hippocampal formation found prominent IL-1R1 protein in the cell soma and molecular
layer of DG granule cells (Liu et al. 2015). The latter is consistent with another study showing
post-synaptic localization of IL-1R1 in hippocampal neurons (Gardoni et al. 2011). Expression
was also detected in the mossy fiber tract of the DG neurons, suggesting a possible presynaptic
release of IL-1b. Vesicles observed in the neuronal processes might be way to transport IL-1b to
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the synaptic locations or indication of pre-synaptic sites, however, further investigations will be
required prior to remarking. As IL-1b release requires P2X7R activation which in turn opens
pore for IL-1b release, sub-cellular localization of P2X7R may also be important in
understanding cellular sites for IL-1b release.

Fig.6.2.
Physiological IL-1b expression in mice hippocampus is present in
CA3/CA1 pyramidal neurons and its subcellular localization shows punctate
vesicle like structure in cell soma and neuronal processes.
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6.2.3

Endogenous IL-1b release from the neuron may be similar to canonical release
pathway – P2X7R dependent

Studies herein have implied inhibiting P2X7R activation possibly blocked IL-1b release from
hippocampal neurons. Both in vivo and in vitro, P2X7R antagonism caused accumulation of
endogenous IL-1b in neurons. P2X7R antagonism also shifted the E/I balance favoring
excitation in hippocampal neurons and lowered seizure threshold in mice. However, it was
acknowledged in section 3.5.3 of chapter 3, that the effect of the P2X7R antagonist on IL-1β
release and E/I balance are correlative yet results herein did not directly addressed cause and
effect. P2X7R is an ATP receptor, which itself functions as a neurotransmitter in CNS
(Burnstock 2016), thereby P2X7R can affect E/I balance independent and/or parallel to
neuromodulation by IL-1β. In the following sections, effect of both possibilities will be
discussed to form alternative theories and understand endogenous release of IL-1β from
hippocampal neurons.
6.2.3.1 P2X7R may be required for physiological IL-1b release from neuron
As discussed in chapter 1, P2X7R in CNS has following functions, firstly it is a low-affinity ATP
receptor, which when activated by ATP, opens a non-selective pore for extracellular ATP
release, IL-1b release and acts as stimuli to activate inflammasome (Sanz and Virgilio 2000;
2000; Sperlagh et al. 2006; Giuliani et al. 2017). Studies herein have shown pharmacologically
inhibiting P2X7R accumulated endogenous IL-1b in hippocampal neurons possibly via blocking
its release. Furthermore, in inflammatory cells, where IL-1b release have been thoroughly
studied, even though mechanism of IL-1b processing and packaging for release varied
[microvesicle shedding (Monteleone et al. 2018), secretory lysosome release (Rubartelli et al.
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1990; Andrei et al. 1999) or exosome secretion (Qu et al. 2007)], every release mechanism from
these cells have been dependent on P2X7R activation (Ferrari et al. 2006; Giuliani et al. 2017).
Herein, parallels are drawn from other studies, which may indicate presence of similar
mechanism by which P2X7R dependent IL-1b release may occur in neurons, even in absence of
inflammatory stimuli.
IL-1b release occurs in response to different endogenous or exogenous stimuli and some of its
mechanism are varied based on cell types (Piccioli and Rubartelli 2013). IL-1b release occurs
after it is packaged in some form of vesicle (microvesicles or secretory lysosomes or exosome).
In CNS, IL-1b is released from microglia by microvesicle shedding (Bianco et al. 2005). In
hypothalamic neurons, osmotic challenge led to complete loss of similar IL-1b containing
vesicle like structure (Watt and Hobbs 2000). Although studies herein have shown punctate IL1b immunoreactivity in cell soma and neuronal processes (similar vesicle like structure), further
investigation will be required to understand , 1) if IL-1b in hippocampal neurons are indeed
packaged in these vesicles for secretion, and 2) these vesicle-like structures are released from
neurons.
Secondly, sub-cellular localization of IL-1b release will depend on P2X7R localization in
neurons. P2X7R has pre-, post, and extra-synaptic localization in neurons (Miras-Portugal et al.
2017), each with specific functions. P2X7R activation also open different sized pores based on
neuronal conductance (Alves et al. 2014). Further experimentation will be required to understand
which localization of activated P2X7Rs required for neuronal IL-1b release.
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6.2.3.1 Possible source of ATP and Caspase-1 in hippocampal neurons
Studies herein implied P2X7R dependent IL-1b release in neurons. P2X7R is an ATP receptor.
The logical question that followed next was to identify the possible source(s) of ATP to activate
P2X7R for IL-1b release. Furthermore, IL-1b release coincidence with IL-1b processing
(Rubartelli et al. 1990; Andrei et al. 1999; Piccioli and Rubartelli 2013). Canonical inflammatory
processing of IL-1b requires functional Caspase-1, which cleaves pro-IL-1b to its active form
(Verhoef et al. 2003; Burns, Martinon, and Tschopp 2003; Brough and Rothwell 2007; Denes,
Lopez-Castejon, and Brough 2012). In the following section, likely source of ATP and possible
involvement of Caspase-1 will be discussed.
Source of ATP for P2X7R activation: It is pertinent to identify the physiological source of ATP,
which is required for P2X7R activation required for IL-1b release. P2X7R is a low-affinity
receptor for ATP, therefore, a sufficient concentration of ATP is required for P2X7R activation.
ATP is a readily available molecule in the nervous system milieu, being produced and released by
both neurons and glial cell types (Sperlagh et al. 2006; Sperlágh and Illes 2014). ATP acts either
as a neurotransmitter or as a neuromodulator to affect neurotransmitter functions. It is taken up
and released in synaptic vesicles in nerve terminals. ATP is released during neuronal activity and
can activate P2X7R receptors in narrow synaptic clefts (Sperlagh et al. 2006).
Owing to neurotransmitter functions, synaptic release of ATP is an obvious possibility
(Pankratov et al. 2006). Astrocytes are also known to release ATP in a glutamate-dependent
manner (Koizumi et al. 2003; Zhang et al. 2003) and microglia can release ATP via exocytosis
under certain conditions (Imura et al. 2013). Combinations of these cells can contribute to
extracellular ATP (Lalo et al. 2016).
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Further investigation will be required to better understand the source of ATP in vivo, required for
P2X7R activation for IL-1b release from neurons. P2X7R dependent IL-1b release from cultured
hippocampus, however, might provide some hint. They are near pure cultures devoid of glial cells.
ATP required for P2X7R activation in culture may be sourced from the hippocampal neurons itself,
however, further experimentation is needed to confirm this possible mechanism .
Requirement of Caspase-1 - possible involvement of inflammasome: Preliminary study herein
have shown that pharmacologically blocking Caspase-1 in cultured hippocampal neurons
elevated pro-IL-1b level in cell lysate. Absence of active IL-1b in cell lysate could have occurred
due to either of the two reasons. Firstly, in hippocampal neurons, processing of IL-1b may
occurs parallel to release, thereby processed IL-1b may only be available post release. Secondly,
active IL-1b bound for release was packaged in microvesicles and got separated in the layer
containing vesicles during centrifugation, therefore absent in lysate supernatant. My study
indicated the possibility of caspase-1 functionality (Fig.7.8, Appendix). This would also suggest
that processing as well as release of IL-1β occurs in a P2X7R-dependent manner in neuron as
reported in inflammatory cells (Piccini et al., 2008).
Caspase-1 is processed from pro-caspase-1 after it is integrated into the inflammasome (van de
Veerdonk et al. 2011). Therefore, the involvement of Caspase-1 also opens the possibility of
inflammasome mediated IL-1b processing. Different elements of the inflammasome are
expressed in CNS and are implicated in CNS physiology and pathophysiology (Xu et al. 2018;
de Rivero Vaccari, Dietrich, and Keane 2014; Walsh, Muruve, and Power 2014; Kaushal et al.
2015; Heneka, McManus, and Latz 2018). Alternatively, inflammasome complex formation
might not occur in endogenous IL-1b release from neurons. An alternative model present in
monocytes shows the presence of ASC and NLRP, which forms a platform for constitutive
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Caspase-1 activation (Netea et al. 2010). A similar protein platform may be present in neurons
instead of the inflammation mediated multimeric protein complex (inflammasome) formation for
constitutive Caspase-1 activation which may be required for constitutive release of endogenous
IL-1b. How processing occurs in neurons under physiological conditions remains to be
determined, although based on studies herein, it is presumed to occur in a P2X7-induced
caspase-1-dependent manner.

6.2.4

Endogenous stimuli for IL-1b production

IL-1b mRNA induction in immune cells require exogenous (bacterial toxin, LPS) or endogenous
(inflammatory mediators, cytokines) stimuli for transcription and subsequent translation of IL-1b
(Fenton 1992; 1988; Pelegrin, Barroso-Gutierrez, and Surprenant 2008). Activation of TLR is
required of IL-1β induction in CNS pathophysiology. Constitutive production of IL-1b transcript
have only been reported in human large granular lymphocytes and in male gonads (Galli et al.
1990; Rozwadowska et al. 2007). Constitutive generation of constitutive IL-1b transcript in
neurons is unknown. This would indicate transcription and translation of IL-1b in neuron may
require a stimulus. In the absence of inflammatory stimuli, the question remains as to what
triggers physiological IL-1b production in neurons.
Recent studies have found several sterile stimuli can initiate a response to release IL-1b (Patel et
al. 2016). One such candidate identified for priming inflammasome is Reactive Oxygen Species
(ROS). Metabolism of mitochondrial energy yields metabolites including ROS in all living cells
including cells of CNS. ROS have both detrimental and beneficial roles in neuronal physiology,
based on its level and stimuli for production (Cid-Castro, Hernández-Espinosa, and Morán 2018)
and implicated in several neurological diseases (Popa-Wagner et al. 2013; Angelova and
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Abramov 2018). However, whether ROS is a possible candidate to initiate endogenous IL-1b in
CNS physiology is not known. The brain is a high energy-consuming organ which generates a
substantial amount of ROS, however, it also has a prominent antioxidant system to limit
oxidative stress (Salim 2017). In a homeostatic system of functional oxidative phase, a limited
low amount of mitochondrial metabolite may function as a stimulus to produce endogenous IL1b. Information on this endogenous stimulus that may initiate physiological IL-1b in neurons is
unknown.
Conversely, studies herein have shown intensive neuronal excitation can act as an endogenous
trigger to rapidly induce IL-1b mRNA in mice hippocampus. Section 4.5.1 discussed in detail,
instances where neuronal activity have induced IL-1b. Therefore, thorough research needs to be
done to understand the possibility of ROS or basal neuronal activity as a potential trigger in
endogenous IL-1b production in the neuron.

6.2.5

COX-2 as a downstream signaling candidate of IL-1b

COX-2 mRNA levels showed dissimilar outcomes when IL-1b signaling was disrupted. Studies
herein demonstrated P2X7R inhibition increased COX-2 mRNA levels in hippocampal neurons
(Chapter 3). On other hand, IL-1R1 KO mice demonstrated no difference in constitutive
hippocampal COX-2 mRNA compared to WT (Chapter 4). The first instance can be explained
by the possible sequence of event, where P2X7R inhibition possibly blocked IL-1b release which
in turn shifted the E/I balance favoring excitation (demonstrated through elevated c-Fos level).
This in turn induced COX-2 mRNA. Spontaneous glutaminergic activity have shown to induce
COX-2 mRNA, which is consistent with this finding (Yamagata et al. 1993; Stark and Bazan
2011; Hewett et al. 2016).
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This differs from how endogenous IL-1b may modulate COX-2 mRNA in IL-1R1 mutant mice.
As demonstrated in chapter 4 and discussed in section 4.5.2, absence of functional IL-1b
signaling in mice did not affect the basal COX-2 mRNA levels. However, it moderated basal
COX-2 expression in hippocampus possibly via maintaining post-transcriptional COX-2 mRNA
stability (Tamura et al. 2002).
Secondly, activity dependent COX-2 expression was also moderated by endogenous IL-1b
signaling. COX-2 expression was induced with PTZ induced convulsive seizure. This is
consistent with previous findings (Claycomb, Hewett, and Hewett 2011; Gong and Hewett
2018). Studies herein showed activity dependent COX-2 induction even in the IL-1R1 KO mice
with PTZ treatment, however in lesser extent. This indicated IL-1b - COX-2 link.
Endogenous IL-1b regulates activity dependent COX-2 possibly via regulation of NMDA
function. IL-1b enhanced NMDA function whereas inhibiting IL-1b abolished this effect (B
Viviani et al. 2003). Also, IL-R1 is coupled with NR2B receptor subunit in post synaptic density
of cultured hippocampal neurons (Gardoni et al. 2011). Absence of functional IL-1R1 in KO
mice therefore, may compromise NMDA receptor function, creating possibility of attenuated
NMDAR function in the mutant mice. As induction of COX-2 is shown to be dependent on
glutaminergic signaling, this in turn, may affect COX-2 expression. NMDAR also mediates
COX-2 dependent PG synthesis (Stark and Bazan 2011). This can explain lower PG levels in
hippocampus of mutant mice following convulsion.
Identifying endogenous IL-1b dependent NMDAR function will require further experimentation.
Identifying sub-cellular localization of IL-1b will be required to understand the above-mentioned
possibilities. Excitatory activity dependent COX-2 is expressed in the dendritic spine of CA3
pyramidal neurons (Kaufmann et al. 1996). IL-1R1 also demonstrates post-synaptic localization
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(Gardoni et al. 2011; Liu et al. 2019). This may indicate a possibility that neuronal IL-1b is
released from pre-synaptic location. Studies herein have shown IL-1b immunoreactivity in
neuronal processes. Further experimentation will be required to understand if these
immunoreactivity colocalizes with the presynaptic sites, to identify possible release sites of IL1b in neurons.

Fig. 6.3.

Dual outcome of COX-2 mRNA induction by disruption of
endogenous IL-1b signaling.
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Fig. 6.4.

Potential location for IL-1b-COX-2 functioning in mice
hippocampus.
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6.3

Future directions

6.3.1

Identifying similarities and uniqueness of the physiological release of IL-1b to the
canonical inflammatory release mechanism.

This dissertation research identified physiological presence of IL-1b in neurons of the
hippocampus. Simultaneously, JNJ studies done herein have shown, physiological IL-1b release
may be P2X7R activation dependent.
Inflammatory IL-1b release requires two distinct signals for its release, firstly, it induces IL-1b
mRNA and pro-IL-1b protein, and secondly, initates formation of the inflammasome to activate
Caspase-1 when P2X7R is activated by extracellular K+ efflux and ATP release. How these
signals may originate without inflammation to release IL-1b in CNS physiology was not studied
in my dissertation research.
The first logical future step in further characterization of IL-1b release mechanism in neuron
would be to identify the cellular source of ATP and possible triggers that will release ATP into
the extracellular milieu. Secondly, study herein also indicated physiological IL-1b release may
require Caspase-1. Further investigation will be required to identify, how Caspase-1 may play a
role in IL-1b release in neurons, and finally, whether or not inflammasome plays a role in
activating Caspase-1.
6.3.2

Identifying the DG-CA3 circuitry as IL-1b communication center in the hippocampus.

Studies in section 7.6 (Appendix) explained the initiative and progression of research involving
use of two mouse lines. The first of these targeted Cre-DNA recombinase to DG granule cells
using the proopiomelanocortin (Pomc) gene promoter (Pomc-Cre; (McHugh et al. 2007)). This
promoter is transcriptionally activated during the late postnatal period of development, lessening
the possibility of a developmental effect of the transgenic manipulation. The second mouse line
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harbored a functional IL-1RI transgene that is transcriptionally activated by Cre in the
background of global IL-1RI gene deficiency (Liu et al. 2015). The transgenic construct was
inserted in the endogenous IL-1RI gene, thus inactivating it. The research plan was to activate
IL-1R1 signaling in DG of the hippocampus and verify the seizure phenotype in lights of IL-1
signaling recovery in DG.
However, as explained in the section 7.6 (appendix), there were several unprecedented problems
in the breeding and maintenance of the transgenic line which attenuated the progression of this
research.
Genetic deletion of IL-1β signaling from the DG of adult mice would have been a logical
approach to test my hypothesis of possible localization of IL-1β functioning in hippocampus.
However, during the origin of this project, a mouse line with loxP-flanked IL-1RI which permits
spatial deletion of IL-1 signaling was yet to be generated. Recently, there is a functional IL-1R1
conditional knock out mouse line (Robson et al. 2016) which can be utilized to knock out
functional IL-1 signaling in DG of the hippocampus and observe the changes in seizure
phenotype. Although similar characterization and breeding protocols have to be followed prior
to generation of double transgenic knock-out, the positives of this project will be, i) it will be one
less step in breeding procedure (no back cross required), and ii) this is a line generated in
C57BL/6J strain, similar to the POMC-Cre mouse line instead of IL-1R1 restore line which was
is C57BL/6N strain (Robson et al. 2016; Liu et al. 2015). Although my study was not able to
pinpoint any of un-precedented problems in breeding with my study due to crossing between two
strains, however, above suggested study can be an alternative to answer our research question.
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8.3.4

Possible neuroprotection of IL-1b via regulation of post-ictal suppression.

Studies herein (Chapter 4) found induction of IL-1β and Caspase-1 mRNA following an acute
seizure. However, there was no immediate change in IL-1β protein level with neuronal
hyperexcitation both in vivo and in vitro. Studies herein also showed IL-1β modulated elevated
COX-2 levels and Prostaglandin E2 production in mice following convulsive seizure (Chapter 4).
Several PGs have shown to have anti-convulsive properties (Kim et al. 2008). It is a plausible
extension of this study to identify the changes in other prostaglandins particularly of PGD2 with
PTZ induced acute convulsion and to identify the role of IL-1β in PG production. PGD2 is shown
to be the most prevalent prostaglandin in the brain and have an anticonvulsive property
(Förstermann et al. 1982; Akarsu, Mamuk, and Comert 1998). Finding the PGD2 level alongside
already obtained PGE2 data can lead to the next step in identifying the role of IL-1β signaling in
post-ictal suppression.
Acute ictal events are typically terminated spontaneously within seconds to several minutes and
are followed by a postictal seizure refractory period that may be linked mechanistically to seizure
resolution (Mucha and Pinel 1977). Elevated levels of PGs due to PTZ induced convulsion have
shown to contribute to post ictal suppression (Förstermann et al. 1982). IL-1 signaling has also
been implicated in post-ictal suppression utilizing a different model of seizure generation (Tao et
al. 2015). To test whether IL-1β signaling contributes to this postictal suppression, maximal
electroshock convulsion (MES) will be given to IL1RI WT and IL1RI KO littermates which will
be followed by a second challenge with a convulsive dose of PTZ at time intervals described
(Förstermann et al. 1982) and the seizure phenotype has to be studied [the reason for selecting
two different modes of seizure generation is to avoid any build-up of the similar stimulus (the
second dose of PTZ immediately after another amplifies seizure responses (unpublished
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observation)]. If IL-1 serves a role in the postictal refractory period following a PTZ-induced
convulsion as hypothesized, a second seizure response would not occur in IL-1RI WT mice
within the postictal time period. In contrast, IL-1RI-/- mice may respond during this period. This
outcome seems plausible since IL-1RI-/- mice exhibit a reduced seizure threshold.
Alternatively, IL-1β signaling may not have any role in post-ictal suppression or already elevated
levels of prostaglandin in IL-1R1 KO mice may keep the refractory time period similar (Results
from this dissertation research (Chapter 4) shows elevation in PGE2 level in WT mice whereas is
KO mice already elevated levels do not change with convulsion). In this case, the seizure
response following the initial convulsion would be suppressed in both IL-1RI-/- and IL-1RI+/+
mice. The outcome would be informative as it is important to understand the mechanisms
involved in postictal seizure suppression because it could lead to the development of new
antiepileptic therapies.
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Chapter 7: Appendix
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Table 7.1
Individual p values (for multiple comparisons) of each pixel points between
treatments for Figure 3.7.
Uncorrected Fisher's LSD
Row 1
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 2
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 3
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 4
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 5
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 6
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 7
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 8
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 9
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 10
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 11
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 12
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 13
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 14
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 15
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 16
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 17
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 18
Control vs. 0.1 µM JNJ

Significant?

Summary

Individual p-Value

No
Yes

ns
****

0.6194
<0.0001

No
Yes

ns
***

0.6384
0.0002

No
Yes

ns
***

0.9697
0.0008

No
Yes

ns
**

0.8348
0.0025

No
Yes

ns
**

0.4894
0.0018

No
Yes

ns
**

0.3749
0.0011

No
Yes

ns
**

0.2736
0.0011

No
Yes

ns
***

0.2977
0.0009

No
Yes

ns
***

0.1888
0.0005

No
Yes

ns
***

0.207
0.0006

No
Yes

ns
***

0.2824
0.0006

No
Yes

ns
***

0.3299
0.0005

No
Yes

ns
***

0.3238
0.0003

No
Yes

ns
***

0.429
0.0004

No
Yes

ns
***

0.4442
0.0005

No
Yes

ns
**

0.6142
0.0025

No
Yes

ns
**

0.7065
0.0054

No

ns

0.7007
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Control vs. 0.3 µM JNJ
Row 19
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 20
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 21
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 22
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 23
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 24
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 25
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 26
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 27
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 28
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 29
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 30
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ
Row 31
Control vs. 0.1 µM JNJ
Control vs. 0.3 µM JNJ

Yes

**

0.0063

No
Yes

ns
**

0.3737
0.0068

No
Yes

ns
**

0.2919
0.0083

No
Yes

ns
**

0.3284
0.0062

No
Yes

ns
*

0.5618
0.0188

No
Yes

ns
*

0.8157
0.0357

No
Yes

ns
*

0.6254
0.0347

No
Yes

ns
*

0.5402
0.0142

No
Yes

ns
*

0.664
0.0133

No
Yes

ns
*

0.6725
0.0223

No
Yes

ns
*

0.7591
0.0389

No
Yes

ns
*

0.8138
0.0291

No
Yes

ns
*

0.9576
0.0272

No
Yes

ns
*

0.8216
0.047
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7.1

IL-1R1 and P2X7R localization in hippocampus of murine brain.

Constitutive IL-1R1 expression was reviewed in saline treated CD-1 mice hippocampus. To
understand which cell type expresses IL-1R1, brain tissues were counterstained with NeuN
(neuronal marker).
Next, constitutive P2X7R expression was reviewed in saline treated CD-1 mice hippocampus. To
understand which cell type expresses P2X7R in mice hippocampus, brain tissues were
counterstained with NeuN (neuronal marker) or with P2Y12R (microglial marker).
7.1.1

Methods

Immunohistochemistry: as described in section 3.3.4 of chapter 3.
Antibody used:
Primary: IL-1R1, NeuN, P2X7R, P2Y12R.
Secondary: Goat anti-Mouse Alexa Flour 350, Goat Anti-Rabbit Alexa Fluor 488, Goat Anti-Rat
Dylight 549, Goat anti-Hamster Dylight 405 (details in table 1.3)
7.1.2

Comments

IL-1R1 immunoreactivity is seen in granule cells of DG and also expressed in CA1 pyramidal
neurons. Few CA3 pyramidal neurons also express IL-1R1 immunoreactivity. Endogenous P2X7R
immunoreactivity is observed in both neuronal and non-neuronal cells of hippocampus.
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Fig 7.1. Localization of endogenous IL-1R1 immunoreactivity in neurons of the mice
hippocampus.
Representative photomicrographs from saline treated mice brain section (panel A. CA3, B. CA1 and C.
DG sub-regions of the hippocampus) demonstrated IL-1R1 immunoreactivity (blue) and NeuN (green)
and merged (cyan) (10X objective). Headings indicate immunoreactivity coloration for each column of
images. Scale bar = 100µM.
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Fig 7.2. Constitutive P2X7R expression in neurons of hippocampus.
Representative photomicrographs from saline treated mice brain section (panel A. CA3, B. CA1, and C.
DG sub-region of hippocampus) demonstrated P2X7 immunoreactivity (red), NeuN (blue) and merged
(pink). (20X objective). Headings indicate immunoreactivity coloration for each column of images. Scale
bar = 100µM. Inset in the merged section was enlarged to demonstrate P2X7 immunoreactivity in
hippocampal neurons.

203

Fig 7.3. Constitutive P2X7R expression in non-neuronal cells of hippocampus.
Representative photomicrographs from saline treated mice brain section (panel A. CA3, B. CA1, and C.
DG sub-region of hippocampus) demonstrated P2X7 immunoreactivity (red), P2Y12 (green), DAPI
(blue) and merged (20X objective). Headings indicate immunoreactivity for each column of images. Scale
bar = 100µM. Inset in the merged section was enlarged to demonstrate P2X7R immunoreactivity in
microglial cells in mice hippocampus.
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7.2

IL-1β Antibody validation

IL-1β antibodies (Ab) used for studying expression (ICC and WB) were validated prior to
utilization.
7.2.1

Methods

Western blot analysis: as described in section 3.3.8 of chapter 3.
Immunocytochemistry: as described in section 3.3.5 of chapter 3.
Fluorescence intensity quantification: as described in section 4.3.7.4 of chapter 4.
7.2.2

Comments

IL-1β antibodies, i) rabbit anti-IL1β polyclonal antibody, 1:500 (Abcam Cat# ab9722,
RRID:AB_308765) and ii) Rabbit polyclonal anti-IL-1β IgG, 1:100 (H-153, 200 µg/mL, Santa
Cruz Biotechnology, Cat# sc-7884, RRID:AB_2124476) were validated with western blot using
the recombinant mouse IL-1β peptide (Peprotech Inc., Cat# 211-11B) where protein expression
was observed on the expected size (17 kDa for active IL-1β peptides and also on 31kDa, possibly
pro-IL-1β peptide). (Fig 7.4)
Rabbit polyclonal anti-IL-1β IgG, 1:250 (H-153, 200 µg/mL, Santa Cruz Biotechnology, Cat#
sc-7884, RRID:AB_2124476) was also validated through lowering of its immunoreactivity level
when pretreated with recombinant mouse IL-1β blocking peptide (the antibody was incubated
with 4X blocking peptide and mixed by gentle rocking on a shaker for 30 min in room
temperature). Hippocampal neurons were treated either with DMSO (control) or with 0.3µM JNJ
and then immunostained with either only IL-1β Ab or IL-1β Ab + blocking peptide. IL-1β
expression significantly elevated with JNJ treatment. Blocking peptide bound antibody showed
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reduced fluorescence intensity in both control and JNJ treatment, indicating specific binding of
the antibody in question to IL-1β protein (Fig 7.5).

Fig.7.4.
peptide.

Immunoblots to verify the specificity of antibodies which bind to IL-1β

Blots showing antibodies’ immunoreactivity to IL-1β (Abcam Cat# ab9722, RRID:AB_308765 on left and
H-153, 200 µg/mL, Santa Cruz Biotechnology, Cat# sc-7884, RRID:AB_2124476 on right) by detection
of the active IL-1β and possibly pro-IL-1β band in recombinant mouse IL-1β peptide. The known molecular
weight is indicated through protein molecular weight ladder that was ran parallelly.
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Fig.7.5.

IL-1β immunoreactivity with and without pretreatment of blocking peptide:
antibody validation.

Representative photomicrograph of hippocampal neurons in culture (DIV 14) showed constitutive
expression of IL-1β (green) co-stained with DAPI (20X objective). Headings indicate specific treatment
for individual image. IL-1b fluorescence intensity between treatments were compared by ordinary oneway ANOVA test followed by uncorrected Fisher’s LSD test for multiple comparison (*,p<0.001).
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7.3.

Sub-cellular localization of IL-1β in hippocampal neurons may be extra-synaptic.

High-resolution microscopy was utilized to further understand if the subcellular localization of
IL-1β is synaptic in hippocampal neurons in vitro and to identify if P2X7R antagonist caused any
change in the compartmentalization of IL-1β immunoreactivity within these cells. For this study,
hippocampal neurons were counterstained with synaptic terminal marker, Synaptophysin, and
post-synaptic density marker, PSD-95 and compared between DMSO and JNJ treated neurons.
7.3.1

Methods

Immunocytochemistry: as described in section 3.3.5 of chapter 3.
Colocalization analysis: Co-localization tests are readily available in FIJI to estimate Meander’s
Coefficient and Pearson’s coefficient via plugins. Setting correct threshold for estimating colocalization using these plugins is important as it may generate false-positive results unless done
rightly. Prior to setting threshold for colocalization test, images (merged z-stacks) were checked
for any colocalization via orthogonal view function through its z-axis utilizing FIJI. Only in case
of images that provided any color merge in orthogonal view (yellow in color merge of red and
green/cyan in green and blue/magenta in blue and red), colocalization tests were run.
7.3.2

Comments

Fig. 7.6 demonstrated cells with IL-1b immunoreactivity counterstained with PSD-95 without
(Fig..7.6, Panel A) and with JNJ treatment (Fig.7.6, Panel B). The XY coordinates showed no
visible colocalization with PSD-95 (absence of yellow) across the z-axis (5µm). Similarly, IL-1b
immunoreactivity did not co-localize with synaptophysin either with DMSO (Fig.7.7, Panel A)
or with JNJ treatment (Fig.7.7, Panel B) as seen through absence of cyan coloration across the zaxis (5 µm). All the fields were tested similarly to identify if there was any colocalization to
indicate IL-1b to have synaptic presence. Preliminary studies herein, indicated otherwise.
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This study indicated absence of IL-1b immunoreactivity either in synaptic terminal or in post
synaptic density as seen through absence of co-localization with Synaptophysin or PSD-95. This
may suggest sub-cellular localization of IL-1b to be extra-synaptic. Alternatively, it may be still
synaptic, but not in the similar subcellular domain which contains synaptophysin or PSD-95.
However, further investigations using confocal microscopy and co-localization techniques will
be required to confirm this fact.

Fig.7.6. IL-1β may not be localized in the postsynaptic density.
Deconvolution images of A. DMSO and B. 0.3µM JNJ treated hippocampal neuronal cells in culture (DIV
14) demonstrated IL-1β (green) immunoreactivity co-stained with PSD-95 (red) to identify postsynaptic
density. Each treatment is represented with two microscopic fields (i and ii) (40X objective). Figure panel
on bottom and right of each image represents the orthogonal view [pixels of X and Y axis (enlarged) across
z-axis (XZ and YZ pixel coordinates mentioned at bottom right)]. Scale bar = 2.5µm.
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Fig.7.7. IL-1β may not be localized in the presynaptic terminal.
Deconvolution images of A. DMSO and B. 0.3µM JNJ treated hippocampal neuronal cells in culture (DIV
14) demonstrated IL-1β (green) immunoreactivity co-stained with synaptophysin (blue) to identify synaptic
terminal. Each treatment is represented with two microscopic fields (i and ii) (40X objective). Figure panel
on bottom and right of each image represents the orthogonal view [pixels of X and Y axis (enlarged) across
z-axis (XZ and YZ pixel coordinates mentioned at bottom right)]. Scale bar = 2.5µm.
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7.4

Effect of Caspase-1 inhibition on IL-1β release from hippocampal neurons in vitro.

7.4.1

Methods

Ac-YVAD-CHO treatment: To inhibit caspase-1mediated proteolytic cleavage of pro-IL-1b
(31kD) to functional IL-1b (17kD) in hippocampal neurons, a stock solution of 50mM of AcYVAD-CHO was prepared in DMSO and stored at -20°C. This solution was diluted in
maintenance medium and administered to DIV 14/15 cells for 60 min (for protein analysis) at
concentrations of 10 or 30μM at 37°C in a humidified 5.5% CO2-containing-normotoxic
incubator.
Western blot analysis: as described in section 3.3.8 of chapter 3.
7.4.2

Results

To understand the mechanism of activation of constitutive IL-1β prior to release, the cellpermeable Caspase-1 inhibitor, Ac-Tyr-Val-Ala-Asp-CHO (Ac-YVAD-CHO) (10 and 30µM)
were added to the neuronal culture for 60 min and compared with vehicle-treated cultures. IL-1β
expression in cell lysate was altered by Caspase-1 inhibition.
Caspase-1 inhibition treatment showed trends in increased expression of IL-1b in hippocampal
neurons with 60 min treatment of 30µM yVAD-CHO as assessed by western blot analysis (Fig.
7.8). Western blot analysis showed the expression of only pro-IL-1β (31kD).
7.4.3

Comments

Caspase-1 inhibition treatment which exhibited increase (although not significant) in IL-1b in
hippocampal neurons with 60 min treatment of 30µM yVAD-CHO may indicate role of Caspase1 in IL-1b processing during release.
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i.
ii.

Fig. 7.8.

IL-1β protein accumulated in hippocampal neurons with Caspase-1 inhibitor
treatment.

Immunoblot analysis using anti-IL-1β and anti-β-actin antibodies was performed on cell lysates harvested
after 1 hours following treatment with vehicle (DMSO) or yVAD-CHO (10µM and 30µM)as described in
methods.
i.
ii.

Representative blot showing IL-1β immunoreactivity compared to β-actin.
Fluorescence intensity of IL-1β in cell lysate treated either with 10µM or 30µM yVAD-CHO
(N=3,each treatment) or its vehicle (DMSO) (N=3) for 1 hour was quantified, normalized to βactin fluorescence intensity and was analysed using ordinary one-way ANOVA (p=0.2397)
followed by uncorrected Fisher’s LSD test for multiple comparisons (p = 0.7705, DMSO vs.
10µM and p = 0.124, DMSO vs. 30µM yVAD-CHO). Equal variance was validated by Brown
Forsythe test (p=0.1058, F (DFn, DFd) = (2, 6)).
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7.5

Excitatory neuronal activity phosphorylates IRAK-1 in IL-1β dependent manner.

Interleukin-1 receptor-associated kinases (IRAKs) are serine threonine kinases for the
interleukin-1 (IL-1) and for other members of the IL-1 receptor (IL-1R) and Toll-like receptor
(TLR) family. Four IRAK molecules have been identified: two active kinases, IRAK-1 and
IRAK-4, and two inactive, IRAK-2 and IRAK-M. IRAKs mediate activation of NF- kB and
MAPK pathways. IRAK-4 functions upstream of IRAK-1 and phosphorylates it which then
binds to TRAF-6 to mediate MAP kinase and NF-kB signaling (Li et al. 2002).In brain injury,
IL-1R1 mediated IRAK-1/4 inhibition provided neuroprotection with rat brain injury model
(Yang et al. 2011). Overexpression of Irak1 mimicked the reduced dendritic complexity of
Mecp2-null cortical callosal projection neurons associated with Rett Syndrome (Kishi et al.
2016). These studies indicate role of IRAKs in neuroinflammatory diseases and neurological
disorders. As referred in chapter 4, the goal of the study was to identify any changes in any
downstream molecules of IL-1b signaling in acute seizure paradigm with an aim to identify a
biomarker/effector molecule of IL-1b signaling in neuronal hyperexcitation. Phosphorylation of
IRAK-1 was studied as one such candidate in PTZ induced convulsive seizure.
7.5.1

Methods

Mice
CD-1 mice: Brain sections of mice utilized for studies in chapter 4.
IL-1R1 mutant mice line: Brain sections of mice utilized for studies in chapter 2 & 4.
PTZ seizure paradigm
CD-1 mice: Acute seizure paradigm as described in methods () of chapter 3, PTZ dose of
60mg/kg was used.
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IL-1R1 mutant line: Acute seizure paradigm as described in methods () of chapter 4, PTZ dose of
43.5mg/kg was used.
Immunohistochemistry: As described in section 3.3.3 (Chapter 3).
Antibody utilized: Primary – pIRAK-1, Secondary – Donkey anti-Rabbit Alexa Fluor 488
Immunofluorescence quantification - as described in section 3.3.3.4 (Chapter 3).
7.5.2

Results

7.5.2.1 Change in the phosphorylation level of IRAK-1 with acute convulsive seizure may
be dependent on IL-1β signaling.
Time course (15 min, 30 min and 60 min following PTZ injection in CD-1 mice) study showed a
significant transient increase in phosphorylated IRAK-1 immunoreactivity in all three subregions of hippocampus within 15 min of PTZ injection. Although, there was no p-IRAK-1
immunoreactivity in saline-treated mice hippocampus, mice with PTZ induced convulsive
seizure showed an immediate bi-phasic increase in p-IRAK-1(lowered expression at 30 min and
goes up again by 1 hour). The phosphorylated protein immunoreactivity was seen to be
significantly elevated even at 1 hour following PTZ injection (Fig.7.9i) as quantified in Fig.7.9ii.
To test if IRAK-1 phosphorylation was dependent on IL-1β signaling, both saline and PTZ
treated wildtype and IL-1r1 mutant mice brain section were stained for p-IRAK-1
immunoreactivity. Similar to saline treated CD-1 mice, no p-IRAK-1 immunoreactivity was
found in saline treated hippocampi of C57BL/6J mice (both wildtype and IL-1r1 mutant
littermates) (Fig. 7.10). However, p-IRAK-1 immunoreactivity was significantly lower in all
three sub-regions of hippocampus in KO mice compared to the WT littermates 1 hour after PTZ
induced convulsive seizure (Fig. 7.10 i & ii). This study indicated IRAK-1 phosphorylation in
mice due to excitatory neuronal activity may be dependent on IL-1β signaling.
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Fig.7.9.
i.

ii.

p-IRAK1 immunoreactivity in mice hippocampus following acute convulsive
seizure.

Representative photomicrograph of mice hippocampus with p-IRAK1 (green) immunoreactivity
following PTZ induced convulsive seizures in mice [60mg/kg b.w., 15 min, 30 min and 60 min
(N=3,each time point)] and saline-treated mice hippocampus (N=3) (10X objective). Headings
indicate time-points for each column of images. Scale bar =100µm.
Immunofluorescence intensity in the subregions of hippocampus was quantitated as described in
Materials and Methods and results are the average from duplicate sections. Significant differences
were analyzed using 2-way ANOVA followed by Dunnett’s multiple comparisons test. (p-IRAK1
immunoreactivity post injection, a, significantly different from respective vehicle-treated controls
(*, p<0.001) and b, significantly different between subregions (*, p= 0.024)). No p-IRAK1
expression were detected in the saline treated mice.
Dunnett's multiple
comparisons test
DG
Saline vs. 15 min
Saline vs. 30 min
Saline vs. 60 min
CA1
Saline vs. 15 min
Saline vs. 30 min
Saline vs. 60 min
CA3
Saline vs. 15 min
Saline vs. 30 min
Saline vs. 60 min

Significant?

Summary

Adjusted P Value

Yes
Yes
Yes

****
**
****

<0.0001
0.0092
<0.0001

Yes
No
Yes

****
ns
****

<0.0001
0.0531
<0.0001

Yes
Yes
Yes

****
**
****

<0.0001
0.0019
<0.0001
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Fig.7.10

IRAK-1 phosphorylation may be dependent on IL-1β signaling.

i. Representative photomicrograph of WT and IL-1R1 KO mice hippocampus with p-IRAK1 (green)
immunoreactivity with saline or PTZ treatment [60mg/kg b.w., 60 min post injection (N=4,each time
point)] (10X objective). Headings indicate sub-regions of hippocampus under specific treatment for each
column of images. Scale bar =100µm.

i.

Immunofluorescence intensity in the subregions of hippocampus of WT or IL-1R1 KO mice
1hour post PTZ injection was quantitated as described in Materials and Methods and results
are the average from duplicate sections. Significant differences were analyzed using 2-way
ANOVA followed by Bonferroni’s multiple comparisons test. [p-IRAK1 immunoreactivity
post injection, a, significantly different within genotypes (*, p<0.001) and b, significantly
different between subregions of hippocampus (*, p= 0.006)].
Bonferroni's multiple comparisons test
WT - KO
CA3
CA1
DG

Significant?

Summary

Adjusted P Value

Yes
Yes
Yes

**
***
*

0.0011
0.0001
0.0396
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7.6

To test the possibility that IL-1 signaling in the DG of hippocampus is key to the

maintenance of the innate seizure threshold.
7.6.1 Introduction
As mentioned in Aim 1, mice lacking the obligate signaling receptor for IL-1 signaling, IL-1R1,
are more prone to convulsive seizures (i.e., have a reduced seizure threshold). Basal expression
of the IL-1R1 is particularly prominent in the neurons of the dentate gyrus (DG), with lower
expression in the CA3-CA4 regions (Parnet et al. 1994; Eriksson et al. 1999; Friedman 2001).
Consistent with this, ligand binding studies indicate that the IL-1 binding is highly concentrated
in the DG (Ban et al. 1991). Together, these results raise the intriguing possibility that the
neuromodulatory effects of IL-1β may be concentrated in the DG. The hippocampal formation
plays an important role in the process of seizure induction and epileptogenesis (Sloviter 1994;
Sutula et al. 1998; Ang, Carlson, and Coulter 2006; Fujita et al. 2014; Sloviter 2005). The DG is
an important control point for information entering the hippocampus from the entorhinal cortex
particularly in the epileptic brain (Gloveli, Schmitz, and Heinemann 1998; Sutula and Dudek
2007; Houser et al. 2012; Ang, Carlson, and Coulter 2006; Kobayashi and Buckmaster 2003).
Because IL-1β is released in the hippocampus and its binding sites are concentrated in the
granular cell layer of the DG (Ban et al. 1991; French et al. 1999; Friedman 2001), the DG may
be a site of IL-1β signaling and loss of signaling in the DG may account for the seizure
phenotype of IL-1RI mutant mice.
These studies will also be pertinent because 1) the DG is considered a key regulatory point in the
circuitry between the cortex and hippocampus and 2) this circuit is implicated in epilepsy, the
clinical relevance of this proposal (Sloviter 1994; Sutula et al. 1998; Sloviter 2005; Ang,
Carlson, and Coulter 2006). Using a novel Cre-dependent transgenic approach that permits cell-
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type specific restoration of functional IL-1 signaling in the null background which will permit to
restore IL-1 signaling in the DG areas of the hippocampal formation in IL-1R1 deficient mice. If
IL-1 signaling in these neuronal population is necessary to maintain the innate seizure threshold
the goal is to restore IL-1 function will re-establish the wild-type phenotype (Aim 1).
7.6.2 Methods
7.6.2.1 Mice:
7.6.2.1.1

POMC-Cre colony: Cre-dependent DNA recombinase to DG granule cells using

the proopiomelanocortin (POMC) gene promoter [POMC-Cre;(McHugh et al. 2007)] in mouse
targets recombination in the DG specifically. This promoter is transcriptionally activated during
the late postnatal period of development, lessening the possibility of developmental effect of the
transgenic manipulation. Importantly, our laboratory has shown that the cross between this line
and a line harboring a loxP-flanked transgene is capable of driving recombination of a transgene
in the hippocampal formation of mice but not in the cortex. This mouse line, which is referred to
as POMC-Cre (Cre/+), is available from Jackson Laboratory (stock no. 010714).
Breeding: The Cre hemizygous males were crossed with C57BL/6J WT female mice for
maintenance of the line. Due to leakiness of Cre gene reported, for Cre-Lox breeding, it is
advisable to maintain this Cre in males.
Genotyping: Genotyping was done following section 2.3.2 on Chapter 2. All genotyping was
performed through PCR analysis (Protocol 22392, The Jackson Laboratory) of tail genomic
DNA samples using allele-specific primers ((50µM), Integrated DNA technologies):
Cre1a: 5’- GTA ACT AAA CTG GTC GAG CGA TG-3’
Cre1b: 5’- CTG TTT CAC TAT CCA GGT TAC GG -3’
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7.6.2.1.2

IL-1R1 restore colony: This mouse line on C57BL/6N harbors a functional

IL1RI transgene that is transcriptionally activated by Cre in the background of global IL1RI gene
deficiency (X. Liu et al. 2015). The transgenic construct was inserted in the endogenous IL-1RI
gene, thus inactivating it. Once the transgene is activated by Cre, transcription of a function
receptor is driven by the endogenous IL-1RI gene promoter region. Transgene expression can be
monitored at the mRNA or protein level using tdTomato fluorescence and 3xHA epitope,
respectively. This mouse line, which is referred to as IL-1RIr/r, is available from Jackson
Laboratory (stock no. 024101).
Breeding: Filial male wildtype (WT or +/+) and mutant (IL-1R1 restore or r/r) littermates for
studies were derived from parental heterozygous (Het or +/r) breeding units that were obtained
from Jackson Laboratory after recovering the cryogenically preserved embryos. The female and
the male hets (+/r) were utilized for subsequent breeding. The above breeding and caging
strategy followed previous study (Claycomb, Hewett, and Hewett 2012) to control for potential
non-specific differences in environmental or genetic factors.
Genotyping: Genotyping was done following section 2.3.2 on Chapter 2. All genotyping was
performed through PCR analysis (Protocol 28334, The Jackson Laboratory) of tail genomic
DNA samples using allele-specific primers ((50µM), Integrated DNA technologies):
PRIMER
19775
23160
23550

7.6.2.1.3

SEQUENCE 5' → 3'
TGC ATC GCA TTG TCT GAG TAG
TCA GAG ATG AAA TGA CTA CAA GCT G
TTG TGC ATA AAG TGA ATG CTA GTG

PRIMER TYPE
Common
Wild type Forward

Cre-Lox breeding scheme: To restore the IL-1R1 expression in the DG, the

POMC-Cre+ and IL1RIr/r lines (Fig.7.11) were crossed. An initial cross between female IL1R1r/r
(IL1R1-/-) and male POMC-Cre+ (IL1R1+/+) mice would yield POMC-Cre+/ IL1R1+/r offspring.
These males are back-crossed with female IL-1R1r/r to yield POMC-Cre+/ IL-1R1r/r offspring.
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These mice will be IL-1R1+/+ in the DG granule cells (IL1R1DG/DG/POMC-Cre+), while all other
cell types will be IL1R1-/-.

Fig.7.11

Breeding scheme for the study.

7.6.2.2

PTZ seizure paradigm: described in section 2.3.3 of chapter 2.

7.6.2.2.1

Dose response study: Male wildtype C57BL/6N and IL-1R1r/r were dosed with

43.5mg/kg PTZ as this dose showed an array of seizure response in IL-1R1 traditional KO
colony (Fig 2.2A).
For this analysis, littermates of wild-type (WT) C57BL/6N+/+ andIL-1R1 restore (IL1R1deficient globally) genotypes from breeding heterozygous IL-1RI r/+ were dosed with 43.5 mg/kg
and seizure behavior was scored as described. Although a greater number of KO showed more
severe seizure, the difference was not significant. The restore mice and WT mice which showed
the median score of 4 (p= 0.2, Mann Whitney Test, two tailed) (Fig. 7.12 A). To represent
incidence of convulsion, although there is a trend of higher incidence of convulsion in restore
mice, Fisher’s exact test showed no significant difference in restore mice (100%) having
convulsive seizures compared to WT littermates (67%) (p= 0.4667, 2x2, two tailed Fisher’s exact
test) (Fig. 7.12 B).
Although the result did not yield any significant difference between the genotypes, it generated a
trend similar to IL-1R1 traditional KO colony. One of the reasons may be that, as PTZ induced

220

seizure occurs in a dose dependent manner, this dose of 43.5 mg/kg is approaching a ceiling
effect and a lower dose should be tested to see the array of seizure response.

Fig.7.12

The innate seizure threshold of mice lacking IL-1 signaling.

Mice from each genotype (WT (N=8) and Restore(N=8)) were treated with 43.5mg/kg b.w. PTZ and
seizure behavior were scored a 5-point scale of increasing severity as described in the methods.
A. Seizure severity. Each point represents the maximum seizure score for an individual mouse. The
median seizure scores within the two genotypes were statistically significant ( p= 0.2, Mann Whitney
Test, two tailed).
B. Incidence of convulsions. Histogram represents the % convulsing to total number of mice injected
with PTZ.

7.6.3

Cre-Lox Breeding

Crossing POMC-Cre with IL-1R1 restore mice yielded POMCCre/+/IL-1R1r/+ and
POMC+/+/IL-1R1r/+ genotypes. However, owing to leakiness of Cre in females only
POMCCre/+/IL-1R1r/+ males were backcrossed with IL-1R1r/r females yielding 4 different
genotypes, POMCCre/+/IL-1R1r/+ (the IL-1R1 gene will be functional in DG of hippocampus in
brains of this genotype in heterozygous fashion), POMC+/+/IL-1R1r/+, POMC+/+/IL-1R1r/r and
POMCCre/+/IL-1R1r/r (the IL-1R1 gene will be functional in DG of hippocampus in brains of this
genotype). Three cohorts of breeding utilizing breeding pairs yielded a total of 34 mice.
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When genotyped, I obtained,
POMC+/+/IL-1R1r/+ POMC+/+/IL-1R1r/r POMCCre/+/IL-1R1r/+ POMCCre/+/IL-1R1r/r
Males
7

4

4

1

3

10

0

Females
5

Table 7.2. Total offspring obtained from Cre-Lox breeding.
7.6.4

Unprecedented problems in breeding and maintenance of colony:

IL-1R1 restore line: This line was restored from cryogenic preservation of embryos. When
maintained in our animal house, several mice of this colony irrespective of gender or genotypes
suffered from mild to severe hair loss followed by ulcerative dermatitis in extreme cases
particularly in winter. Several males and females (35%) which had mild to medium ulcerative
dermatitis failed to mate or become pregnant reducing the total fecundity.A distinct number of
hets and restore mice irrespective of age would develop constant shaking of unreported nature
which developed around 10-12 weeks of age. As the Cre-Lox recombination occurred around 1216 weeks, these mice were scheduled for the PTZ study around 13-16 weeks. However, mice that
showed this symptom were taken out of the study. Several breeders (20%) were also euthanized
and could not be used because of this condition, reducing the total fecundity and mice obtained
through breeding.
POMC-Cre Hemizygous/IL-1R1 restore het males: The expected ratio of obtaining male
double transgenic genotype is 1/8th of total pups according to Mendelian law. However, in
nature, such ratio varies widely sometimes lowering the actual number of the desired genotype.
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The IL-1R1 restore/Cre hemizygous males showed an unique phenotype, which hindered our
breeding process severely. Firstly, after following general rule of breeding and setting up
younger females with older males to avoid aggressive behavior, several of the males were
attacked in their genitalia by female IL-1R1r/r mice. In one breeding cohort, 3 out of 5 males
were attacked severely, out of which 2 died due to excessive bleeding. The remaining one had to
be euthanized as per veterinarian’s advice. Out of the surviving males, out of 2 males from that
cohort and 4 from the next, 3 died of unknown cause (as reported by Laboratory animal research
personnel) at age of 14-16 weeks. Unprecedented deaths of these rare breeders affected the entire
Cre-Lox breeding process in terms of cost and time required to breed a generation of littermates.
Obtaining double transgenics:
As seen in table 7.2, with 3 cohorts of breeding, I did not obtain any female double transgenic
(POMCCre/+/IL-1R1r/r females) although the chances of obtaining this particular genotype was
1/8th or out of female mice. Similarly, I obtained only 1 male double transgenic (POMCCre/+/IL1R1r/r males), although chances of obtaining this particular genotype was again 1/8th or out of
male mice. Although, the number is too small to pinpoint towards any developmental reasons,
but it may be indicative of either embryonic lethal or neonatal deaths of these double transgenic
pups. As, the entire study was pivoted on the seizure phenotype of the double transgenic, not
obtaining any through all the breeding stalled the entire study. In research, we often come across
unprecedented problems or pitfalls, which required troubleshooting. As breeding requires
resources and is time consuming, often troubleshooting may not provide the answer. We looked
for alternative strategies. Instead, studying the tissue specific relevance of IL-1 signaling in mice
utilizing IL-1R1conditional knock out mice which will selectively knock-out IL-1 signaling was
proposed, which may be able to bypass these above-mentioned complications.
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